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resumo 
 
 
A Doença Pulmonar Obstrutiva Crónica (DPOC) é uma doença multifatorial e 
heterogénea que apresenta impactos diferentes em pacientes com estadios da 
doença semelhantes. Isto sugere que outros fatores para além da função 
pulmonar podem afetar a forma como o paciente experiencia a sua doença. As 
medidas reportadas pelo paciente (PROs) são um conjunto de variáveis que 
permitem avaliar a autoperceção e experiência dos doentes em relação à sua 
doença. Estudos recentes reportaram a existência de associações entre 
polimorfismos de nucleótidos simples (SNPs) e PROs, mas pouco ainda se sabe 
sobre estas associações e seu significado. Assim, este estudo teve como 
objetivo principal explorar possíveis associações entre variantes genéticas 
específicas e medidas clínicas, entre as quais PROs. Pretendeu também 
contribuir para a caracterização dos genótipos dos doentes com DPOC em 
Portugal. 
Realizou-se um estudo transversal com 60 doentes com DPOC. As PROs 
avaliadas foram 1) frequência de exacerbações autoreportadas pelos doentes, 
2) dispneia com a modified medical Research Council Scale e Borg, 3) fadiga 
com a Borg, 4) ansiedade e depressão através da escala de ansiedade e 
depressão hospitalar, 5) impacto da doença com o teste de avaliação da DPOC 
e 6) qualidade de vida relacionada com a saúde (QVRS) com questionário do 
hospital de St. George na doença respiratória. Adicionalmente, outras medidas 
clínicas também foram avaliadas, i. é., função pulmonar, força muscular 
periférica com dinamometria digital, força dos músculos respiratórios com a 
medição das pressões respiratórias e capacidade funcional através do teste de 
levantar e sentar cinco vezes e 1 minuto. Zaragatoas orofaríngeas e amostras 
de saliva foram recolhidas de todos os pacientes para genotipagem. 
Foram encontradas associações significativas entre variantes genéticas e 
dispneia (rs1143634, rs1042717, rs1138272 e rs12504628), fadiga (rs1042714 
e rs1138272), ansiedade (rs1051303, rs1800450 e rs1131620), impacto da 
doença (rs10461985 e rs1172113) e QVRS (rs11172113, rs1042713, rs1138272 
e rs12504628). Também foram encontradas variantes significativamente 
associadas à função pulmonar (rs1042713, rs1042717 e rs5030737), força dos 
músculos respiratórios (rs1130866), força muscular periférica (rs1042713, 
rs1042717, rs11172113 e rs11556218) e capacidade funcional (rs12899618, 
rs11046966 e rs1138272). 
Este foi um estudo exploratório e mais investigações são necessárias para 
confirmar os resultados obtidos e para explorar mais profundamente a 
associação e interpretação entre a genética e a trajetória da DPOC. 
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abstract 
 
 
Chronic Obstructive Pulmonary Disease (COPD) is a multifactorial and 
heterogeneous disease which impacts differently on patients with similar 
grades. This suggests that factor others than lung function may affect patients 
experience of the disease. Patient-reported outcomes (PROs) are a set of 
measures that allow to assess patients’ self-perception and experience of the 
disease. Recent studies have reported associations between specific single 
nucleotide polymorphisms (SNPs) and PROs, however not much is known 
about these associations and their meanings. Thus, this study had as main 
objective to explore possible associations between specific genetic variants and 
clinical measures, including PROs. It also sought to contribute for a 
characterization of the genotypes from patients with COPD in Portugal. 
A cross-sectional study was conducted in a total number of 60 patients with 
COPD. The PROs assessed were: 1) self-reported frequency of exacerbations, 
2) dyspnoea with modified Medical Research Council and Borg scales , 3) 
fatigue with Borg scale, 4) anxiety and depression with Hospital Anxiety and 
Depression scale; 5) impact of the disease with COPD Assessment Test and 6) 
health-related quality of life (HRQOL) with St. George Respiratory 
questionnaire; Additionally, several surrogate outcomes were also assessed i. 
e., lung function, peripheral muscle strength with digital dynamometer, 
respiratory muscle strength with the respiratory pressure assessment and 
functional capacity through the 1 minute and 5 time sit-to-stand. Both 
oropharyngeal swabs and saliva samples were collected from the patients for 
genotyping. 
Significant associations were found between genetic variants and dyspnoea 
(rs1143634, rs1042717, rs1138272 and rs12504628), fatigue (rs1042714, 
rs1138272), anxiety (rs1051303, rs1800450 and rs1131620), impact of the 
disease (rs10461985 and rs11172113) and HRQOL (rs11172113, rs1042713, 
rs1138272 and rs12504628). Significant associations were also found between 
genetic variants and lung function (rs1042713, rs1042717, rs5030737), 
respiratory muscle strength (rs1130866), peripheral muscle strength 
(rs1042713, rs1042717, rs11172113, rs11556218) and functional capacity 
(rs12899618, rs11046966 and rs1138272). 
This was an exploratory study and more investigations are necessary to confirm 
the results obtained and to explore deeply the associations and interpretations 
between genetics and COPD trajectory.  
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Chronic	obstructive	Pulmonary	Disease	(COPD)	is	a	major	public	health	problem	(1)	known	
to	affect	210	million	people	worldwide(2)	and	800.000	in	Portugal	(3).	By	2020	it	will	be		the	3rd	
leading	 cause	 of	 mortality	 accounting	 already	 for	 3.2	 million	 deaths	 in	 2015(4).	 Given	 the	
substantial	and	growing	economic	costs,	ascending	a	more	than	38.6	billion	of	Euros	in	Europe	and	
49.9	billion	in	the	USA(5),	but	also	the	social	burden,	significant	research	efforts	have	been	made	
in	 the	 last	 decade	 to	 enhance	 our	 understanding	 of	 COPD	development,	 diagnosis,	 impact	 and	
management.	
The	risk	of	developing	COPD	is	usually	associated	to	an	interaction	between	genetics	and	
environmental	 factors(1).	 Genetic	 factors	 have	 been	 associated	with	 risk	 for	 COPD	 such	 as	 the	
deficiency	of	a1-antytripsine	(AAT)(6).	Nevertheless,	 	this	deficiency	only	affects	1/3	of	all	COPD	
cases,	thus	there	has	been	successive	efforts	to	find	other	candidate	genes	that	may	also	be	a	risk	
for	COPD(7).	In	the	last	years,	hundreds	of	studies	were	conducted	in	an	attempt	to	find	genetic	
variants	in	candidate	genes	associated	to	the	disease	pathogenesis,	susceptibility	and	progression.	
However,	these	studies	have	mainly	focus	on	associating	these	variants	with	lung	function	(main	
criteria	 for	 establishing	 COPD	 diagnosis),	 neglecting	 the	 impact	 of	 this	 condition	 on	 patients.	
Patient-reported	outcomes	(PROs)	are	a	set	of	measures	about	patients’	health	status	which	are	
directly	reported	by	the	patient.	They	provide	the	real	perception	of	the	impact	of	the	disease	on	
patients’	 life	and	guide	meaningful	 interventions(8).	Nevertheless,	associations	between	genetic	
variants	 and	 PROs	 have	 been	 poorly	 investigated,	 as	 demonstrated	 in	 our	 systematic	 review	
conducted	 within	 the	 scope	 of	 this	 dissertation	 and	 currently	 under	 consideration	 in	 PLOSone	
(Appendix	 I).	 If	 this	 patient-centered	 information	was	 to	 be	 integrated,	 a	 significant	 knowledge	
advance	would	certainly	be	achieved	on	our	understanding	of	COPD	development,	diagnosis	and	
management.	
Although	significant	number	of	international	studies	have	been	conducted	to	characterise	
the	 genetic	 of	 these	patients,	 in	 Portugal,	 the	 genetics	 of	 COPD	 is	 a	 theme	 yet	 to	 be	decoded.	
Nevertheless,	one	study	has	been	conducted	in	Madeira	Island	to	assess	the	prevalence	of	the	AAT	
genotypes	in	young	males	between	18	and	23	years	old	and	consequently	risk	for	COPD(9).	
Therefore,	this	study	aimed	to	explore	associations	between	specific	genetic	variants	and	
several	clinical	measures,	some	of	which	PROs	of	COPD.	Additionally,	it	was	also	aimed	to	contribute	
with	an	exploratory	study	for	the	genotype	characterisation	of	patients	with	COPD	in	Portugal.	
4	
	
Here,	the	introduction	of	this	dissertation	is	presented	(chapter	1).	Chapter	2	provides	a	
deeper	knowledge	to	the	state	of	the	art	and	is	followed	by	chapter	3	which	describes	the	settings	
where	patients	with	COPD	were	contacted	and	recruited	as	well	as	all	measures	collected	and	the	
laboratorial	 and	 clinical	 procedures	 carried	 out.	 Chapter	 4	 presents	 the	 results	 obtained	 in	 the	
clinical	and	genetic	fields.	Finally,	chapter	5	presents	the	discussion	about	the	results	obtained	and	
chapter	6	the	conclusions	and	future	implications.
		
	
	
	
	
2.	STATE	OF	THE	ART	
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2.1.	Brief	overview	
Chronic	obstructive	pulmonary	disease	(COPD)	is	one	of	the	deadliest	pathologies	worldwide.	
Defined	 by	 the	 Global	 Initiative	 for	 Chronic	 Obstructive	 Lung	 Disease	 (GOLD)	 as	 “common,	
preventable	and	 treatable	disease	 that	 is	 characterized	by	persistent	 respiratory	 symptoms	and	
airflow	limitation”(1),	COPD	accounts	for	3.2	million	deaths	in	2015,	which	represents	an	increase	
of	12%	since	1990	(4).	It	is	currently	estimated	that	the	observed	increase	in	risk	factors	such	as,	
aging	 of	 the	 populations	 (10),	 and	 emissions	 of	 air	 pollutants(11),	 may	 increase	 the	 mortality	
numbers	 to	 6	millions	 deaths	 by	 2020(12).	 In	 Portugal	 this	 disease	 has	 a	 known	 prevalence	 of	
14%(13),	and	killed	2365	people	 in	2013	which	corresponded	to	20,04%	of	all	deaths	caused	by	
respiratory	diseases	in	Portugal(14).	
The	high	prevalence,	mortality	 and	morbidity	of	COPD,	makes	 this	disease	a	major	health,	
economic	and	social	burden.	Worldwide	between	one	and	thirty	thousand	dollars	are	spent	every	
year	per	patient(15).	A	substantial	portion	of	these	expenses	are	due	to	exacerbations,	i.e.,”	acute	
worsening	 of	 respiratory	 symptoms	 that	 results	 in	 additional	 therapy”(1)	 .	 Therefore,	 early	
identification	of	those	at	risk	of	developing	COPD	is	nowadays,	together	with	COPD	diagnosis	and	
management,	a	top	priority	for	research.	
2.2.	Risk	Factors	
The	 risk	 of	 developing	 COPD	 is	 usually	 associated	 to	 an	 interaction	 between	 genetics	 and	
environmental	 factors(1).	 Smoking	 is	 considered	 the	 environmental	 risk	 factor	most	 commonly	
associated	with	COPD(1).	In	fact,	it	has	been	shown	that	cigarette	smokers	usually	present	more	
airflow	 limitations	 and	 other	 abnormalities	 than	 non	 or	 ex-smokers(16).	 However,	 only	 a	 small	
fraction	(20%)	of	smokers	develop	the	disease(7),	which	suggests	that	other	factors	may	be	involved	
and	contribute	to	the	risk	of	developing	COPD.		
Genetic	factors	have	also	been	considered	as	a	risk	for	COPD	such	as		the	deficiency	of	a1-
antytripsine	(AAT)(6).	This	serine	protease	plays	an	important	role	in	the	inhibition	of	the	functions	
of	 neutrophil	 elastase	 in	 the	 lungs,	 but	 polymorphisms	 responsible	 for	 decreasing	 the	
concentrations	of	AAT	 in	plasma	when	combined	with	 risk	 factors	may	 lead	to	emphysema(17).	
Nevertheless,	this	deficiency	only	affects	1-3%	of	all	COPD	cases,	thus	there	has	been	successive	
efforts	to	find	other	candidate	genetic	variants	with	relevance	for	COPD(7).	
Exposure	to	outdoor	and	indoor	air	pollution	is	also	a	risk	factor	to	develop	COPD(7).	It	has	
been	 shown	 that	 exposure	 to	 toxicity	 of	 particles	 from	 outdoor	 air	 may	 play	 a	 heavy	 role	 in	
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increasing	the	number	of	exacerbations	in	patients	with	COPD(18).	Moreover,	the	fact	that	most	
people	spend	more	hours	indoors,	makes	indoor	pollution	(vapours,	fireplaces)	a	higher	risk	factor	
to	develop	COPD(1,	7,	19).	
Other	 risk	 factors	 that	 have	 been	 associated	 to	 COPD	 are	 ageing	 and	 gender,	 asthma,	
infections	 in	 early	 life,	 and	 socioeconomic	 problems(7).	 Figure	 1	 summarises	 the	 identified	 risk	
factors	for	developing	COPD.	
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Figure	1-	Risk	factors	for	developing	Chronic	Obstructive	Pulmonary.	
Disease.	
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	 	2.3.	Chronic	Obstructive	Pulmonary	Disease	and	its	clinical	manifestations	
	 Patients	 with	 COPD	 usually	 present	 symptoms	 as	 cough,	 dyspnoea,	 increased	 sputum	
production	and	wheezing(20).	Cough	may	be	the	only	symptom	present	in	patients	and	also	may	
be	more	prominent	 in	the	morning.	Furthermore,	cough	 is	usually	accompanied	by	sputum	that	
usually	vary	in	amount(21).	Dyspnoea,	which	refers	to	the	sensation	of	breathlessness,	is	one	of	the	
most	important	and	commonly	observed	symptoms	in	patients	with	COPD(22).	This	symptoms	is	
usually	 associated	 with	 limited	 physical	 activity,	 which	 may	 lead	 to	 anxious	 and	 depressive	
behaviours(22).	Wheezing,	 is	usually	described	as	a	noisy	breathing	and	vary	between	days(21).	
Additionally,	since	COPD	shares	risk	factors	with	other	pathologies	may	lead	to	a	coexistence	of	this	
disease	with	other	comorbidities	as	cardiovascular	diseases,	obstructive	sleep	apnoea,	diabetes,	
cachexia	or	osteoporosis,	which	may	lead	to	onset	of	other	symptoms	(23).		
2.4.	Disease	classification	
According	to	GOLD	guidelines(1),	diagnosis	and	assessment	of	the	disease	is	based	on	a	lung	
function	 test,	 usually	 performed	with	 spirometry	which	 assesses	 forced	 expiratory	 volume	 in	 1	
second	 (FEV1)	 and	 forced	 vital	 capacity	 (FVC).	 In	 conjunction	 with	 patients’	 clinical	 history,	
symptoms	and	exposure	to	risk	factors	history	assessment,	a	post-bronchodilator	FEV1/FVC	inferior	
to	0.70	may	represent	a	diagnosis	of	COPD(20).	
In	previous	 versions	of	GOLD	 (1),	 some	 cut-of	 values	 from	 spirometry	 test	were	used	as	 a	
method	 to	assess	 the	 severity	of	airflow	obstruction,	which	has	been	divided	 in	 four	 categories	
(Table	1).		
	
Table	1-Global	Initiative	for	Chronic	Obstructive	Pulmonary	Disease	classification	of	airflow	limitation	
severity.	Adapted	from	[1]	
	 	
GOLD	1	 Mild	 FEV1³80	predicted	
GOLD	2	 Moderate	 50%	£FEV1<80%	predicted	
GOLD	3	 Severe	 30%	£FEV1<50%	predicted	
GOLD	4	 Very	severe	 FEV1<30%	predicted	
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Recently,	 a	 new	 classification	 for	 COPD	 severity	 was	 proposed.	 In	 addition	 to	 the	 GOLD	
classification	of	airflow	severity	previously	referred	(GOLD	1,2,3,4),	this	new	classification	also	takes	
into	 account	 patients-reported	 outcomes	 (PROs),	 i.e.,	 the	 modified	 Medical	 Research	 Council	
Dyspnoea	Scale	(mMRC)	and	COPD	Assessment	test	(CAT).	Thus,	four	new	categories	were	created:	
A	(patients	with	mMRC	between	0	and	1,	CAT	score	<10	and	0	or	1	exacerbation	that	not	lead	to	
hospital	admission),	B	(patients	with	mMRC³2,	CAT³10	and	0	or	1	exacerbation	that	not	lead	to	
hospital	admission),	C	(patients	with	mMRC	between	0	and	1,	CAT<10	and	³2	or	³1	exacerbation	
that	leads	to	hospital	admission)	and	D	(patients	with	mMRC³2,	CAT³10	and	³2	or	³1	exacerbation	
that	leads	to	hospital	admission)	(Figure	2)(1).		
	
	
	
2.5.	Patient-reported	outcomes	
PROs	are	a	set	of	measures	about	patients’	health	status	which	are	directly	reported	by	the	
patient(8).	
Since	the	insertion	of	the	new	ABCD	disease	classification	based	on	PROs,	a	new	attention	and	
importance	has	been	given	to	these	outcomes.	COPD	is	a	heterogeneous	disease,	that	impacts	not	
only	at	a	pulmonary	level,	but	also	at	a	extrapulmonary	level	(e.g.,	muscle	strength,	balance,	quality	
of	 life,	 emotional	 well-being,	 among	 many	 others)(24).	 FEV1	 is	 one	 of	 the	 most	 common	 lung	
function	parameters	to	assess	disease	progression	and	to	evaluate	treatments,	however	FEV1	does	
C	 D	
A	 B	
0<mMRC<1	
CAT<10	
mMRC³2	
CAT³10	
0	
or
	1
	(n
ot
	
le
ad
in
g	
to
	
ho
sp
ita
l	
ad
m
iss
io
n	
		
≥2
	o
r	≥
1	
le
ad
in
g	
to
	
ho
sp
ita
l	
ad
m
iss
io
n	
		
Symptoms	
Ex
ac
er
ba
tio
n	
hi
st
or
y	
Figure	2-The	Global	Initiative	for	Chronic	Obstructive	Lung	Diseases	ABCD	assessment.	Adapted	from	(1).	
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not	correlate	with	changes	in	symptoms,	COPD	comorbidities	or	respective	consequences	that	may	
lead	to	a	decline	in	the	quality	of	life	(24,	25).	Additionally,	patients	with	similar	FEV1	values	may	
have	 different	 experiences	 of	 the	 disease(25).	 Thus,	 the	 inclusion	 of	 PROs	measures	 (PROM)	 is	
fundamental	 to	 assess	 patient’s	 perception	 and	 progression	 of	 the	 disease	 adequately	 and	
consequently	adapt	treatments	according	to	their	specific	needs.		
There	are	already	a	significant	number	of	valid,	reliable	and	responsive	PROM	used	to	assess	
outcomes	of	interest	as	health-related	quality	of	life	(HRQOL),	self-reported	exercise	capacity	and	
frequency	of	exacerbations	among	others.	Additionally,	other	PROs	are	being	proposed	under	the	
scope	 of	 COPD	 which,	 although	 some	 have	 not	 yet	 been	 validated,	 do	 show	 the	 increased	
awareness	for	this	type	of	measurements	to	better	assess	patients	with	this	disease	(Figure	3)(24,	
25).	
	
Figure	3-Commonly	used	patient-reported	outcomes	measures	in	Chronic	Obstructive	Pulmonary	Disease	
and	other	patient-reported	outcomes	used.	Adapted	from	(25).	
	
	
	
Commonly	used	PRO	instruments	 Other	PRO	instruments	
• Health	status	and	HRQOL	
St.	George	Respiratory	Questionnaire	(SGRQ)	
SGRQ	for	COPD	(SGRQC-C)	
Chronic	Respiratory	Disease	Questionnaire	(CRQ)	
Short	Form	Chronic	Respiratory	Disease	
Questionnaire	(SF-CRQ)	
Clinical	COPD	Questionnaire	(CCQ)	
COPD	Assessment	Test	(CAT)	
	
• Symptom	Diary	Measures		
	
EXACT-PRO	and	E-RS	diaries		
Breathlessness,	cough	and	sputum	
	
• Breathlessness/dyspnoea	measures	
	
Baseline	Dyspnea	Index	and	Transition	Dyspnea	
Index	
Medical	Research	Council	(MRC)	
Modified	Medical	Research	Council	(mMRC)	
	
	
	
	
McGill	COPD	Quality	Questionnaire	
Visual	Simplified	Respiratory	Questionnaire	
Dyspnea-12	
Dyspnea	Management	Questionnaire	Computer	
Adaptative	Test	
Shortness	of	Breath	with	Daily	Activities	
questionnaire	
Global	Chest	Symptoms	Questionnaire	
Capacity	of	Daily	Living	during	the	Morning	
questionnaire		
Living	with	COPD	questionnaire		
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2.6.	Genetics	of	Chronic	Obstructive	Pulmonary	Disease	
COPD	is	a	multifactorial	disease,	caused	by	an	association	of	alleles	found	in	multiple	genes,	
environmental	 factors	 and	 interactions	 between	 these	 two	 factors.	 Since	 the	 discovery	 of	 AAT	
variants	(more	than	57	years	ago)	as	a	risk	factor	for	COPD,	the	role	of	genetics	has	gained	a	new	
attention	to	understand	the	onset	and	evolution	of	this	disease(26).	
In	the	last	years,	hundreds	of	studies	were	performed	in	an	attempt	to	find	genetic	variants	in	
candidate	genes	associated	to	the	disease	pathogenesis,	susceptibility	and	progression.		
Single	nucleotide	polymorphisms	(SNPs)	are	the	exchange	of	single	bases	at	specific	positions	
and	are	one	of	the	genetic	variants	most	common	and	studied	relative	to	any	pathology.	In	fact,	
more	 than	 four	hundred	SNPs	 in	 two	hundred	genes	were	already	associated	with	COPD	 in	 the	
literature,	 in	 different	 genome-wide	 association	 studies	 (GWAS)	 (for	 further	 information,	 see	
genetic	variants	table	in	Appendix	II).	Additionally,	with	the	appearance	of	DNA	genotyping	arrays,	
these	genetic	variants	may	be	measured	more	economically	and	in	greater	quantity.	An	array	is	a	
container	 object	 that	 may	 be	 composed	 of	 thousands	 of	 specific	 short	 fragments	 of	 DNA	
(oligonucleotides)	 which	 hybridize	 with	 sequences	 of	 target	 DNA	 being	 analysed,	 allowing	 to	
genotype	thousands	of	SNPs	simultaneously	in	different	patients(27).	
Despite	all	this	progress,	there	are	still	several	problems	associated	with	the	genetics	of	this	
disease.	 First,	 controversial	 results	 were	 being	 obtained	 among	 studies	 investigating	 the	 same	
specific	 genetic	 variant(28).	 This	 may	 be	 explained	 by	 the	 different	 populations	 from	 different	
ethnicities	being	studied,	use	of	small	sample	sizes	or	different	environments	among	populations	
(29,	 30).	 Second,	 all	 the	 efforts	 of	 the	 genetic	 studies	 have	 been	 concentrated	 on	 finding	
associations	between	specific	genetic	variants	with	lung	function	or	with	smoking	to	enhance	our	
understanding	of	 the	susceptibility	 to	 the	disease(6).	However,	 the	association	between	genetic	
variants	 and	 other	 important	 outcomes	 such	 as	 PROs,	 which	 provide	 the	 real	 impact	 and	
progression	of	the	disease	via	patients’	perception	have	been	poorly	investigated.	This	has	been	
the	theme	of	our	systematic	review	currently	under	consideration	in	PLOSone,	which	demonstrates	
the	exiguity	of	data	relating	genetic	factors	with	PROs	in	COPD	(Appendix	I).		
Therefore,	research	is	needed	at	a	worldwide	level	to	integrate	all	the	important	information	
provided	and	to	enhance	our	understanding	on	COPD	development,	diagnosis	and	management.	In	
Portugal,	the	genetics	of	COPD	is	a	theme	yet	to	be	decoded,	since	only	one	study	was	conducted	
in	Madeira	Island	to	assess	the	prevalence	of	the	AAT	genotypes	in	young	males	between	18	and	
23	years	old	and	consequently	risk	for	COPD(9).	
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2.7.	Patient-reported	outcomes	and	genetics	
COPD	is	without	doubts	a	complex	and	heterogeneous	disease,	with	different	morphological	
manifestations,	different	comorbidities,	that	may	impact	differently	on	patients	at	similar	grades	
and	may	have	implications	for	disease	progression	and	management(31).	Thus,	personalized	and	
tailored	interventions	are	needed	for	these	patients	based	not	only	on	patients	attributes,	but	also	
on	biomarkers	and	other	variables(32).	
In	the	last	years,	it	has	become	more	evident	that	there	is	a	strong	association	between	PROs	
and	genetics	at	different	fields(33,	34).	PROs	are	important	mainly	to	assess	conditions	that	only	
patients	may	report	as	pain,	 fatigue,	depression	or	anxiety	however,	 they	are	also	 important	 to	
understand	 the	 biological	 pathways	 associated	 with	 this	 condition(32).	 In	 the	 respiratory	 field,	
more	 precisely	 in	 lung	 cancer,	 associations	 between	 PROs	 and	 specific	 genetic	 variations	 have	
already	been	demonstrated	(35).	Thus,	by	knowing	which	genetic	variant	is	associated	with	each	
PRO,	professionals	will	be	able	to	identify	patients	genotype	that	makes	them	more	susceptible	to	
a	PRO.	With	this	information,	tailored	intervention	may	be	applied,	which	can	contribute	positively	
for	increasing	patients’	quality	of	life	and	behavioural	changes,	resulting	in	a	significant	reduction	
in	health	care	system	expenditures	(32).	
2.8.	Objectives	
The	 main	 goal	 of	 this	 masters’	 dissertation	 was	 to	 explore	 associations	 between	 specific	
genetic	variants	and	several	clinical	measures	some	of	which	PROs	in	patients	with	COPD.	This	will	
allow	a	better	understanding	of	the	susceptibility	of	these	patients	to	the	PROs	deficits,	predict	the	
disease	progression	and	later	inform	the	development	of	tailored	interventions.	Additionally,	this	
dissertation	 also	 aimed	 to	 contribute	 for	 the	 genetic	 characterisation	 of	 patients	with	 COPD	 in	
Portugal,	since	this	theme	is	still	poorly	explored.
	
		
	
	
	
3.	METHODS	
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This	study	is	part	of	a	larger	study	entitle	“GENIAL	–	Marcadores	genéticos	e	clínicos	na	trajetória	
da	DPOC”,	funded	by	Programa	Operacional	de	Competitividade	e	Internacionalização	-	COMPETE,	
through	 Fundo	 Europeu	 de	 Desenvolvimento	 Regional	 -	 FEDER	 (POCI-01-0145-FEDER-016701),	
Fundação	 para	 a	 Ciência	 e	 Tecnologia	 (PTDC/DTPPIC/2284/2014)	 and	 under	 the	 project	
UID/BIM/04501/2013.		
3.1.	Ethics	
Ethical	approval	was	previously	obtained	from	Administração	Regional	de	Saúde	Centro	(ARS-
Centro)	 (64/2016),	 from	 Centro	 Hospitalar	 do	 Baixo	 Vouga	 (CHBV)	 (08-03-17),	 Hospital	 Pedro	
Hispano	 (10/CE/JAS)	 and	Hospital	 Distrital	 da	 Figueira	 da	 Foz.	 Documents	may	 be	 consulted	 at	
Annex	I.	Prior	to	any	data	collection,	written	informed	consents	were	collected	from	patients.	
3.2.	Design	and	Participants	
A	cross-sectional	study	was	conducted	in	the	north	and	center	region	of	Portugal.	Hospitals	
and	Primary	Care	Centres	of	Baixo	Vouga	and	Baixo	Mondego,	Hospital	Pedro	Hispano	and	Hospital	
Distrital	 da	 Figueira	 da	 Foz	 were	 contacted,	 from	 which	 three	 hospitals	 and	 two	 primary	 care	
centres	accepted	to	participate.	Patients	were	eligible	if	i)	diagnosed	with	COPD	according	to	GOLD	
criteria(1)	ii)	presented	in	a	stable	state,	i.e.,	no	acute	exacerbations	in	the	previous	month,	iii)	were	
able	 to	 give	 informed	 consent.	 Exclusion	 criteria	 were	 the	 presence	 of	 severe	 cardiac,	
musculoskeletal	 or	 neuromuscular	 diseases,	 cognitive	 impairment	 or	 a	 history	 of	 neoplasia	 or	
immune	 disease	 that	 would	 interfere	 with	 patients’	 collaboration	 in	 data	 collection	 or	
interpretation.	 Patients	 with	 COPD	 were	 recruited	 from	 the	 emergency	 and	 internal	 medicine	
services	 of	 the	 Centro	Hospitalar	 do	 Baixo	 Vouga,	 Hospital	 Pedro	Hispano,	 Hospital	 Distrital	 da	
Figueira	da	Foz	or	by	contacting	patients	previously	 informed	by	the	referred	institutions.	 In	the	
hospital	services,	the	physician	informed	each	potential	participant	about	the	study.	Only	patients	
that	 showed	 interest	 to	 participate	 were	 approached	 by	 the	 researcher	 to	 provide	 more	
information	 about	 the	 study	 and	 ask	 about	 their	 willingness	 to	 participate.	 Patients	 recruited	
through	telephone	calls	were	informed	about	the	study	and	if	they	agreed	to	participate,	they	were	
integrated	as	stable	patients	with	COPD	(stCOPD).		
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3.3.	Measures	
A	structured	questionnaire	was	first	used	to	collect	socio-demographic	(name,	gender,	date	of	
birth,	 address,	 academic	 qualifications,	marital	 status	 and	 occupation),	 anthropometric	 (height,	
weight,	 percentage	 of	 body	 fat	 and	 body	 mass	 index	 [BMI])	 and	 clinical	 (smoking	 habits,	
comorbidities,	medication,	home	oxygen	or	ventilation	supplies,	dyspnoea,	hospital	admission	in	
the	past	3	months/year,	exacerbations	in	the	past	year	and	physical	activity	levels)	data	in	order	to	
characterise	the	population.	This	questionnaire	was	followed	by	several	other	measures	that	are	
described	below.	
Dyspnoea.	 This	 parameter	 was	 assessed	 using	 mMRC,	 a	 reliable,	 valid	 and	 responsive	
questionnaire	 to	assess	activity	 limitations	due	 to	dyspnoea	 in	patients	with	chronic	 respiratory	
diseases,	namely	COPD(36,	37).		It	is	composed	of	5	statements	on	a	scale	from	0	to	4,	with	higher	
scores	indicating	higher	respiratory	limitation(38).		
Dyspnoea	and	fatigue.	The	modified	Borg	scale	is	a	valid,	reliable(39)	and	commonly	used	tool	
to	assess	dyspnoea	and	fatigue	at	rest	in	patients	with	COPD(40,	41).	This	is	a	0	to	10	rated	scale,	
where	 the	 patient	 points	 his/her	 perception	 of	 dyspnoea/fatigue(42).	 The	modified	 Borg	 scale	
allows	a	score	interpretation,	in	which	0	corresponds	to	an	absence	of	dyspnoea	or	fatigue	and	10	
corresponds	 to	 patient’s	 maximum	 sensation	 of	 dyspnoea/fatigue,	 existing	 also	 intermediate	
options	according	to	patients’	perception	of	the	symptoms(43).	
Anxiety	and	depression.	These	parameters	were	assessed	using	the	Portuguese	version	of	the	
Hospital	Anxiety	and	Depression	Scale	(HADS)(44).	This	is	reported	as	a	valid	and	reliable	instrument		
and	 is	 commonly	 used	 in	 patients	 with	 COPD(45,	 46).	 This	 scale	 contains	 14	 questions,	 seven	
questions	measuring	 symptoms	 of	 anxiety	 (HADS-A)	 and	 7	measuring	 symptoms	 of	 depression	
(HADS-D).	 Each	 question	 has	 four	 possible	 answers	 ranged	 from	 0	 to	 3,	 so	 the	 possible	 scores	
ranged	from	0	(patient	has	no	depression	or	anxiety)	to	21	(maximum	depression/anxiety	reported	
by	 the	 patient).	 Scores	 inferior	 to	 8	were	 considered	 “normal	 values”,	 between	 8	 and	 10	were	
interpreted	as	“mild	values”,	between	11	and	14	as	“moderate	values”	and	between	15	and	21	as	
“severe	values”	of	anxiety	and	depression	symptoms(44).	
Impact	of	COPD.	To	assess	the	disease	impact	on	well-being	and	daily	life	of	participants,	the	
CAT	was	used(47).	This	is	a	simple,	reliable,	responsiveness	and	validated	test	in	COPD(47,	48).	This	
scale	is	composed	of	8	questions	with	6	options	each	numbered	from	0	to	5	with	a	maximum	score	
of	40,	that	intends	to	explore	the	impact	of	COPD	on	patient’s	health	status,	mainly	daily	symptoms	
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and	other	manifestations	of	the	disease(49).	Higher	scores	indicate	higher	impact	of	the	disease	on	
patients’	life.		
Health-related	Quality	of	life.	St.	George	Respiratory	Questionnaire	(SGRQ)(50)	was	used	to		
assess	 health-related	 quality	 of	 life	 in	 patients	 with	 COPD.	 This	 tool	 is	 validated	 and	 has	 been	
consistently	 used	 in	 patients	 with	 COPD	 (51-53).	 It	 is	 composed	 of	 76	 items	 divided	 in	 three	
domains,	which	measure	symptoms,	the	impact	of	disease	and	the	activity	limitations.	The	score	
ranges	from	0	to	100,	with	higher	scores	indicating	poor	health-related	quality	of	life	(54).			
Vital	signs	and	oxygen	saturation.	In	order	to	establish	a	baseline	and	monitor	the	patient,	
both	vital	signs	and	oxygen	saturation	(SpO2%)	were	initially	assessed.	Blood	pressure	was	verified	
using	a	portable	automatic	sphygmomanometer	which	also	provided	the	heart	rate	(Medel	Elite,	
S.Polo	di	Torrile,	Italy),	SpO2%	was	monitored	using	a	pulse	oximeter	(Konica	Minolta,	Pulsox-300i,	
United	Kingdom),	and	the	respiratory	rate	was	assessed	using	a	stopwatch	to	monitor	the	number	
of	respiratory	cycles	taken	in		one	minute.	
Lung	 function.	 This	was	 assessed	 by	 spirometry	 (MicroLab	 3500,	 CareFusion,	 Kent,	 United	
Kingdom),	a	simple	and	non-invasive	test	that	may	identify	the	presence	of	obstructive	respiratory	
abnormalities(55).	 It	 is	 valid,	 reliable	 and	 commonly	 used	 in	 the	 COPD	 population(56).	 It	 was	
performed	according	to	the	current	guidelines(57).		
Peripheral	 muscle	 strength.	Muscle	 dysfunction	 and	 poor	 exercise	 capacity	 is	 one	 of	 the	
biggest	concerns	 in	COPD(58).	For	 that	 reason,	quadriceps	muscle	strength	was	assessed	with	a	
hand-held	 dynamometer	 (Hoggan	 MicroFET2	 Muscle	 Tester,	 Model	 7477,	 Pro	 Med	 Products,	
Atlanta,	GA).	This	test,	previously	used	in	patient	with	COPD	(59),	is	valid	and	reliable(60)	to	assess	
lower-extremity	muscle	strength	in	older	adults,	similar	to	the	study	population.	Additionally,	the	
isometric	handgrip	force	was	measured	with	a	hydraulic-hand	dynamometer	(Model	12-0241	Lite,	
Fabrication	Enterprises	 Inc.,	White	Plains,	NY,	USA).	This	 is	a	valid	measurement	of	mobility	and	
quality	of	life	in	patients(61).		
Respiratory	muscle	strength.	Measurement	of	static	maximum	inspiratory	pressure	(MIP)	and	
maximum	expiratory	(MEP)	pressures	are	commonly	performed	in	patients	with	COPD	(62,	63)	to	
assess	 inspiratory/expiratory	 muscle	 strength,	 since	 respiratory	 (specially	 inspiratory)	 muscle	
function	is	frequently	altered	in	these	patients(62).	MIP	and	MEP	were	assessed	using	respiratory	
pressure	gauge	(MicroRPM,	CareFusion,	Kent,	United	Kingdom).	
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Functional	capacity.	Five	times	sit-to-stand	test	(5STS)	and	1-minute	sit-to-stand	(STS)	were	
used	 to	assess	 functional	 capacity.	5STS	and	STS	 test	are	a	 reliable,	valid	and	 responsive	 test	 in	
patients	with	COPD.	Both	tests	are	commonly	used	in	COPD	patients	to	determine	functional	state	
with	 less	 stress	 for	 the	 patient	 comparing	 with	 other	 tests	 as	 the	 6	 minutes	 walking	 test	 for	
example(64).		
Genetic.	 	Oropharyngeal	 swabs	and	 falcons	were	used	to	collect	buccal	detached	cells	and	
saliva	respectively.		
3.4.	Procedures	
Assessment	sessions	took	place	at	the	School	of	Health	Sciences,	University	of	Aveiro	(ESSUA)	
in	 the	 Respiratory	 Research	 and	 Rehabilitation	 Laboratory	 (Lab3R),	 participating	 hospitals	 or	 at	
patient’s	home.	Initially,	a	brief	description	of	the	study	purpose	was	provided	by	the	researcher	
and	time	was	given	for	the	participant	to	read	the	information	sheet,	clarify	any	doubts	and	sign	
the	 informed	 consent.	 Then,	 a	 code	 was	 assigned	 to	 each	 participant,	 to	 guarantee	 the	
confidentiality	of	the	participation,	and	socio-demographic,	anthropometric	and	clinical	data	were	
collected	to	characterise	the	population.	Sequentially,	questionnaires	were	completed	according	to	
the	guidelines	and	always	under	supervision	of	the	researcher.		
Vital	 signs	and	SpO2	were	measured	and	dyspnoea/fatigue	were	quantified	using	modified	
Borg	scale	and	mMRC.		
Participant’s	 lung	 function	was	then	assessed	 (57),	and	the	most	 frequently	measurements	
considered	in	spirometry:	FVC,	FEV1	and	FEV1/FVC	ratio	were	registered(55).	
Quadriceps	muscle	strength	was	assessed	based	on	O’shea	protocol	(59),	where	patients	were	
asked	to	sit	on	a	chair	with	the	knee	flexed	70°.	The	hand-held	dynamometer	was	placed	in	the	
anterior	tibia	region,	5	cm	above	the	lateral	malleolus	from	the	dominant	lower	limb	and	the	patient	
was	instructed	to	stretch	the	knee	over	a	4-second	period	against	the	resistance	applied	(Figure	4).	
This	process	was	repeated	3	times	with	a	recovery	period	of	30	seconds	to	avoid	fatigue	and	the	
best	result	was	recorded(59).	
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Additionally,	 the	 isometric	 handgrip	 force	 was	 also	 assessed	 according	 to	 international	
recommendations(65).Strength	was	assessed	at	 the	dominant	hand	with	 the	elbow	90º	 flexion.	
Three	attempts	were	performed	and	the	highest	value	was	taken.	
Respiratory	muscle	 strength	 assessment	was	 performed	 as	 previously	 described	 (62),	with	
some	minor	alterations.	In	a	first	step,	all	the	procedure	was	demonstrated	to	the	patient	using	a	
spare	mouthpiece.	Starting	with	MIP,	firstly	patients	were	instructed	to	sit	on	a	chair	in	the	upright	
position.	 Then	a	nasal	 clip	was	placed	 in	patients’	nose	 to	guarantee	 that	 there	was	no	air	 lost	
through	the	nasal	passages.	After	this,	with	the	mouth	out	of	the	rubber	buccal,	patients	were	asked	
to	expire	as	slowly	as	possible	and	when	there	was	no	more	air	to	expire,	patients	were	instructed	
to	put	their	mouth	in	the	buccal	and	inspire	as	fast	and	intense	as	possible.	MEP	was	exactly	the	
reverse	process.	Once	again	with	a	nasal	clip	in	patients’	nose,	they	were	asked	to	inspire	in	a	slow	
and	relaxed	way	with	the	mouth	outside	of	 the	buccal.	When	there	was	no	more	air	 to	 inspire,	
patients	were	instructed	to	put	the	buccal	in	the	mouth	and	to	expire	as	fast	as	possible	(Figure	5).	
For	both	cases,	three	trials	were	performed	with	rest	periods	of	30	seconds	between	trials.	The	best	
MIP	and	MEP	values	from	the	three	trials	were	registered.	
Figure	 4-	 Test	 of	 quadriceps	 muscle	 strength	 using	
hand-held	dynamometer.	
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Functional	muscle	strength	was	then	assessed	with	the	5STS	and	1	minute	STS	(66).	Patients	
were	asked	to	sit	on	a	chair	(floor	to	seat	height	48	cm)	well	stabilized	against	the	wall	and	with	
upper	limbs	across	the	chest	and	knees	and	hips	flexed	to	90°.	Then	patients	were	asked	to	stand	
up	and	sit	down	5	times	as	fast	as	possible	with	the	arms	crossed	on	their	chest.	The	duration	of	
each	test	was	timed	with	a	stopwatch,	that	started	on	the	command	“go”,	and	stopped	at	the	fifth	
sit-to-stand	repetition.	1	minute	STS	was	performed	as	reported	for	5STS	but	with	the	arms	along	
the	body,	and	in	this	test	the	stopwatch	started	on	the	command	“go”,	the	patient	performed	the	
manoeuvre	sit-to-stand-to-sit	as	fast	as	possible	for	1	minute.		Time	for	rest	was	provided	between	
repetitions	and	tests	to	restore	basal	vital	signs,	SpO2%,	dyspnoea	and	fatigue	values	according	to	
participant’s	need	in	both	tests.	
Oropharyngeal	swabs	and	falcons	with	saliva	were	collected	from	each	participant	in	order	to	
extract	 DNA	 for	 genetic	 analysis.	 For	 both	 cases,	 specific	 precautions	 were	 taken	 during	 this	
procedure	to	avoid	contamination	of	the	samples.		Patients	were	advised	to	avoid	ingestion	of	any	
acidic	substances,	aliments	rich	in	sugar	or	in	caffeine,	before	data	collection	since	these	can	cause	
changes	in	the	saliva	pH	and	lead	to	increased	bacterial	development.	Patients	were	also	advised	
to	mouthwash	with	water	10	minutes	before	the	sample	collection	to	minimise	the	presence	of	
food	particles	and	any	modification	in	saliva	pH(67).	Additional	care	was	taken	to	avoid	the	swab	
touching	in	any	other	surface	other	than	the	patient’s	mouth,	to	prevent	any	contamination.	Swabs	
were	scrapped	inside	the	participant’s	mouth	during	30	seconds	with	rotational	movements,	taking	
into	account	 the	care	referred	above(67)	and	patients	were	asked	to	spit	several	 times	 into	the	
Figure	5-	 Initial	position	of	the	maximal	 inspiratory/expiratory	
pressure.	
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falcons	 during	 the	 entire	 protocol.	 Once	 finished	 the	 collection,	 the	 swabs	 and	 falcons	 were	
properly	 labelled,	 transported	 in	 portable	 freezers	 to	 the	 Institute	 for	 Research	 in	 Biomedicine	
(iBiMED)	where	were	preserved	in	freezers	at	-80ºC.		
	
3.5.	Data	analysis	
3.5.1.	Sample	analysis	
3.5.1.1	DNA	extraction		
Prior	 to	manipulation,	 samples	were	unfrozen	 at	 room	 temperature.	 Total	DNA	was	
extracted	 using	 QIAamp	 DNA	mini	 kit	 (Qiagen,	 Hilden,	 Germany)	 following	 the	manufacturer’s	
instructions,	with	slight	modifications.		
Before	 the	 beginning	 of	 the	 extraction,	 all	 samples	 and	 reagents	 were	 at	 room	
temperature.	First,	20	μl	of	Qiagen	proteinase	K	was	pipetted	into	two	1.5	ml	microtubes.	Then	200	
μl	of	saliva	was	added	followed	by	200	μl	of	buffer	AL	to	lysis	cells.	To	ensure	an	efficient	lysis,	both	
microtubes	with	the	samples	and	buffer	AL	were	mixed	by	vortexing	for	30	seconds	and	incubated	
at	56	°C	for	10	minutes.	After	incubation,	samples	were	briefly	spinned	to	remove	drops	produced	
by	 the	 condensation.	 In	 order	 to	 precipitate	DNA,	 200	μl	 of	 100%	ethanol	were	 added	 to	both	
microtubes	followed	by	a	15	seconds	vortexing	and	spinning	to	remove	droplets.	Afterwards,	the	
mixture	of	both	microtubes	was	carefully	applied	in	a	QIAamp	Mini	spin	column.	The	column	was	
washed	with	both	washing	buffers:	AW1	and	AW2.	Finally,	the	DNA	was	eluted	with	200	μl	of	milli	
Q	water,	incubated	at	room	temperature	(15-25	°C)	for	10	minutes	to	assure	a	efficient	elution	and	
the	final	extract	was	obtained	by	centrifugation	at	6000	g	for	1	minute.	All	samples	were	stored	at	
-20	°C.	
	
3.5.1.2.	DNA	quantification	
The	concentration	of	DNA	samples	was	measured	by	two	methods,	absorbance	and	a	
fluorimetric	 method.	 Absorbance	 measurements	 were	 performed	 using	 Denovix	 DS-11	 FX+	
spectrophotometer.	1	μl	of	mili	Q	water	was	used	as	a	blank.	The	same	volume	of	sample	used	to	
obtain	concentration	and	absorbance	ratios	values	(A260/A280	and	A260/A230).		
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To	 ensure	 an	 accurate	 quantification	 process,	 the	 amount	 of	 recovered	 DNA	 was	
quantified	by	using	a	Qubit	dsDNA	BR	assay	kit	(Life	technologies),	a	fluorimetric	method,	according	
to	 the	manufacturer’s	 instructions	 (Life	 technologies	Cat#	Q32850,	Q32853).	First,	 to	obtain	 the	
optimal	performance	of	the	reagents,	these	were	placed	at	room	temperature	before	the	beginning	
of	the	process.	Qubit	working	solution	was	prepared	by	diluting	1	μl	of	Qubit	dsDNA	BR	reagent	in	
199	μl	of	Qubit	dsDNA	BR	buffer	for	each	sample/standard.	Each	standard	and	sample	requires	190	
μl	and	199	μl	of	Qubit	working	solution	respectively	so,	enough	Qubit	working	solution	must	be	
prepared	for	2	standards	and	the	number	of	samples	to	be	analysed.	
To	prepare	the	two	standards,	190	μl	of	Qubit	working	solution	was	added	to	each	tube.	
Then	10	μl	of	each	Qubit	standard	was	added	to	both	tubes	followed	by	a	vortex	during	3	seconds.	
This	process	was	carefully	conducted	to	prevent	 the	creation	of	bubbles	 that	may	 influence	the	
process.	
Each	 sample	was	 prepared	 adding	 199	 μl	 of	Qubit	working	 solution	 and	 1	 μl	 of	 the	
previously	 vortexed	 sample.	 Both	 tubes	 (samples)	were	 vortexed	 by	 3	 seconds,	 and	 then	were	
incubated	 at	 room	 temperature	 for	 2	 minutes	 to	 allow	 the	 Qubit	 assay	 to	 reach	 optimal	
fluorescence.		
The	Broad	Range	Assay	programme	was	chosen	and	reading	process	started	with	Qubit	
fluorometer	calibration.	In	this	phase	standard	1	and	standard	2	were	read	and	a	line	corresponding	
to	the	curve-fitting	algorithm	was	constructed.	Then,	each	sample	was	read	and	the	corresponding	
yields	values	were	registered.		
	
3.5.1.3.	DNA	integrity	
In	order	 to	assess	 the	DNA	samples	 integrity	and	degradation,	a	1%	agarose	gel	was	
conducted	based	on	Lee	et	al(68).		
In	a	first	step	0.5	g	of	agarose	was	placed	in	a	flask	containing	50	ml	of	TAE	1×	running	
buffer.	Then,	to	dissolve	the	mixture	was	heated	until	the	agarose	was	totally	dissolved.	To	detect	
nucleic	acids	in	the	agarose	gel,	3	μl	of	GreenSafe	Premium	was	added	to	mixture.	This	nucleic	acid	
stain	emits	green	fluorescence(68)	when	bounded	to	DNA.	Finally,	the	agarose	gel	was	placed	to	
cool	during	10	minutes	before	being	placed	in	the	gel	tray	previously	levelled.	
In	order	to	allow	a	visual	tracking	of	DNA	migration	during	electrophoresis,	loading	dye	
6×	was	added	to	the	samples.	Running	buffer	TAE	1×	was	added	until	the	surface	of	the	gel	was	
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covered	and	the	loading	process	was	ready	to	be	started.	The	first	well	was	carefully	loaded	with	
GeneRuler	1kb	DNA	Ladder,	which	is	composed	of	DNA	fragments	ranging	from	250	to	10	000	bp	
to	allow	for	DNA	sizing.	Samples	were	slowly	loaded	in	the	other	wells.	
With	the	sample	loading	process	completed,	the	lid	was	closed	and	the	leads	of	the	gel	
box	were	attached	to	the	power	supply	programmed	with	a	voltage	of	120	V	and	the	gel	was	run	
for	30	minutes.	
Images	 of	 the	 final	 gel	 were	 obtained	 using	 a	 GelDoc	 XR+	 Imaging	 System	 (Bio-Rad	
Laboratories,	Hercules,	CA).	
	
3.5.1.4.	DNA	samples	SpeedVac	
DNA	 samples	 extracted	 were	 concentrated	 in	 a	 speed	 vacuum	 (ScanSpeed	 MaxiVac,	
Labogene,	Denmark),in	order	 to	achieve	 the	concentration	values	 requested	 for	 the	genotyping	
analysis	institute	(minimum	sample	concentration	of	60	ng/μl;	A260/280	ratio	between	1.8	and	2;	
A260/230	ratio	between	1.7	and	2).	Each	sample	was	placed	on	the	speed	vacuum	rotor	in	counter	
balanced	positions	with	the	lid	open.	Then,	the	rotor	was	programmed	for	30	minutes.	Temperature	
and	rotation	led	to	water	evaporation	resulting	in	a	 less	diluted	DNA.	However,	to	avoid	sample	
degradation,	at	the	end	of	30	minutes,	samples	were	placed	on	ice	for	10	minutes,	and	then	the	
process	was	repeated.	Finally,	DNA	concentration	and	A260/280;	A260/230	ratios	were	measured	
using	DenoVix	D-11.		
	
3.5.1.5.	Array	genotyping	
To	 provide	 a	 comprehensive	 understanding	 of	 which	 specific	 genetic	 variants	 were	
significantly	associated	with	PROs,	a	systematic	review	was	conducted	(Appendix	I).	Additionally,	it	
was	important	to	find	all	the	genetic	variants	associated	with	COPD	in	the	literature	and	whether	
of	these	may	also	be	associated	with	PROs	.	Thus,	a	targeted	gene	sequencing	panel	(Appendix	II)	
was	constructed	based	on	a	databases	review.	
Since	the	DNA	microarray	technology	is	not	yet	available	at	iBiMED,	we	decided	to	use	
the	Infinium	Global	Screening	Array-24	v1.0	from	Illumina	(Illumina,	San	Diego,	CA,	USA).	This	is	an	
array	mainly	used	for	population	studies	where	genotyping	is	required	and,	therefore,	is	expected	
to	 produce	 a	 good	 genetic	 stratification	 of	 our	 patients,	 that	 can	 be	 later	 connected	 to	 COPD	
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outcomes.	To	run	these	samples,	we	have	chosen	the	laboratory	of	Life	&	Brain	GmbH	institute,	
Germany.	This	laboratory	has	plenty	experience	on	the	array	and	has	been	recommended	by	the	
Illumina	dealer	in	Portugal	(ILC,	Portugal).	
According	 to	 the	 respective	 literature,	 Infinium	Global	Screening	array	was	based	on	
Illumina	 Infinium	HTS	Assay	protocol,	which	 is	composed	of	nine	steps:	1)	DNA	amplification;	2)	
DNA	incubation;	3)	DNA	fragmentation;	4)	DNA	precipitation;	5)	DNA	resuspension;	6)	Hybridiation	
to	BeadChip;	7)	BeadChip	washing;	8)	Extend	and	stain	the	BeadChip	and	9)	Image	BeadChip.	In	the	
first	 stage,	 samples	were	denaturated	with	 sodium	hydroxide	 and	neutralized	with	 the	 reagent	
“Multi-amplification	2	mix”,	followed	by	an	incubation	(step	2)	with	a	time	range	of	20/24	hours	at	
37ºC.	In	this	step,	genomic	DNA	was	amplified,	resulting	in	a	sufficient	quantity	of	DNA	to	the	entire	
process.	 Then,	 an	 enzymatic-based	 fragmentation	 occurred	 using	 a	 fragmentation	 solution.	 To	
avoid	 an	 excess	 of	 fragmentation,	 an	 end-point	 was	 used.	 	 DNA	 was	 then	 precipitated	 with	
isopropanol.	 DNA	 is	 less	 soluble	 in	 solutions	 with	 isopropanol,	 facilitating	 the	 precipitation	
process(69).	 Finally,	 samples	 were	 resuspended	 in	 hybridization	 and	 washing	 buffer	 (step	 6),	
genomic	DNA	was	dispensed	onto	BeadChips.	The	loaded	BeadChip	was	incubated	overnight	until	
efficient	 annealing.	 In	 the	 next	 phase,	 the	 BeadChip	was	washed	 to	 remove	 non-connected	 or	
unhybridized	primers	(step	7)	and	was	prepared	to	be	stained	and	extended	(step	8).	In	this	last	
step,	detectable	labels	were	incorporated	on	the	BeadChip.	Finally,	with	the	micro-array	Hi-scan,	a	
laser	was	used	to	excite	the	fluorophore,	and	to	read	the	different	colours,	according	to	the	probe.	
All	 information	was	provided	as	files	from	the	GenomeStudio	software	(Illumina,	San	
Diego,	 CA,	 USA),	 which	 included	 all	 the	 basic	 information	 about	 the	 genotyping	 conditions	
(replication	errors,	call	frequencies)	and	the	genotypes	and	genotypes	frequencies	for	each	SNP	for	
all	the	population.	
	
3.5.2.	Statistical	analysis	
A	code	was	attributed	to	each	participant	and	data	was	analyzed	anonymously.		
Data	was	analyzed	using	IBM	Statistics	version	23	(SPSS	Inc.,	Chicago,	Illinois,	IL).	Descriptive	
statistics	was	used	 to	describe	 socio-demographic	 and	 clinical	 outcomes.	Continuous	data	 (age,	
spirometry	test,	MIP/MEP,	quadriceps	muscle	strength,	handgrip,	and	5STS)	was	described	as	mean	
±	standard	deviation,	ordinal	data	(frequency	of	exacerbations,	mMRC,	dyspnoea	and	fatigue	scores	
from	Borg	scale,	anxiety	and	depression	scores	from	HADS,	CAT	scores	and	1	minute	STS	results)	
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was	described	as	median	and	interquartile	range	and	categorical	data	(gender,	Gold	classification	
and	smoking	status)	was	described	as	percentages	and	frequencies.		
One-way	 ANOVA	 test	 was	 used	 to	 compare	 mean	 values	 of	 continuous	 measures	
(spirometry,	 SGRQ,	 MIP,	 MEP,	 quadriceps	 muscle	 strength,	 handgrip	 muscle	 strength,	 5STS)	
between	genotypes	of	each	SNP	assessed.	When	significant	differences	were	obtained,	Bonferroni	
correction	test	was	used	for	multiple	comparisons	with	a	level	of	significance	of	p<0.05.	
Kruskal	Wallis	non-parametric	test	was	used	to	compare	ordinal/categorical	non-normally	
distributed	data	among	groups	(frequency	of	exacerbations,	mMRC,	Borg	scale,	HADS,	CAT	and	1	
minute	 STS).	 When	 significant	 differences	 were	 verified,	 Mann-Whitney	 U	 test	 was	 used	 for	
multiple	 comparisons.	 Bonferroni	 corrections	 were	 applied	 for	 the	 number	 of	 comparisons	
performed	per	SNP	(i.e.,	3	comparisons)	between	outcomes.	Thus,	the	level	of	significance	was	set	at	
0.017. 
Genotypes	 characteristics	 (genotype	 frequencies,	 call	 frequencies	 and	 number	 of	 calls)	
were	 assessed	 using	 GenomeStudio	 software	 (Illumina,	 San	 Diego,	 CA,	 USA)	 and	 graphs	 were	
plotted	in	GraphPad	Prism	5	(GraphPad	Software,	La	Jolla,	CA,	USA).	
	
		
	
	
	
4.	RESULTS	
________________________________________
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4.1.	Sample	recruitment	
Eighty-two	patients	with	COPD	from	five	institutions	were	included	in	the	study.	Twenty-two	
patients	were	excluded	due	to	sample	impurities	(e.g.,	food	particles,	excess	of	sputum,	lipstick)	
and	consequent	difficulties	in	DNA	extraction.	A	total	of	sixty	patients	with	COPD	were	enrolled	in	
this	study	(Figure	6).	
	
4.2.	Sample	characterization	
Patients	were	mostly	male	(n=52)	and	ex-smokers	(n=42)	with	a	mean	age	of	67.87	(±	8.59)	
years	old.	Eleven	patients	were	classified	as	GOLD	A,	 twenty-two	as	GOLD	B,	six	as	GOLD	C	and	
twenty-one	as	GOLD	D.	A	range	of	PROs	and	clinical	outcomes	(lung	function,	muscular	and	function	
tests)	were	assessed	and	global	scores	may	be	consulted	in	table	2.	
	 	
Centro	Hospitalar	do	Baixo	Vouga	
	Centros	de	Saúde	do	Aces	do	Baixo	Vouga	
Hospital	Pedro	Hispano	
Hospital	Distrital	da	Figueira	da	Foz	
82	patients	with	COPD	22	patients	excluded	due	to:	
• Unsuccessful	DNA	
extraction	
	
60	patients	with	COPD	
Figure	6-Sample	recruitment	process.	
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Table	2-Sample	characterisation.	
Characteristics	 Patients	with	COPD	(n=60)	
• Age	(years)	 67.87±8.59	
• Gender,	n	(%)	
	
• M/F	
	
Masculine	 52	(86.7)	
Feminine	 8	(13.3)	
• Body	Fat	Percentage,	(%)	 30.13±7.81	
• Body	Mass	Index,	(%)	 29.45±27.59	
• Weight,	(Kg)	 70.60±18.44	
• GOLD	classification,	n	(%)	
• 	
	
A	(MIld)	 11	(18.3)	
B	(Moderate)	 22	(36.7)	
C	(Severe)	 6	(10)	
D	(Very	Severe)	 21	(35)	
• Smoking	Status,	n	(%)	 	
Ex	 42	(70)	
Never	 10	(16.7)	
Current	 8	(13.3)	
LUNG	FUNCTION	TESTS	
• Predicted	FEV1,	(%)	
• FEV1	
33.92±8.67	
VC,	(%)	 63.08±15.84	
• FEV1,	(L)	 0.98±0.28	
• FVC,	(L)	 2.22±0.69	
• FEV1/FVC,	(%)	 45.45±17.47	
MUSCULAR	AND	FUNCTIONAL	TESTS	
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• Maximum	Inspiratory	Pressure,	(cmH2O)	 65.23±24.65	
• Maximum	Expiratory	Pressure,	(cmH2O)	 110.35±40.23	
• Quadriceps	muscle	strength	(KgF)	 21.87±9.39	
• Handgrip	(KgF)	 37.82±8.76	
• 5	repetition	sit-to-stand,	(seconds)	 9.73±4.84	
• 1	minute	sit-to-stand,	(repetitions)	 27.24±10.26	
PATIENT-REPORTED	OUTCOMES	
• Frequency	of	exacerbations,	M,	(IQR),		
(episodes)	
1	(0	to	3)	
• Modified	British	Medical	Research	Council	
questionnaire,	M,	(IQR),			
2	(1	to	3)		
• Borg	Scale,	M,	(IQR),			 	
Dyspnoea	 1	(0	to	3)	
Fatigue	 0	(0	to	3)	
• Hospital	Anxiety	and	Depression	Scale	M,	
(IQR),			
	
Anxiety	Score	 7	(5	to	11)	
Depression	Score	 8	(3.25	to	9)	
• COPD	Assessment	Test	M,	(IQR),			 20.50	(13.25	to	25)	
• St.	George	Respiratory	Questionnaire	 	
Symptoms	score	 53.03±20.24	
Activity	score	 68.92±20.63	
Impact	score	 44.18±19.33	
Total	Score	 53.08±17.67	
Results	are	presented	in	mean	±	standard	deviation,	unless	otherwise	stated.	
COPD-	chronic	obstructive	pulmonary	disease;	F-	female;	M-male;	FEV1-	forced	expiratory	volume-one	second;	FVC-	forced	vital	
capacity;	M-	median;	IQR-	inter-quartile	range.	
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4.3.	Samples	quality	
4.3.1.	Buccal	cell	samples	from	Oropharyngeal	Swabs	
Material	 from	 buccal	 cells	 collected	 with	 the	 oropharyngeal	 swabs	 revealed	 low	 DNA	
concentrations	as	well	as	poor	A260/280	and	A260/230	ratios.	Therefore,	DNA	extraction	was	not	
well	succeeded	and	all	results	were	obtained	from	saliva	samples.		
4.3.2.	Saliva	
Eighty-two	saliva	samples	were	obtained	 from	patients	with	COPD	at	 the	north	and	centre	
regions	of	Portugal.	Only	sixty	samples	were	chosen	for	genotyping,	since	DNA	from	twenty-two	
samples	were	 unsuccessful	 extracted	 due	 to	 visible	 impurities	 (Figure	 7)	 such	 as	 food	 particles	
(Figure	7b),	a	brown	coloration	possibly	associated	with	tobacco	(Figure	7c)	and	in	some	cases	a	
red	coloration	(Figure	7e),	representing	possible	lipstick	contamination(70).	
	
	
	
	
	
	
	
4.4.	DNA	quantification	
DNA	 was	 successfully	 extracted	 from	 sixty	 samples.	 The	 yield	 of	 DNA	 obtained	 was	
34,58±30,98	 ng/μl	 measured	 with	 Denovix	 D-11,	 compared	 with	 the	 27,71±27,98	 ng/μl	 when	
measured	with	Qubit	(Table	3).	All	individual	samples	measurements	(Mean	DNA	concentrations;	
A260/280	 ratios;	 A260/230	 ratios)	 assessed	 with	 DenoVix	 D-11	 and	 mean	 DNA	 concentration	
assessed	with	Qubit	may	be	consulted	in	Appendix	III.	
A													B														C												D												E	
Figure	7-	Saliva	samples	with	visible	impurities.	Sample	
A-sample	 with	 normal	 appearance;	 Sample	 B-	
agglomerate	 of	 food	 particles	 and	 other	 impurities;	
Sample	 C-	 brown	 coloration	 from	 a	 smoker	 patient;	
Sample	 D-	 sample	 with	 sputum;	 Sample	 E-	 red	
coloration	from	lipstick.	
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Table	3-Characteristics	of	the	60	saliva	DNA	samples	that	were	selected	for	genotyping	analysis.	Data	for	
individual	samples	can	be	consulted	in	Appendix	III	
		
4.5.	DNA	integrity	
Extracted	DNA	from	individual	samples	were	run	on	agarose	(1%)	gels.	Results	of	this	process	
revealed	that	DNA	extracted	was	most	of	the	times	intact	with	minimum	degradation	as	in	samples	
A,	C	and	D.	In	these	samples,	a	well-defined	band	was	detected	(Figure	8).	Sample	B	revealed	some	
degree	of	degradation	(a	well-defined	band	was	not	observed	on	the	top)	however,	this	was	not	
observed	in	any	other	sample.		
	
Figure	8	-	Agarose	gel	of	four	samples	to	detect	degradation.	
4.6.	DNA	samples	SpeedVac	
DNA	samples	were	concentrated	at	Speed	Vac	concentrator	 to	 increase	 the	values	of	DNA	
concentration	required	for	the	genotyping	analysis.	At	the	end	of	the	process,	the	sixty	samples	
obtained	 at	 least	 the	 minimum	 values	 required,	 reaching	 a	 mean	 DNA	 concentration	 of	
143.90±110.75	ng/μl	and	a	A260/280	and	A260/230	ratios	of	1.84±0.09	and	1.27±0.31	respectively	
(Table	4).		
	
	 Denovix	 	 	 Qubit	
Sample	Source	 Mean	DNA	
concentration	(ng/μl)	
	
Mean±SD	
A260/280	
Mean±SD	
A260/230	
Mean	DNA	
concentration	(ng/μl)	
	
Saliva	(n=60)	 34,58±30,98	 1,89±0,10	 1,50±0,41	 27,71±27,98	
Control									A																			B																	C																	D		
Results	are	mean	±	standard	deviation	
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Table	4-Characteristics	of	the	60	saliva	DNA	samples	selected	for	genotyping	after	speed	vacuum	
concentration.	
4.7.	COPD-related	genotyping	targets	
Results	from	the	systematic	review	conducted	to	find	genetic	variants	associated	to	PROs	in	
COPD,	 showed	that	 there	are	 twelve	SNPs	 from	eight	different	genes	associated	with	 five	PROs	
(Figure	9).	Additionally,	when	a	broad	COPD-related	search	was	conducted	in	the	literature,	more	
than	four	hundred	SNPs	were	identified	as	having	significant	association	with	the	disease	(Appendix	
II).	
	
Figure	9-	Genetic	variants	associated	with	patient-reported	outcomes	in	chronic	obstructive	pulmonary	
disease	(Adapted	from	poster	(PA4713)	at	European	Respiratory	Society	(ERS)	2017-Appendix	IV).	
	
Denovix	
Sample	Source	 Mean	DNA	
concentration	(ng/μl)	
	
Mean±SD	
A260/280	
Mean±SD	
A260/230	
Saliva	(n=60)	 143.90±110.75	 1.84±0.09	 1.27±0.31	
Results	are	mean	±	standard	deviation	
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From	this	panel	of	SNPs,	one	hundred	and	thirty-five	matched	those	of	the	Infinium	Global	
Screening	Array-24	v1.0	SNPs	collection	and	from	the	twelve	associated	with	PROs	(presented	on	
Figure	9),	four	matched	with	the	referred	array.	Samples	were	genotyped	with	the	GSA	microarray	
under	the	scope	of	this	dissertation.	However,	we	only	had	time	to	analyse	the	four	PRO-related	
SNPs	together	with	a	randomly	selected	panel	of	thirty-two	SNPs	from	the	one	hundred	and	thirty-
five	 set	 (rs10011792;	 rs1042522;	 rs1042713;	 rs1042714;	 rs1042717;	 rs10461985;	 rs1051303;	
rs10516526;	 rs1051740;	 rs1059823;	 rs10844154;	 rs11001819;	 rs11046966;	 rs11172113;	
rs1129055;	 rs1130866;	 rs1131620;	 rs1138272;	 rs1143634;	 rs1155563;	 rs11556218;	 rs11614913;	
rs11677877;	rs11739136;	rs12477314;	rs12504628;	rs12899618;	rs12922394;	rs1303;	rs1800450;	
rs5030737;	rs7041)	(Figure	10).	Further	information	about	the	SNPs	analysed	within	the	scope	of	
this	dissertation	may	be	found	in	Appendix	II.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	10-Process	conducted	to	obtain	the	32	SNPs	analysed	in	this	dissertation.	
32	SNPs	randomly	
selected	were	
analysed	in	this	
dissertation	for	
associations	with:	
Systematic	
Review	
(n=12)	
Targeted	gene	
sequencing	panel	
(n=401)	
Infinium	Global	
Screening	Array		
413	SNPs	 16.545	SNPs	
MATCH	
135	SNPs	
Patient-
reported	
outcomes	
Surrogate	
Outcomes	
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4.7.1.	Significant	associations	between	Patient-reported	outcomes	and	genetic	variants	
Significant	associations	were	obtained	between	SNPs	and	all	the	PROs	assessed,	except	for	
self-reported	frequency	of	exacerbations	and	depression	assessed	with	HADS.		
	
4.7.1.1	Dyspnoea	
Significant	 differences	 were	 obtained	 between	 genotypes	 of	 the	 SNP	 rs1143634	 and	
dyspnoea	scores	assessed	with	mMRC	(p=0.009),	specifically	between	the	genotypes	AA,	associated	
with	the	highest	and	GG,	associated	with	the	lowest	dyspnoea	scores	(AA:	3	[3	to	3.5]	and	GG:	2	[1	
to	3]	p=0.012)	(Figure	11).	
	
Figure	11-Significant	differences	obtained	between	GG	and	AA	genotypes	from	rs1143634	SNP	and	dyspnoea	
scores	 registered	with	Modified	medical	 research	 council.	Horizontal	 lines	 in	 the	box	plot	 represents	 the	
medians,	the	limits	of	the	box	plot	represent	the	25th	and	75th	percentiles	and	the	vertical	lines	(whiskers)	are	
the	minimum	and	maximum	values.	*p<0.05	(Mann-Whitney	U	test	with	Bonferroni	correction).	
	
4.7.1.2.	Dyspnoea	and	fatigue	
The	 three	 SNPs	 rs1042717,	 rs1138272	 and	 rs12505628	 SNPs	 were	 associated	 with	
dyspnoea	scores	assessed	with	the	Borg	scale	(p=0.004,	p=0.026	and	p=0.011	respectively)	(Figure	
12).	 In	 the	 case	 of	 the	 first	 SNP	 (rs1042717),	 significant	 differences	 between	 the	 heterozygotic	
patients,	that	presented	higher	values	of	dyspnoea	and	the	other	two	genotypes	were	observed	
(CC:	0	[0	to	3]	and	CT:	3	[0.25	to	4],	p=0.08;	CT:	3	[0.25	to	4]	and	TT:	0	[0	to	0],	p=0.013).	For	the	
second	SNP	(rs1138272),	significant	differences	of	scores	between	patients	carrying	the	CC	and	CT	
genotypes	(CC:	0	[0	to	3]	and	CT:	3	[2.5	to	4],	p=0.026)	were	observed,	however	patients	with	the	
TT	 genotype	 were	 not	 found	 in	 this	 population.	 Finally,	 significant	 differences	 of	 scores	 were	
observed	between	patients	with	the	TT	genotype	from	rs12505628	SNP,	who	had	lower	scores	of	
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dyspnoea	and	patients	with	TC	genotype,	who	obtained	the	higher	scores	(TT:	0	[0	to	1.50]	and	TC:	
3	[0	to	4],	p=0.004).	
Borg	 scale	 was	 also	 used	 to	 assess	 fatigue	 (Figure	 13).	 Scores	 between	 the	 rs1042714	
genotypes	(p=0.034)	were	significantly	different,	more	specifically	between	patients	with	the	GG	
and	 GC	 genotypes	 (GG:	 0	 [0	 to	 1.25]	 and	 GC:	 3	 [0	 to	 4]	 p=0.011).	 rs1138272	 also	 originated	
significantly	 different	 scores	 between	 genotypes,	 specifically	 between	 patients	 with	 CC	 and	 CT	
genotypes	(CC:	0	[0	to	3]	and	CT:	3	[1.75	to	4],	p=0.020).	For	this	last	SNP,	patients	carrying	the	TT	
genotype	were	not	found.	
	
Figure	12-Significant	differences	obtained	between	
genotypes	of	rs1042717,	rs1138272	and	rs12504628	
SNPs	 and	 dyspnoea	 scores	 registered	 with	 Borg	
scale.	Horizontal	lines	in	the	box	plot	represent	the	
medians,	 the	 limits	 of	 the	 box	 plot	 represent	 the	
25th	 and	 75th	 percentiles	 and	 the	 vertical	 lines	
(whiskers)	 are	 the	minimum	and	maximum	values.	
*p<0.05	 (Mann-Whitney	 U	 test	 with	 Bonferroni	
correction).			
	
	
	
Figure	13-Significant	differences	obtained	between	
genotypes	of	rs1042714	and	rs1138272	SNPs	and	
fatigue	 scores	 registered	 with	 Borg	 scale.	
Horizontal	 lines	 in	 the	 box	 plot	 represents	 the	
medians,	 the	 limits	of	 the	box	plot	 represent	 the	
25th	 and	 75th	 percentiles	 and	 the	 vertical	 lines	
(whiskers)	are	the	minimum	and	maximum	values.	
*p<0.05	 (Mann-Whitney	 U	 test	 with	 Bonferroni	
correction).	
	
	
4.7.1.3	Anxiety	and	depression	
No	SNPs	were	found	associated	with	depression	assessed	with	HADS,	but	three	significant	
associations	were	found	between	rs1051303,	rs1800450	and	rs1131620	and	anxiety	assessed	with	
the	 same	 scale	 (p=0.045,	 p=0.017	 and	 p=0.024,	 respectively)	 (Figure	 14).	 For	 the	 first	 SNP	
(rs1051303),	 significant	differences	of	 scores	between	patients	 carrying	 the	CC	genotypes	 (with	
higher	scores	of	anxiety)	and	the	heterozygote	genotypes	(with	the	lower	scores)	(CC:	11	[7.50	to	
13.75]	and	CT:	6	 [4	to	9.25],	p=0.016)	were	observed.	Likewise,	 for	the	second	SNP	(rs1800450)	
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significant	differences	between	the	CC	and	CT	genotypes	(CC:8	[6	to	12.50]	and	CT:6	[2	to	6.50],	
p=0.009)	were	 observed.	 For	 this	 last	 case,	 patients	 carrying	 the	 TT	 genotype	were	 not	 found.	
Finally,	 for	 the	 rs1131620	SNP,	 significant	differences	were	observed	between	patients	with	CC	
genotype,	with	higher	scores	of	anxiety	and	patients	with	CT	genotype	(CC:	13	[8	to	13.50]	and	CT:	
6	[4	to	9.25],	p=0.006).		
	
Figure	14-Significant	differences	obtained	between	genotypes	 from	rs1051303,	rs1800450	and	rs1131620	
SNPs	and	anxiety	scores	registered	with	Hospital	Anxiety	and	Depression	scale.	Horizontal	 lines	in	the	box	
plot	represents	the	medians,	the	limits	of	the	box	plot	represent	the	25th	and	75th	percentiles	and	the	vertical	
lines	 (whiskers)	 are	 the	minimum	 and	maximum	 values.	 *p<0.05	 (Mann-Whitney	U	 test	with	 Bonferroni	
correction).	
	
4.7.1.4	Impact	of	COPD	
	 Impact	 of	 the	 disease	 was	 assessed	 with	 CAT.	 rs10461985	 and	 rs11172113	 SNPs	 were	
significantly	associated	with	CAT	scores	(p=0.048	and	p=0.008	respectively)	(figure	15).	For	the	first	
SNP	(rs10461985),	significant	differences	of	scores	between	patients	carrying	the	GG	genotype	with	
higher	impact	of	disease	and	patients	with	GA	genotype	with	the	lower	values	(GG:	21	[14	to	26]	
and	 GA	 12	 [7.50	 to	 16.50],	p=0.048)	were	 observed.	 Patients	 carrying	 the	 AA	 genotype	 in	 this	
population	were	not	found.	For	the	second	and	 last	SNP	(rs11172113),	significant	differences	of	
score	between	patients	with	AA	genotypes,	with	higher	scores	and	patients	with	AG	genotypes	(AA:	
23	[20.50	to	28.50]	and	AG:	15	[8.75	to	21.25],	p=0.004)	were	obtained.	
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Figure	15-Significant	differences	obtained	between	genotypes	 from	rs10461985	and	 rs1172113	SNPs	and	
health-related	quality	of	life	scores	registered	with	Chronic	Obstructive	Pulmonary	Disease	Assessment	Test.	
Horizontal	lines	in	the	box	plot	represents	the	medians,	the	limits	of	the	box	plot	represent	the	25th	and	75th	
percentiles	and	the	vertical	lines	(whiskers)	are	the	minimum	and	maximum	values.	*p<0.05	(Mann-Whitney	
U	test	with	Bonferroni	correction).	
	
4.7.1.5	Health-related	quality	of	life	
HRQOL	was	assessed	with	SGRQ	and	significant	associations	were	found	with	four	different	
SNPs	and	the	four	categories	of	SGRQ	–	symptoms,	activities,	impact	of	the	disease	and	total	score.	
Symptoms	score	was	significant	associated	with	the	rs11172113	SNP	(p=0.004)	(Figure	16).	In	this	
case,	significant	differences	between	patients	homozygotes	AA,	with	higher	score	and	consequently	
more	severe	symptoms	and	the	heterozygotes	(AA:	66.93±18.40;	AG:42.58±19.78,	p=0.006)	were	
found.	 In	the	activity	score,	three	significant	associations	between	this	outcome	and	rs1042713,	
rs11172113	and	rs1138272	(p=0.036;	p=0.021	and	p=0.017	respectively)	were	found	(Figure	17).	
For	 the	 first	 SNP	 (rs1042713),	 significant	 differences	 of	 score	between	patients	 carrying	 the	CC	
genotype,	 with	 a	 higher	 activity	 limitation,	 and	 patients	 with	 the	 heterozygote	 genotype	
(CC:79.03±15.91	and	CT:63.23±22.08,	p=0.042)	were	observed.	 In	the	second	SNP	(rs11172113),	
significant	differences	between	patients	carrying	the	heterozygote	genotype	and	patients	carrying	
the	 GG	 genotype	 (AG:58.79±22.24	 and	 GG:73.90±17.69,	 p=0.032)	 were	 observed.	 For	 the	 last	
SNP(rs1138272),	 the	 heterozygotes	 CT	 revealed	 significant	 higher	 values	 of	 activity	 score,	
comparing	to	the	CC	genotypes	(CC:66.32±20.24;	CT:89.24±13.98,	p=0.017).	No	patients	with	TT	
genotype	for	this	last	SNP	were	found.	The	impact	score	was	associated	with	two	SNPs:	rs1138272	
(p=0.045)	and	rs12504628	(p=0.011)	(Figure	18).	For	the	rs1138272	SNP	case,	significant	differences	
between	 patients	 carrying	 the	 CT	 genotype,	 associated	 with	 higher	 impact	 of	 the	 disease,	
comparing	with	the	CC	genotypes	(CC:	42.27±18.97	and	CT:	60.65±20.15,	p=0.045)	were	observed.	
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For	the	rs12504628	SNP,	significant	differences	of	scores	between	patients	carrying	TT	genotype	
and	patients	carrying	the	TC	genotype	(TT:37.08±16.61;	TC=50.27±18.72,	p=0.032)	were	observed.	
Finally,	in	the	total	score,	similar	associations	with	SNPs	previously	reported	in	other	categories	of	
this	scale	were	found	(rs11172113,	p=0.006	and	rs1138272,	p=0.021)	(Figure	19).	For	the	first	SNP	
(rs11172113),	 significant	 differences	 of	 score	were	 observed	between	 the	 patients	 carrying	 the	
heterozygote	 genotype	 and	 patients	 carrying	 the	 AA	 genotype	 (AA:	 62.12±14.39	 and	 AG	
43.53±18.33,	p=0.020)	and	between	patients	carrying	the	heterozygote	genotype	and	the	patients	
with	the	GG	genotype	(AG	43.53±18.33	and	GG=	57.00±15.47,	p=0.021).	Finally,	for	the	second	SNP	
(rs1138272),	 significant	 differences	 between	 patients	 with	 the	 heterozygotes	 genotypes,	 with	
higher	score	and	the	CC	genotypes	(CC:	51.14±17.46	and	CT:	70.39±13.48,	p=0.021)	were	observed.	
Patients	with	the	TT	genotype	were	not	found	for	this	last	SNP.		
	
	
Figure	 16-	 Significant	 differences	 obtained	
between	AA	 and	AG	 genotypes	 from	 rs11172113	
SNP	and	health-related	quality	of	life	assessed	with	
St.	 George	 Respiratory	 Questionnaire	 (symptoms	
score).	Horizontal	 lines	 in	the	box	plot	represents	
the	medians,	 the	 limits	of	 the	box	plot	 represent	
the	25th	and	75th	percentiles	and	the	vertical	lines	
(whiskers)	are	the	minimum	and	maximum	values.	
*p<0.05	 (One-way	 ANOVA	 test	 with	 Bonferroni	
correction).	
	
Figure	17-	Significant	differences	obtained	between	
genotypes	 from	 rs1042713,	 rs11172113	 and	
rs1138272	 SNPs	 and	 health-related	 quality	 of	 life	
assessed	with	St.	George	Respiratory	Questionnaire	
(activity	 score).	 Horizontal	 lines	 in	 the	 box	 plot	
represents	 the	medians,	 the	 limits	 of	 the	 box	 plot	
represent	 the	 25th	 and	 75th	 percentiles	 and	 the	
vertical	 lines	 (whiskers)	 are	 the	 minimum	 and	
maximum	 values.	 *p<0.05	 (One-way	 ANOVA	 test	
with	Bonferroni	correction).	
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Figure	 18-	 Significant	 differences	 obtained	
between	 genotypes	 and	 rs1138272	 and	
rs12504628	 SNPs	 and	 health-related	 quality	 of	
life	 assessed	 with	 St.	 George	 Respiratory	
questionnaire	(impact	score).	Horizontal	lines	in	
the	box	plot	represents	the	medians,	the	limits	of	
the	 box	 plot	 represent	 the	 25th	 and	 75th	
percentiles	and	 the	vertical	 lines	 (whiskers)	are	
the	 minimum	 and	 maximum	 values.	 *p<0.05	
(One-way	ANOVA	with	Bonferroni	correction).	
	
Figure	 19-	 Significant	 differences	 obtained	
between	 genotypes	 and	 rs1138272	 and	
rs11172113	SNP	and	health-related	quality	of	life	
assessed	 with	 St.	 George	 Respiratory	
questionnaire	(total	score).	Horizontal	lines	in	the	
box	plot	represents	the	medians,	the	limits	of	the	
box	plot	 represent	 the	25th	and	75th	percentiles	
and	the	vertical	lines	(whiskers)	are	the	minimum	
and	maximum	values.	*p<0.05	(One-way	ANOVA	
with	Bonferroni	correction).	
Figure	20	summarizes	all	 the	associations	 found	between	the	SNPs	and	the	PROs	 in	 this	
population.					
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Figure	20-Summary	of	the	associations	between	single	nucleotide	polymorphisms,	patient-reported	outcomes	and	patient-reported	outcomes	measures.	
	
Patient-reported	
outcomes;
<->
Genetic	variants
Frequency	of	
exacerbations Questionnaire No	associations	found
Dyspnoea
modified	Medical	
Reseach	Council rs1143634	(IL1B	gene)	
Borg	Scale rs1042717	(ADRB2	gene);	rs1138272(GSTP1	gene);	rs12504628	(HHIP	gene)
Fatigue Borg	Scale
rs1042714	(ADRB2	gene);	
rs1138272	(GSTP1	gene)
Anxiety Hospital	Anxiety	and	Depression	Scale
rs1051303	(LTBP4	gene);	rs1800450	(MBL2	
gene);	rs1131620	(LTBP4	gene)
Depression Hospital	Anxiety	and	Depression	Scale No	associations	found
Impact	of	the	disease COPD	Assessment	Test	
rs10461985	(GDNF-AS1	gene)
rs11172113	(LRP1	gene)
Health-related	
quality	of	life
St.	George	
Respiratory	
Questionnaire
rs11172113	(LRP1	gene);	rs1042713	(ADRB2	
gene);	rs1138272	(GSTP1)	and	rs12504628	
(HHIP	gene)
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4.7.2.	Significant	associations	between	Surrogate	Outcomes	and	genetic	variants	
A	 total	 number	 of	 nine	 different	 SNPs	 were	 associated	 with	 the	 surrogate	 outcomes	
assessed	in	patients	with	COPD.	Only	maximum	inspiratory	pressure	did	not	obtain	any	association.	
4.7.2.1	Lung	function	
A	total	of	four	SNPs	presented	significant	associations	with	FEV1pp,	FVCpp	and	FEV1/FVC	
ratio.	Rs1042713	was	the	SNP	significantly	associated	with	FEV1	pp	(p=0.027).	Significant	differences	
between	patients	carrying	the	CC	genotype,	who	had	the	lower	values	of	FEV1pp	comparing	with	
patients	 carrying	 the	 CT	 genotype	 (CC:29.82±8.97%;	 TC:36.46±7.81%,	 p=0.027)	 were	 observed	
(Figure	21).	Additionally,	it	was	also	observed	that	rs1042717	and	rs5030737	SNPs	had	significant	
associations	with	FVCpp	(p=0.039	and	p=0.007,	respectively)	(Figure	22).	In	both	cases,	significant	
differences	were	observed	between	the	heterozygotes,	which	obtained	significant	lower	values	of	
FVCpp,	 when	 compared	 with	 patients	 carrying	 CC	 genotype	 for	 the	 rs1042717	 SNP	
(CC:67.27±12.99%	 and	 CT:57±17.65%,	 p=0.045)	 and	 GG	 genotype	 for	 the	 rs5030737	 SNP	
(GG:65.20±14.89%	and	GA:49.33±15.82%,	p=0.007).	A	significant	association	between	this	last	SNP	
(rs5030737)	and	FEV1/FVC	ratio	was	also	found	(p=0.000)	(Figure	23).	Patients	with	heterozygotes	
genotypes	 obtained	 higher	 ratios	 when	 compared	 with	 patients	 with	 the	 GG	 genotype	
(GG:42.27±13.32%	 and	 GA:	 66.13±26.74%,	 p=0.000).	 For	 this	 SNP,	 no	 patients	 carrying	 the	 AA	
genotype	were	found.	
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Figure	21-Significant	differences	obtained	between	
CC	 and	 CT	 genotypes	 from	 rs1042713	 SNP	 and	
FEV1pp.	Horizontal	lines	in	the	box	plot	represents	
the	medians,	the	limits	of	the	box	plot	represent	the	
25th	 and	 75th	 percentiles	 and	 the	 vertical	 lines	
(whiskers)	are	the	minimum	and	maximum	values.	
*p<0.05	 (One-way	 ANOVA	 with	 Bonferroni	
correction).	
	
	
Figure	22-Significant	differences	obtained	between	
genotypes	 from	 rs1042717	 and	 rs5030737	 SNPs	
and	 FVCpp.	 Horizontal	 lines	 in	 the	 box	 plot	
represents	 the	medians,	 the	 limits	of	 the	box	plot	
represent	 the	 25th	 and	 75th	 percentiles	 and	 the	
vertical	 lines	 (whiskers)	 are	 the	 minimum	 and	
maximum	 values.	 *p<0.05	 (One-way	 ANOVA	with	
Bonferroni	correction).	
	
	
	
Figure	 23-Significant	 differences	 obtained	 between	 GG	 and	 GA	 genotypes	 from	 rs5030737	 SNP	 and	
FEV1/FVC	ratio.	Horizontal	lines	in	the	box	plot	represents	the	medians,	the	limits	of	the	box	plot	represent	
the	 25th	 and	 75th	 percentiles	 and	 the	 vertical	 lines	 (whiskers)	 are	 the	minimum	and	maximum	 values.	
*p<0.05	(One-way	ANOVA	with	Bonferroni	correction).	
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4.7.2.2	Respiratory	muscle	strength	
For	 respiratory	 muscles	 assessment,	 it	 was	 observed	 that	 rs1130866	 was	 significantly	
associated	with	MEP	(p=0.036)	(Figure	24).	More	specifically,	significant	differences	were	observed	
between	patients	carrying	the	CC	genotype,	with	higher	values	of	the	expiratory	muscle	strength,	
compared	with	patients	who	had	genotype	TC	(TC:104.67±41.19	cmH2O;	CC:	141.67±32.84	cmH2O,	
p=0.03).		
	
Figure	24-Significant	differences	obtained	between	TC	and	CC	genotypes	from	rs1130666	SNP	and	maximum	
expiratory	 pressure.	 Horizontal	 lines	 in	 the	 box	 plot	 represents	 the	 medians,	 the	 limits	 of	 the	 box	 plot	
represent	 the	 25th	 and	 75th	 percentiles	 and	 the	 vertical	 lines	 (whiskers)	 are	 the	minimum	and	maximum	
values.	*p<0.05	(One-way	ANOVA	with	Bonferroni	correction).	
	
4.7.2.3	Peripheral	muscle	strength	
Significant	associations	between	the	SNPs	rs1042713	and	rs1042717	and	the	quadriceps	
muscle	 strength	 (p=0.043	 and	 p=0.017,	 respectively)	 were	 obtained	 (Figure	 25).	 In	 the	 first	
case(rs1042713),	 significant	 differences	 of	 muscle	 strength	 were	 observed	 between	 patients	
carrying	the	genotype	CT,	with	more	quadriceps	strength	compared	with	the	CC	group	who	were	
significantly	 weaker	 (CC:17.88±9.44	 KgF;	 CT:25.07±9.76	 KgF,	 p=0.038).	 Furthermore,	 rs1042717	
SNP	 revealed	 significant	 differences	 in	 patients	 carrying	 the	 CC	 genotype	 that	 showed	 more	
quadriceps	muscle	strength	when	compared	with	the	heterozygote	genotype	(CC:25.20±9.97	KgF;	
CT:18.33±7.57	KgF,	p=0.020).	
Upper	limb	muscle	strength	also	originated	significant	differences	between	other	two	SNPs	
(rs11172113,	p=0.011	and	rs11556218,	p=0.021)	(Figure	26).	In	the	case	of	the	first	SNP(rs1172113)	
a	significant	difference	between	the	heterozygotes	which	presented	higher	values	of	upper	 limb	
muscle	strength	and	patients	with	the	genotype	GG	who	showed	the	lowest	values	(AG=42.35±7.23	
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KgF	 and	 GG=	 33.56±7.00	 KgF,	 p=0.009),	 was	 observed.	 Additionally,	 for	 the	 second	 SNP	
(rs11556218),	 patients	 carrying	 the	 TT	 genotype	 were	 significantly	 weaker	 compared	 to	 the	
patients	carrying	the	heterozygote	genotype	(TT=	36.05±8.14	KgF;	TG=43.30±8.74	KgF,	p=0.021).	In	
this	population,	patients	carrying	the	genotype	GG	were	not	found.	
	
Figure	25-Significant	differences	obtained	between	
genotypes	from	rs1042713	and	rs1042717	SNP	and	
quadriceps	 muscle	 strength	 assessed	 with	
dynamometer.	 Horizontal	 lines	 in	 the	 box	 plot	
represents	the	medians,	the	limits	of	the	box	plot	
represent	 the	 25th	 and	 75th	 percentiles	 and	 the	
vertical	 lines	 (whiskers)	 are	 the	 minimum	 and	
maximum	values.	 *p<0.05	 (One-way	ANOVA	with	
Bonferroni	correction).	
	
	
Figure	26-	Significant	differences	obtained	between	
genotypes	 from	 rs11172113	 and	 rs11556218	 SNP	
and	handgrip	 test.	Horizontal	 lines	 in	 the	 box	 plot	
represents	 the	medians,	 the	 limits	 of	 the	 box	 plot	
represent	 the	 25th	 and	 75th	 percentiles	 and	 the	
vertical	 lines	 (whiskers)	 are	 the	 minimum	 and	
maximum	 values.	 *p<0.05	 (One-way	 ANOVA	 with	
Bonferroni	correction).	
4.7.2.4	Functional	capacity	
Finally,	for	the	functional	capacity,	significant	associations	were	also	obtained	with	three	
distinct	SNPs	and	the	5STS	and	1	minute	STS	tests.	Rs12899618	revealed	associations	with	the	5STS	
test	(p=0.018)	(Figure	27).	For	this	SNP,	it	was	possible	to	observe	significant	differences	between	
patients	with	the	heterozygote	genotype,	slower	to	conduct	the	five	repetitions,	compared	with	
patients	with	the	genotype	CC	(CC:	8.84±3.26	seconds;	CT:	12.45±7.51	seconds,	p=0.018).	For	this	
SNP,	patients	with	the	genotype	TT	were	not	found.	1	minute	STS	also	found	significant	associations	
with	 the	 two	 SNPs	 rs11046966	 (p=0.013)	 and	 rs1138272	 (p=0.012)	 (Figure	 28).	 For	 the	 first	
SNP(rs11046966),	significant	differences	were	observed	between	patients	carrying	the	genotype	
GG,	which	performed	a	higher	number	of	repetitions	compared	with	patients	with	the	AA	genotype	
(AA:	24	[18	to	29]	repetitions	and	GG:	35.50	[29	to	47]	repetitions,	p=0.005).	 In	the	second	SNP	
(rs1138272),	 patients	 with	 the	 CC	 genotype	 conducted	more	 repetitions	 that	 patients	 with	 CT	
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genotype	(CC:	29	[22.75	to	34.25]	repetitions	and	CT:	20	[14	to	21.50]	repetitions,	p=0.012).	For	this	
last	SNP,	there	were	no	patients	carrying	the	TT	genotype.	
	
	
Figure	27-Significant	differences	obtained	between	
genotypes	from	rs12899618	SNP	and	5	time	sit-to-
stand	 test	 scores.	Horizontal	 lines	on	 the	box	plot	
represents	 the	medians,	 the	 limits	of	 the	box	plot	
represent	 the	 25th	 and	 75th	 percentiles	 and	 the	
vertical	 lines	 (whiskers)	 are	 the	 minimum	 and	
maximum	 values.	 *p<0.05	 (One-way	 ANOVA	with	
Bonferroni	correction).	
	
	
Figure	28-Significant	differences	obtained	between	
genotypes	 from	 rs11046966	 and	 rs1138272	 SNPs	
and	 1	 minute	 sit-to-stand	 test	 scores.	 Horizontal	
lines	on	 the	box	plot	 represents	 the	medians,	 the	
limits	 of	 the	 box	 plot	 represent	 the	 25th	 and	 75th	
percentiles	and	the	vertical	lines	(whiskers)	are	the	
minimum	and	maximum	values.	*p<0.05	(One-way	
ANOVA	with	Bonferroni	correction).	
	
Figure	 29	 summarizes	 all	 the	 associations	 found	 between	 the	 SNPs	 and	 the	 surrogate	
outcomes	assessed.	
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Figure	29-	Summary	of	the	associations	between	single	nucleotide	polymorphisms	and	surrogate	outcomes	and	outcome	measures.	
	
Surrogate	
Outcomes	
<->
Genetic	variants
Lung	function
FEV1pp rs1042713	(ADRB2	gene)
FVCpp
rs1042717	(ADRB2	gene)
rs5030737	(MBL2	gene)
FEV1/FVC rs5030737	(MBL2	gene)
Peripheral	
muscle	strentgh
Quadricep	
muscle	strength
rs1042713	(ADRB2	gene)	
rs1042717	(ADRB2	gene)
Handgrip	
strength
rs11172113	(LRP1	gene)	
rs11556218	(IL16	gene)
Respiratory	
muscle	strength
Maximum	
inspiratory	
pressure
No	associations	found
Maximum	
expiratory	
pressure
rs1130866	(SFTPB)
Functional	
Capacity
Five	time	sit-to-
stand rs12899618	(THSD4	gene)
One	minute	sit-
to	stand
rs11046966	(SOX5	gene)	
rs1138272	(GSTP1	gene)
		
	
	
	
	
5.	DISCUSSION	
________________________________________	
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5.1.	Overview	
The	first	objective	of	this	dissertation	was	to	conduct	a	customized	genotyping	for	patients	
with	COPD	using	the	SNPs	from	the	targeted	gene	sequencing	panel.	Due	to	economic	and	technical	
reasons,	this	study	opted	for	a	genotyping	array	non-directed	for	these	SNPs,	but	commonly	used	
to	stratify	human	populations	(GSA	array).	Thus,	we	were	limited	to	the	intersection	between	our	
SNPs	of	 interest	and	 the	 list	of	 SNPs	which	composed	 the	array.	This	 intersection,	by	one	hand	
limited	our	analysis	to	only	135	SNPs	previously	associated	with	COPD	in	the	literature,	32	of	which	
were	analysed	in	this	dissertation.	On	the	other	hand,	this	chip	revealed	genotypes	of	our	patients	
in	relation	to	thousands	of	SNPs,	some	of	which	have	never	been	studied	for	this	disease,	providing	
the	opportunity	of	carrying	out	new	studies.	
5.2.	Samples	quality	and	quantity	
Our	first	idea	was	to	obtain	DNA	from	cells	using	oropharyngeal	swabs.	This	method	is	non-
invasive,	usually	 fast	 and	very	easy	 to	apply.	 The	protocol	of	 sample	 collection	had	a	minimum	
duration	of	an	hour	and	half	and	was	often	performed	in	hospital	contexts,	thus,	swabs	seemed	to	
be	the	best	way	to	obtain	genetic	data	in	a	quick	and	efficient	way.	However,	this	was	not	verified.	
We	 had	 several	 difficulties	 during	 the	 DNA	 extraction,	 because	 only	 residual	 and	 insufficient	
amounts	of	DNA	were	obtained.	The	poor	yields	may	be	due	to	degradation	of	DNA	from	buccal	
cells	which	may	influence	the	genotyping	efficiency(71).	One	of	the	options	to	solve	this	problem	
was	 to	 increase	 the	 number	 of	 swabs	 collected	 by	 patient,	 which	 would	 be	 economically	
unbearable,	 would	 cause	 patients’	 discomfort	 and	 would	 cause	 DNA	 extraction	 process	 more	
timing-consuming.	Other	option	was	to	change	the	source	of	DNA.	According	to	Hansen	et	al(72),	
the	use	of	saliva	is	the	best	alternative	to	obtain	DNA	with	good	quality.	Thus,	saliva	samples	were	
obtained	 from	all	patients	under	 study.	Nevertheless,	 impurities	and	an	excess	of	 sputum	were	
detected	 in	 a	 few	 samples.	 These	 impurities,	 in	 some	 cases,	 led	 to	 QIAamp	Mini	 spin	 column	
obstruction.	To	overcome	this,	we	increased	the	time	of	vortexing,	the	number	of	washing	steps	
and	incubation	time	before	elution.	Despite	the	difficulties	of	COPD	patients	to	produce	saliva	due	
to	the	effects	of	bronchodilator(73),	with	few	millilitres	(1-2)	we	obtained	enough	DNA	to	perform	
genotyping	analysis.		
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5.3.	Microarray	genotyping	
	 5.3.1.	Associations	between	Patient-reported	Outcomes	and	genetic	variants	
A	total	number	of	eleven	different	SNPs	from	8	genes	were	associated	with	all	the	PROS	
assessed,	except	for	the	frequency	of	exacerbations	and	depression	score	assessed	with	HADS.	
According	 to	 the	 systematic	 review	 performed	 (Appendix	 I),	 it	 was	 expected	 to	 find	
associations	 between	 rs7041,	 rs5030737	or	 rs1800450	 SNPs	 from	MBL2	 gene	 and	 frequency	of	
exacerbations,	but	this	has	not	occurred.	Possible	explanations	for	this	absent	association	are	the	
different	characteristics	between	this	population	and	the	populations	of	other	studies,	different	
environments	or	different	exposure	to	risk	factors.		
Dyspnoea	 was	 assessed	 using	 two	 different	 scales,	 mMRC	 and	 Borg.	 Both	 obtained	
significant	 associations	with	 SNPs,	 but	none	of	 the	 SNPs	was	 common	 to	both	 scales.	Although	
dyspnoea	is	a	symptom	with	a	single	interpretation,	both	scales	assessed	it	differently.	mMRC	scale	
assesses	the	dyspnoea	associated	with	activities	of	daily	life	whereas	Borg	scale	assesses	dyspnoea	
at	the	exact	moment	of	the	evaluation(74).	For	this	reason,	patient’s	response	to	both	cases	could	
have	 been	 different,	 which	 may	 explain	 our	 result.	 Homozygotes	 AA	 for	 the	 SNP	 rs1143634	
obtained	 the	 highest	 values	 of	 dyspnoea	 assessed	with	mMRC.	 Based	 on	 these	 results,	we	 can	
assume	that	the	allele	A	was	the	risk	allele	for	dyspnoea.	However,	this	is	 in	contrast	with	some	
results	of	the	literature.	Some	studies	have	reported	that	this	SNP	does	not	have	any	association	
with	COPD(75)	and	others	have	found	the	A	allele	of	this	SNP	with	a	protective	role	against	lung	
cancer	 in	COPD(76).	Therefore,	as	 in	our	 study,	 this	allele	does	not	 seem	to	be	protective	 in	all	
outcomes	of	the	disease.	Furthermore,	the	associations	of	rs1042717	SNP	from	ADRB2	gene	with	
dyspnoea	assessed	with	the	Borg	scale	was	an	expected	result.	ADRB2	encodes	a	receptor	involved	
on	the	relaxation	and	dilatation	of	smooth	muscles(77).	In	addition,	it	has	been	already	reported	
that	the	rs1042717	SNP	is	significantly	associated	with	airway	wall	thickness(78)	and	bronchodilator	
response(79),	so	its	association	with	dyspnoea,	could	have	been	expected.	
Anxiety	 score	 obtained	with	 HADS	was	 significantly	 associated	with	 three	 SNPs,	 two	 of	
which	from	the	LTBP4	gene	(rs1051303	and	rs1131620).	Both	SNPs	have	been	previously	reported	
as	 being	 associated	with	 low	exercise	 capacity	 and	6	minutes	walking	distance	 in	 patients	with	
COPD(80).	Although	these	SNPs	were	not	directly	associated	with	anxious	behaviours,	it	has	been	
previously	 reported	 that	 physical	 activity	 deficits	 may	 lead	 to	 obesity	 and	 increase	 depressive	
symptoms	and	anxiety	(81).	Thus,	the	association	of	these	SNPs	with	anxious	behaviours	seems	to	
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be	 somewhat	 expected	 also	 in	 patients	with	 COPD,	 emphasizing	 once	 again	 the	 importance	 of	
analysing	not	only	genetic	variants	directly	associated	with	the	outcomes,	but	also	other	variants	
indirectly	associated,	as	well	as	possible	interactions	between	these	different	genetic	variants.			
HRQOL	and	impact	of	the	disease	were	assessed	with	two	different	tools,	SGRQ	and	CAT,	
respectively.	 Since	 these	 two	 scales	 are	 strongly	 correlated	with	 each	 other,	 and	 patients	 that	
usually	presented	higher	 impact	of	 the	disease,	also	had	worst	HRQOL(82),	we	expected	to	 find	
some	common	SNPs	to	both	scales.	Significant	associations	with	five	different	SNPs	were	obtained,	
however,	one	specific	variant	(rs11172113	from	LRP1	gene)	was	common	to	both	scales	(CAT	score,	
and	SGRQ	symptoms,	activity	and	total	scores).	This	SNP	was	previously	associated	to	lung	function	
in	the	literature,	where	patients	carrying	the	risk	allele	A	had	lower	FEV1	and	FEV1/FVC	values(83).	
Therefore,	since	patients	with	airflow	limitations	usually	show	higher	impact	of	the	disease(84)	and	
worst	 HRQOL(85),	 it	 was	 expected	 that	 patients	 carrying	 genotypes	with	 this	 allele	 had	 higher	
impact	 of	 the	 disease	 and	 consequently	 worst	 HRQOL.	 In	 this	 study,	 patients	 carrying	 the	 AA	
genotype	reported	higher	scores	in	CAT,	which	represents	a	higher	impact	on	patient	life’s.	A	similar	
effect	 was	 observed	 on	 symptoms	 and	 total	 score	 obtained	 with	 SGRQ,	 where	 homozygotes	
patients	AA,	once	again,	obtained	higher	scores.	Surprisingly,	on	the	SGRQ	activity	domain,	patients	
with	the	GG	genotype	obtained	higher	scores,	very	similar	to	those	patient’s	homozygotes	to	the	
risk	allele	(AA).	This	was	not	expected,	since	this	genotype	does	not	have	the	risk	allele,	and	this	
may	be	due	once	again	to	the	small	sample	size.	Finally,	it	is	important	to	point	out	that	in	all	cases	
(CAT	and	SGRQ),	patients	carrying	the	heterozygote	genotype	for	this	SNP	always	obtained	the	best	
scores	for	disease	impact	and	HRQOL.	Thus,	despite	the	fact	that	patients	with	this	genotype	also	
had	a	risk	allele,	we	suspect	that	this	genotype	may	confer	protection	to	patients	with	COPD	at	least	
in	this	population.	
5.3.2.	Associations	between	Surrogate	Outcomes	and	genetic	variants	
Significant	 associations	 were	 observed	 between	 nine	 different	 SNPs	 and	 all	 clinical	
outcomes	assessed	except	for	MIP.	
Two	 different	 SNPs	 affecting	 ADRB2	 (rs1042713	 and	 rs1042717)	 and	MBL2	 (rs5030737)	
genes	were	 significantly	 associated	with	 lung	 function.	 It	 was	 expected	 that	 some	 SNPs	 of	 the	
ADRB2	 gene	 were	 associated	 with	 this	 outcome,	 for	 the	 same	 reason	 that	 were	 previously	
associated	 to	 dyspnea.	 Patients	 with	 TT	 genotype	 (rs1042713),	 for	 example,	 were	 previously	
associated	 with	 better	 improvements	 in	 spirometric	 measures	 and	 HRQOL	 when	 treated	 with	
anticholinergic	bronchodilators(86).	However,	 in	 this	population,	patients	with	 the	heterozygote	
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genotype	 (TC)	 revealed	 higher	 values	 of	 FEV1pp,	 but	 with	 values	 very	 similar	 with	 previously	
referred	TT	genotype	(TC:	36.46±7.81%	vs	TT:34.90±7.73%).	Additionally,	we	did	not	expect	to	find	
SNPs	of	MBL2	(rs5030737)	associated	with	lung	function.	This	SNP,	as	observed	in	our	systematic	
review,	was	associated	with	the	frequency	of	exacerbations	in	patients	with	COPD,	where	patients	
containing	 genotypes	 with	 allele	 A	 were	 more	 susceptible	 to	 have	 higher	 frequency	 of	
exacerbations(87).	Thus,	patients	carrying	this	risk	allele	may	have	a	worst	lung	function,	possibly	
due	to	the	damage	caused	by	the	high	number	of	exacerbations(88).	For	this	SNP,	patients	carrying	
the	GA	genotype	had	lower	values	of	FVCpp,	and	consequently	also	had	higher	values	of	FEV1/FVC	
ratio,	as	expected.	
From	all	variants	associated	with	muscle	strength	in	this	study,	none	was	directly	associated	
with	this	phenotype	in	patients	with	COPD	in	the	literature,	up	to	this	point.	In	fact,	de	vast	majority	
of	 these	 SNPs	have	been	previously	 associated	 to	 lung	 function	 (89-91).	Nevertheless,	 previous	
studies	 already	 reported	 significant	 correlations	 between	 lung	 function	 (FEV1)	 and	 muscle	
endurance(92)	and	lung	function	and	quadriceps	muscle	strength(93),	where	patients	with	lower	
FEV1	also	had	weaker	quadriceps	muscle	strength	and	less	muscle	endurance.	Thus,	it	seems	likely	
that	 SNPs	with	 genotypes	 responsible	 for	 lower	 FEV1	may	 also	 influence	 negatively	 the	muscle	
strength	 of	 the	 patient.	 For	 example,	 relative	 to	 the	 rs1042713	 SNP	 affecting	 the	ADBR2	 gene,	
significant	associations	were	found	in	both	lung	function	and	quadriceps	muscle	strength,	assessed	
with	 hand-held	 dynamometer.	 Patients	 with	 CC	 genotypes	 were	 associated	 to	 lower	 values	 of	
FEV1pp	(lung	function)	and	also	to	the	lowest	values	of	quadriceps	strength.	However,	this	was	not	
verified	in	all	of	cases.	Rs1130866	SNP	(SFTPB	gene)	was,	in	this	study,	significantly	associated	with	
respiratory	muscle	strength	as	assessed	through	MEP.	Previous	reports	showed	that	patients	with	
TT	genotype	had	higher	values	of	FEV1pp(90),	thus	following	the	same	rationale,	it	was	expected	
that	 patients	with	 the	 same	genotype	would	 also	 show	higher	 values	of	MEP.	However,	 in	 this	
specific	case,	patients	carrying	the	TT	genotype	showed	the	lowest	values	of	MEP,	contrary	to	what	
we	expected.	This	difference	of	what	was	expected	and	what	was	observed	may	be	due	to	the	fact	
that	only	a	single	SNP	may	not	explain	this	dysfunction	on	the	respiratory	muscles.	Despite	this,	
interactions	between	genes	or	an	interaction	between	this	gene	and	the	environment	may	lead	to	
distinctive	 values.	 For	 example,	 the	 common	 practice	 of	 physical	 activity	 or	 integration	 in	 a	
rehabilitation	program,	may	lead	to	values	completely	different	of	what	was	expected.	
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5.3.3.	Limitations	
This	work	had	some	limitations	that	need	to	be	considered.	The	reduced	sample	size,	may	
had	some	influence	in	our	results,	for	example	it	may	explain	why	some	of	genotypes	of	the	SNPs	
were	not	found.	Furthermore,	there	were	also	some	missing	clinical	data	which	could	be	important	
and	may	have	influenced	our	results.	Plus,	we	had	not	a	control	population	and	we	did	not	take	
into	account	some	variants	as	gender,	weight,	body	mass	index.		
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In	 this	 dissertation,	we	assessed	which	 specific	 genetic	 variants	may	be	 associated	with	
PROS	and	surrogate	outcomes	commonly	used	in	patients	with	COPD.	To	our	best	knowledge,	this	
was	the	first	study	reporting	associations	between	SNPs	and	some	of	the	PROs	(i.e.,	CAT,	mMRC	
and	Borg)	and	clinical	variants	(i.e.,	MEP,	handgrip,	5STS	and	1	minute	STS)	in	patients	with	COPD.	
Significant	associations	were	observed	between	all	the	PROs	and	surrogate	outcomes,	except	for	
self-reported	 frequency	 of	 exacerbations,	 depression	 and	 MIP.	 This	 allow	 us	 to	 conclude	 that	
genetics	may	play	a	 very	 strong	 role	not	only	 in	 the	 susceptibility	 to	develop	COPD,	but	also	 in	
almost	 all	 outcomes	 of	 this	 disease.	 Furthermore,	 our	 results	 also	 showed	 new	 associations	
between	 some	 of	 the	 genetic	 variants	 and	 outcomes	 which	 were	 not	 directly	 connected.	 This	
reinforces	what	other	studies	had	already	observed:	COPD	is	a	complex	and	heterogeneous	disease	
that	cannot	be	explained	by	a	single	SNP,	thus,	it	is	important	to	also	understand	the	gene-gene	
and	gene-environment	interactions(91,	94)	
In	 future	 studies,	 the	 sample	 size	will	 be	 increased	and	an	age/gender	matched	 control	
population	will	be	added	to	assess	whether	significant	associations	obtained	in	this	study	will	be	
maintained.	We	also	intend	to	assess	the	effect	of	other	variables,	such	as,	the	stage	of	the	disease,	
gender,	smoking	status	and	BMI,	on	the	obtained	results.	The	remaining	SNPs	genotyped	for	this	
population	 and	 the	 other	 SNPs	 of	 the	 chip	 will	 also	 be	 analysed	 and	 new	 PROs	 and	 surrogate	
outcomes	will	be	included.		
Our	investigation	opened	paths	to	the	knowledge	of	the	genetic	variants	associated	with	
the	different	outcomes	of	COPD	and	unravel	the	possibility,	in	a	near	future,	to	anticipate	patients’	
behaviour	and	adjust	tailored	treatments.	
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Abstract	
Background:	 Chronic	 Obstructive	 Pulmonary	 Disease	 (COPD)	 impacts	 differently	 on	 patients	 at	
similar	grades,	suggesting	that	factors	other	than	lung	function	may	influence	patients’	experience	
of	 the	disease.	 Recent	 studies	have	 found	associations	between	genetic	 variations	 and	patient-
reported	 outcomes	 (PROs).	 Identifying	 these	 associations	might	 be	 fundamental	 to	 predict	 the	
disease	progression	and	develop	tailored	interventions.	This	systematic	review	aimed	to	identify	
the	genetic	variations	associated	with	PROs	in	COPD.	
Methods	and	Findings:	Databases	were	searched	until	 July	2017	(PROSPERO:	CRD42016041639)	
and	 additional	 searches	 were	 conducted	 scanning	 the	 reference	 list	 of	 the	 articles.	 Two	
independent	reviewers	assessed	the	quality	of	studies	using	the	Q-Genie	checklist.	This	instrument	
is	composed	of	11	questions,	each	subdivided	in	7	options	from	1	poor-7	excellent.		
Thirteen	 studies	 reporting	5	PROs	 in	association	with	genes	were	 reviewed.	 Studies	were	 rated	
between	“good	quality”	 (n=8)	and	 “moderate”	 (n=5).	The	most	 reported	PRO	was	 frequency	of	
exacerbations	(n=7/13),	which	was	mainly	associated	with	MBL2	gene	variants.	Other	PRO’s	were	
health-related	 quality	 of	 life	 (HRQOL)	 (n=4/13),	 depressive	 symptoms	 (n=1/13),	 exacerbation	
severity	 (n=1/13)	 and	 breathlessness,	 cough	 and	 sputum	 (n=1/13),	 which	 were	 commonly	
associated	with	other	genetic	variants.	
Conclusions:	Although	a	limited	number	of	PRO’s	have	been	related	to	genetic	variations,	findings	
suggest	 that	 there	 is	 a	 significant	 association	 between	 specific	 gene	 variants	 and	 the	
number/severity	of	exacerbations,	depressive	symptoms	and	HRQOL.	Further	research	is	needed	
to	confirm	these	findings	and	assess	the	genetic	influence	on	other	dimensions	of	patients’	lives,	
since	it	may	enhance	our	understanding	and	management	of	COPD.	 	
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Introduction	
Chronic	obstructive	pulmonary	disease	(COPD)	is	a	multifactorial,	heterogeneous	and	progressive	
condition	 that	 affects	 210	 million	 people	 worldwide(1).	 Severity	 of	 COPD	 is	 usually	 classified	
according	to	the	degree	of	airway	obstruction	(assessed	with	spirometry),	nevertheless	it	has	been	
acknowledged	 that	people	at	 similar	 grades	of	COPD	 report	different	disease	 impacts(1).	 These	
different	 reports	 among	 patients	 suggest	 that	 factors	 beyond	 lung	 function	 influence	 patients’	
experience	 of	 the	 disease.	 Indeed,	 upstream	 factors,	 such	 as	 the	 presence	 of	 specific	 genetic	
variants,	have	already	been	reported	to	play	a	role	in	this	matter(2).	For	example,	polymorphisms	
in	SERPINA1	usually	lead	to	a	deficiency	of	the	α1	antitrypsin,	affecting	1-2%	of	all	COPD	cases(3).	
Additionally,	the	role	of	other	candidate	genes	in	the	pathogenesis,	comorbidities	and	outcomes	of	
the	disease	have	been	studied(4).		
Patient-reported	outcomes	(PROs)	are	a	set	of	health	outcomes	directly	reported	by	patients	and	
may	include	symptoms	(dyspnea,	cough,	pain,	fatigue),	exacerbation	frequency	and	health	status,	
among	others	(5).	These	outcomes	are	accepted	as	the	most	faithful	representation	of	patients’	
perspectives	of	the	impact	of	the	disease	and	treatment	benefits(6).	The	needed	of	assessing	PROs	
has	 been	 considerably	 highlighted	 in	 the	 Global	 Initiative	 for	 Chronic	 Obstructive	 Lung	 Disease	
(GOLD)	2017	update,	which	suggests	that	COPD	classification	should	now	be	based	on	exacerbation	
frequency	and	patient’s	perception	of	their	symptoms	rather	than	on	lung	function	only	(1).	
In	the	last	years,	it	has	become	more	evident	that	there	is	a	strong	association	between	PROs	and	
genetics,	 namely	 in	 lung	 cancer(7),	 which	 may	 suggest	 that	 strong	 associations	 may	 also	 exist	
between	genetics	and	PROs	in	COPD.	However,	a	review	of	the	known	correlations	between	these	
two	factors	in	COPD	has	never	been	conducted.	The	combination	of	genetics	and	PROs	would	be	
valuable	to	identify	patients	susceptible	to	PROs	deficits,	understand	the	diagnosis,	predict	disease	
progression	and	develop	tailored	and	timely	interventions	(8).		
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Therefore,	the	focus	of	this	systematic	review	was	to	synthetize	the	genetic	variations	associated	
with	different	PROs	in	COPD.	
Methods	
Search	strategy	
The	 systematic	 review	 protocol	 was	 registered	 at	 Prospective	 Register	 of	 Systematic	 Reviews	
(PROSPERO)	(ref	CRD42016041639).	 	A	comprehensive	systematic	search	was	conducted	in	May	
2016	 and	 weekly	 updates	 were	 performed	 until	 July	 2017	 in	 the	 following	medical	 databases:	
PubMed	 (1950-2016),	 Scopus	 (1960-2016)	 and	 Web	 of	 Science	 (1900-2016).	 The	 PICOS	
(Populations,	 Intervention,	 Comparison,	 Outcome	 and	 Study	 Design)	 framework	 was	 used	 to	
develop	 literature	 search	 strategies,	 however	 Intervention	 (I)	 and	 Comparison	 (C)	 terms	 were	
omitted	as	they	were	not	applicable	to	the	present	review	(9).	Accordingly,	the	search	terms	were	
based	on	 a	 combination	of	 the	 following	 keywords:	 [(COPD	OR	 "chronic	 obstructive	 pulmonary	
disease"	OR	emphysema	OR	"chronic	bronchitis")	AND	("genetic	associations"	OR	"genetic	profile"	
OR	"genetic	analysis"	OR	gene)	AND	(dyspnea	OR	dyspnoea	OR	breathlessness	OR	fatigue	OR	cough	
OR	 depression	 OR	 anxiety	 OR	 "daily	 living"	 OR	 "quality	 of	 life"	 OR	 mood	 OR	 "well-being"	 OR	
“frequency	 of	 exacerbation”	OR	 exacerbations	OR	 "hospital	 admissions"	OR	 "hospital	 length	 of	
stay"	OR	"acute	exacerbations"	OR	“physical	activity”	OR	"physical	fitness"	OR	“physical	function”	
OR	 “sputum	 production”	 OR	 phlegm	 OR	 pain	 OR	 “patient-reported	 outcomes”	 OR	 “patient-
centered	outcomes”	OR	“patient-centered	outcomes”)].	The	reference	lists	of	the	selected	articles	
were	also	scanned	for	other	potential	eligible	studies.	
Eligibility	criteria	
Studies	were	considered	eligible	if	included	adult	patients	(>18	years	old)	diagnosed	with	COPD	and	
associated	a	genetic	profile	to	one	or	more	PRO.	For	the	purpose	of	this	systematic	review,	PRO	
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were	defined,	according	to	the	Cochrane	Collaboration	definition,	as	“reports	coming	directly	from	
patients	about	how	they	feel	or	function	in	relation	to	a	health	condition	and	its	therapy	without	
interpretation	 by	 healthcare	 professionals	 or	 anyone	 else”	 (10).	 Studies	were	 excluded	 if	 were	
conducted	in	animals,	were	written	in	languages	other	than	English,	Spanish,	French	or	Portuguese	
and	did	 not	 differentiate	 chronic	 obstructive	 diseases	 (i.e.,	 presented	pooled	data	 from	 several	
chronic	 obstructive	 diseases	 such	 as	 asthma,	 COPD	 and	 bronchiectasis).	 Book	 chapters,	 review	
papers,	abstracts	of	communications	on	meetings,	letters	to	the	editor,	commentaries	to	articles,	
unpublished	work	 and	 study	 protocols	 were	 not	 considered	 suitable	 and,	 therefore,	 were	 also	
excluded	from	this	study.	This	systematic	review	was	reported	according	to	the	Preferred	Reporting	
Items	for	Systematic	Reviews	and	Meta-Analysis	(PRISMA)	(9,	11).		
	
Quality	Assessment	
The	quality,	internal	validity	and	risk	of	bias	of	the	included	studies	were	assessed	using	the	Quality	
of	genetic	association	studies	checklist	(Q-Genie)	(12).	This	instrument	is	composed	of	11	questions	
to	assess	“rationale	 for	study”,	“selection	and	definition	of	outcome	of	 interest”,	“selection	and	
comparability	 of	 comparison	 groups”,	 “technical	 classification	 of	 the	 exposure”,	 “non-technical	
classification	of	the	exposure”,	“other	source	of	bias”,	“sample	size	and	power”,	“a	priori	planning	
of	 analysis”,	 “statistical	 methods	 and	 control	 for	 confounding”,	 “testing	 of	 assumptions	 and	
inferences	 for	genetic	analysis”	and	“appropriateness	of	 inferences	drawn	from	results”.	The	Q-
Genie	checklist	has	7	possible	answers	for	each	question	(i.e.,	“1	(poor)”,	“2”,	“3	(good)”,	“4”,	“5	
(very	good)”,	“6”,	“7	(excellent)”).	The	overall	quality	of	studies	is	classified	as	“poor	quality”	if	score	
is	 ≤35,	 “moderate	quality”	 if	 score	 is	 >35	and	≤45,	 and	 “good	quality”	 (>45),	 for	 studies	having	
control	groups.	For	studies	without	control	groups	the	values	for	the	parameters	listed	above	are	
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≤32,	 >32	 and	 ≤40,	 and	 >40,	 respectively(12).	 Two	 reviewers	 assessed	 the	 quality	 of	 studies	
independently.	Disagreements	were	solved	consulting	a	third	reviewer.	
	
Studies	selection	and	data	extraction	
First,	duplicates	were	removed	and	one	reviewer	performed	the	initial	screening	of	title,	abstract	
and	keywords	of	studies	based	on	the	type	of	publication	and	relevance	for	the	scope	of	the	review.	
Then	the	full-text	of	each	potentially	relevant	study	was	screened	for	content	to	decide	its	inclusion	
in	the	review.	For	each	accepted	study,	one	reviewer	extracted	the	following	data	to	a	previously	
structured	table:	last	author’s	name	and	year	of	publication,	study	design,	sample	characteristics	
(i.e.,	 sample	size,	age,	gender	and	COPD	severity),	PRO	evaluated	and	outcome	measures	used,	
gene	associated	with	the	identified	PRO	and	type	of	association	between	the	PRO	and	the	identified	
gene.	 Two	 independent	 reviewers	 further	 checked	 the	 extracted	 data	 for	 accuracy	 and	
completeness.	Reviewers	resolved	disagreements	by	consensus.	
	
Data	analysis	
The	consistency	of	the	studies	quality	assessment,	performed	by	the	two	reviewers,	was	explored	
with	the	Cohen’s	kappa.	The	value	of	Cohen’s	kappa	vary	from	0	to	1	and	can	be	interpreted	as:	i)	
0.00-0.20:	slight	agreement;	ii)	0.21-0.40:	fair	agreement;	iii)	0.41-0.60:	moderate	agreement;	iv)	
0.61-0.80:	substantial	agreement;	v)	0.81-1.00:	almost	perfect	agreement(13).	Statistical	analysis	
was	performed	using	IBM	SPSS	Statistics	version	24.0	(IBM	Corporation,	Armonk,	NY,	USA).	
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Results	
Search	strategy	
The	database	search	identified	1889	studies	of	potential	interest.	After	duplicates	removal,	1259	
articles	were	analyzed	for	relevant	content.	From	these,	1206	were	excluded	due	to	the	following	
reasons:	non-original	articles	(n=575),	absence	of	PRO/genetic	associations	(n=387),	non-specific	
for	COPD	(n=122),	studies	conducted	in	animals	(n=98),	studies	written	in	other	languages	rather	
than	English,	Spanish,	French	or	Portuguese	(n=24).	The	full-text	of	the	remaining	53	potentially	
relevant	 articles	 was	 assessed	 and	 40	 articles	 were	 excluded.	 Reasons	 for	 exclusion	 included:	
absence	 of	 PRO	 (n=19),	 absence	 of	 genetic	 association	 (n=19),	 not	 specific	 for	 COPD	 (n=1)	 and	
unavailability	 of	 the	 article	 even	 after	 contacting	 the	 authors	 (n=1).	 In	 total,	 13	 articles	 were	
included,	all	published	in	English.	A	detailed	diagram	of	the	review	process	is	presented	in	Figure	1.	
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Figure	1-Flow	diagram	for	study	selection	according	to	the	preferred	reporting	items	for	systematic	review	and	
meta-analysis	(PRISMA)	guidelines.
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Quality	assessment	
Articles	 scored	 between	 39	 and	 55	 on	 the	Q-Genie	 checklist	 (12)	 (table	 1).	 Six	 articles	were	
classified	as	studies	without	control	group	(14-19),	from	which	five	presented	of	“good	quality”	
and	one	presented	“moderate	quality”.	The	remaining	articles,	were	classified	as	“studies	with	
control	group”,	 from	which	 four	had	“moderate	quality”	and	 the	 remaining	 three	had	“good	
quality”.	 Items	 with	 the	 lowest	 classification	 were	 the	 “selection	 and	 comparability	 of	
comparison	 groups”	 and	 “sample	 size	 and	 power”.	 The	 agreement	 between	 the	 two	
independent	reviewers	was	almost	perfect	(k=0.83;	95%	CI	0.29-1;	p=0.002).		
	
Study	characteristics	
Study	characteristics	are	presented	in	table	2.		A	total	of	6520	patients	with	COPD	with	an	age	
range	of	63.2-71.8	years,	mainly	males	 (4638	males	–	71,13%)	participated	 in	 the	13	 studies	
included.	Studies	designs	were	observational	(n=9)	(14,	15,	19-25)	and	pre	and	post	intervention	
(n=4)(16-18,	26).	
The	most	 frequent	 genetic	 variants	were	 the	mannose-binding	 lectine	 (MBL2)	 gene	 variants	
(n=3)	(14,	20,	22)	and	the	ADRB2	polymorphisms	(n=2)	(16,	17).	Other	genetic	variants	observed	
were	 group	 component	 (GC)	 single	 nucleotide	 polymorphisms	 (SNPs)	 (n=1)	 (25),	
HHIP/CHRNA/FAM13A	 variants	 (n=1)	 (15),	 SERPINA	 11478	 G>A	 variant	 (n=1)	 (23),	 25-
hydroxyvitamin	D	 receptor	 (VDR)	polymorphisms	 (n=1)	 (24),	CCL1	SNPs	 (n=1)	 (19),	 serotonin	
transporter	gene	variant	(SLC6A4)	(n=1)	(21),	HO-1	gene	promotor	polymorphism	(n=1)	(18)	and	
EPHX1	polymorphisms	(n=1)	(26).	
The	PRO	most	assessed	was	the	exacerbation	frequency	(n=7)	(14,	15,	20,	22-25),	followed	by	
health-related	quality	of	life	(n=4)	(16-18,	26),	anxiety	and	depression	(n=1)	(21),	exacerbation	
severity	 (19)	 and	 breathlessness,	 cough	 and	 sputum	 (n=1)(16).	 Exacerbation	 frequency	 was	
assessed	using	daily	diaries	(n=3)(23-25),	phone	calls	(n=3)(14,	15,	20),	questionnaires	(n=1)(15)	
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and	 patient	 interviews	 (n=1)(22).	 Anxiety	 and	 depression	 were	 assessed	 using	 the	 Hospital	
Anxiety	and	Depression	Scale	(HADS)(n=1)(21),	and	health-related	quality	of	life	and	respiratory	
health	 status	 using	 the	 St	 George	 Respiratory	 Questionnaire	 (SGRQ)	 (n=4)	 (16-18,	 26).	
Exacerbation	 severity	 was	 also	 assessed	 with	 questionnaires	 (n=1)(19)	 and	 finally	
breathlessness,	 cough	and	 sputum	were	assessed	using	 the	Breath	Cough	and	 Sputum	 scale	
(BCSS)	(n=1)(16).	
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Table	1-Quality	assessment	score	for	selected	studies	based	on	the	quality	of	genetic	association	studies	(Q-Genie).	
	 	 Items	 	
	 	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 Score	
St
ud
ie
s	
Bleecker		et	al,2012	(16)	 5	 5	 Na	 5	 4	 5	 6	 5	 6	 5	 5	 51	
Ishii		et	al,	2014	(25)	 5	 4	 3	 6	 3	 3	 3	 5	 4	 4	 5	 45	
Ishii		et	al,	2011	(21)	 6	 4	 5	 4	 2	 5	 2	 3	 4	 4	 5	 44	
Lin		et	al,	2011	(22)	 5	 6	 3	 5	 2	 3	 3	 5	 2	 4	 4	 42	
Mandal		et	al,	2015	(14)	 6	 6	 Na	 3	 2	 6	 1	 4	 3	 5	 6	 42	
Pillai		et	al,	2010	(15)	 4	 6	 Na	 5	 5	 4	 5	 6	 5	 4	 6	 50	
Quint		et	al,2011	(23)	 5	 4	 5	 5	 2	 3	 6	 3	 5	 4	 5	 47	
Quint		et	al,	2012	(24)	 4	 5	 3	 4	 5	 4	 2	 6	 3	 4	 4	 44	
Takabatake		et	al,	2006	(19)	 7	 6	 Na	 6	 5	 5	 3	 6	 6	 5	 6	 55	
Umeda		et	al,	2008	(17)	 5	 4	 Na	 4	 4	 5	 2	 4	 4	 3	 4	 39	
Yang		et	al,	2003	(20)	 6	 6	 4	 5	 5	 5	 3	 5	 5	 5	 6	 55	
Zhang		et	al,2015(26)	 5	 5	 5	 4	 4	 5	 4	 6	 4	 4	 4	 50	
Zhang		et	al,2015	(18)	 5	 5	 Na	 4	 4	 4	 5	 6	 4	 4	 5	 46	
Legend:	1-	rationale	for	study;	2-	selection	and	definition	of	outcome	of	interest;	3-	selection	and	comparability	of	comparison	group	(if	applicable);	4-	technical	classification	of	the	
exposure;	5-	non-technical	classification	of	the	exposure;	6	other	sources	of	bias;	7-	sample	size	and	power;	8-	a	priori	planning	of	analysis;	9-	statistical	methods	and	control	for	
confounding;	10-	testing	of	assumptions	and	inferences	for	genetic	analysis;	11-	appropriateness	of	inferences	drawn	from	results.	All	items	have	a	maximum	score	of	7.	
Na	–	not	applicable	
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Synthesis	of	results		
	 Genetic	variants	and	exacerbation	frequency	
Two	coding	GC	SNPs	rs4588	and	rs7041	(25),	5	SNP’s	and	7	haplotypes	from	MBL2	gene	have	
been	investigated	for	associations	with	exacerbation	frequency	(14,	20,	22).	Only	patients	with	
C	 allele	 at	 the	 rs4588	 polymorphism	 (C/C:	 83	 patients;	 A/C:	 45	 patients;	 A/A:	 7	 patients	
(p=0.0048))	 (25),	 3	MBL2	 SNP’s	 and	 1	 haplotype	were	 found	 significantly	more	 prevalent	 in	
frequent	 exacerbators	 (p<0.01)	 (14,	 20,	 22).	 HHIP,	 FAM13A	 and	 CHRNA3/5	 SNPs	 were	 also	
assessed,	however,	only	the	rs13118928	SNP	of	the	HHIP	gene	was	found	to	be	associated	to	
previous	 and	 prospective	 exacerbations	 (Incidence	 Rate	 Ratio=	 0.877;	 p=0.015	 and	
IRR=0.906;p=0.024,	respectively)	(15).	SERPINA1	11478	G>A	variant	(23)	and	25-hydroxyvitamin	
D	receptor	 (VDR)	polymorphisms	 (24)	were	not	associated	with	exacerbations	 frequency	 (α1-
antitrypsine:	 p=0.75;	 VDR	 polymorphisms:	 rs1544410:	 p=0.43;	 rs731236:	 p=0.64	 rs2228570:	
p=0.87)	(23,	24)	
Genetic	variants	and	exacerbation	severity	
The	A	allele	from	the	rs2282691	SNP	in	CCL1	gene	was	found	to	be	a	risk	allele	for	severity	of	
exacerbation	(OR	5.93;	p=0.023)	(19).	
	
	 Genetic	variants	and	depression	
Only	 the	 rs3794808	 SNP	 from	 the	 5	 SLC6A4	 gene	 polymorphisms	 (rs3794808;	 rs140701;	
rs140700;	rs2020939;	rs2020936)	was	considered	significantly	associated	with	HADS	depression	
score	in	patients	with	COPD	(p=0.022)(21).	
	 Genetic	variants	and	health-related	quality	of	life	
The	impact	of	HO-1	and	EPHX1	polymorphisms	on	treatments	with	N-acetylcysteine	(NAC)	was	
assessed	(18,	26).	Better	health-related	quality	of	 life,	assessed	with	the	SGRQ,	was	 found	 in	
patients	without	the	L	allele	(L-)	of	HO-1	gene,	which	is	a	(Gt)n	polymorphism,	than	in	those	with	
	
	
93	
the	L	allele	(L+)	relative	to	the	activity	score	of	SGRQ	(SGRQ	activity	score:	Baseline:	46.2±14,5;	
16	 weeks:	 46.3±11.0;	 32	 weeks:	 46.7±12.2;	 48	 weeks:	 47.4±15.5;	 p=0.02)(18).	 Additionally,	
patients	having	the	slow	activity	group	of	the	EPHX1	genotype	(based	on	exon	3	polymorphism)	
also	revealed	better	health-related	quality	of	life	than	those	having	the	fast	activity	group	for	
the	symptom	score	of	SGRQ	(Slow	activity	group:	baseline:	40.9±12.3;	after	NAC:	37.8±13.1;	Fast	
activity	group:	baseline:	41.7±13.5;	after	NAC	38.7±15.4;	p<0.05)	(26).	
The	impact	of	the	Gly16Arg	polymorphism	of	the	ADRB2	gene	on	health-related	quality	of	life	
HRQOL	was	also	assessed.	Significant	differences	were	observed	in	all	domains	and	total	scores	
of	SGRQ	between	both	genetic	groups	(Arg/Arg	and	non-	Arg/Arg),	however	only	the	impact	and	
total	scores	were	significantly	different	in	patients	with	the	Arg/Arg	genotype	(total	score:	-16.9	
vs.	 -8.1,	 p=0.005;	 impact	 score:	 -19.8	 vs.	 -2.2	 p<0.001)(17).	 No	 significant	 associations	were	
found	 when	 investigating	 impact	 of	 the	 ADRB2	 polymorphism	 on	 treatment	 effect	 with	
budesonide/formoterol	I(p=0.909)	and	II(p=0.648)	on	SGRQ(16).	
	
	 Genetic	variants	and	breathlessness,	cough	and	sputum		
No	significant	association	was	found	between	the	Gly16Arg	possible	genotypes	of	ADRB2	and	
the	scores	for	the	BCSS	scale	(p>0.05)(16).	
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Table	2	-Patient	reported	outcomes,	patient	reported	outcome	measures	and	genetic	associations	assessed.	
First	author’s	
name	
(Year)	
Design	 Population	
Patient	
Reported	
Outcome	(PRO)	
Patient	Reported	
Outcome	
Measure	(PROM)	
Genes	of	
interest	
	
Single	Nucleotide	
Polymorphisms	 Results	
Bleecker	et	al,	
(2012)	(16)		
Intervention,	
pre/post	
study	
Study	I:	n=1483	
Gly/Gly:	n=575	(370	Male,	64%,	
63±9	yrs)	
Smoking	status:	Ex/current:	
319/256	
Pack-years:	n.a.	
FEV1	(%pred):	34.5±9.4	
COPD	grades	(I/II/III/IV):	n.a.	
Arg/Gly:	n=685	(433	Male,	63%,	
63±9	yrs)	
Smoking	status:	Ex/current:	
396/289	
Pack-years:	n.a.	
FEV1	(%pred):	34.4±9.2	
COPD	grades	(I/II/III/IV):	n.a.	
Arg/Arg:	n=223	(139	Male,	62%,	
63±10	yrs)	
Smoking	status:	Ex/current:	130/93	
Pack-years:	n.a.	
FEV1	(%pred):	34.4±9.3	
COPD	grades	(I/II/III/IV):	n.a.	
	
HRQOL;	
Symptoms	
SGRQ	
BCSS	
ADRB2	 rs1042713	 BCSS:	Study	I	(p≥0.378);	Study	II	(p≥0.133)	
SGRQ:	Study	I	(p=0.909);	Study	II	(p=0.648)	
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Study	II:	n=1383	
Gly/Gly:	n=533	(373	Male,	70%,	
64±9	yrs)	
Smoking	status:	Ex/current:	
309/224	
Pack-years:	n.a.	
FEV1	(%pred):	33.9±9.1	
COPD	grades	(I/II/III/IV):	n.a.	
Arg/Gly:	n=635	(451	Male,	71%,	
63±9	yrs)	
Smoking	status:	Ex/current:	
373/262	
Pack-years:	n.a.	
FEV1	(%pred):	34.6±9.7	
COPD	grades	(I/II/III/IV):	n.a.	
Arg/Arg:	n=215	(133	Male,	62%,	
63±9	yrs)	
Smoking	status:	Ex/current:	117/98	
Pack-years:	n.a.	
FEV1	(%pred):	34.1±9.6	
COPD	grades	(I/II/III/IV):	n.a	
Ishii	et	al,	
(2014)	(25)	
Observational	
study	
n=135	(127	Male,	94%,	69.3±7.9	
yrs)	
Smoking	status:	Ex/current:	113/22	
Pack-years:	74.5	±47.6	
FEV1	(%pred):	57.8±20.3	
COPD	grades	(I/II/III/IV):	
22/61/41/11	
Exacerbation	
frequency	
Diary	 GC	 rs4588	
rs7041	
Exacerbation	Frequency:		
rs4588	SNP:	p=0.0048;		
																																															
rs7041	SNP:	p=0.56.	
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Ishii	et	al,	
(2011)	(21)	
Observational	
study	
n=247:	COPD	(228	Male,	92%,	
69.7±8.1	yrs)	
Smoking	status;	Ex/Current:	207/40	
Pack-years:	69.4±42.6	
FEV1	(%pred):	58.3±19.5	
COPD	grades(I/II/III/IV):	n.a		
	
Depressive	
symptoms	
HADS	 SLC6A4	 rs3794808	
rs140701	
rs140700	
rs2020939	
rs2020936	
rs3794808,	 p(adjusted)/	 Depression	 score	 HADS:	
Trend:	0.016;	Genotype:	0.052	
rs140701,	 p(adjusted)/	 Depression	 score	 HADS:	
Trend:	0.093;	Genotype:	0.246	
rs140700,	 p(adjusted)/	 Depression	 score	 HADS:	
Trend:	0.559;	Genotype:	0.844	
rs2020939,	 p(adjusted)/	 Depression	 score	 HADS:	
Trend:	0.13;	Genotype:	0.261	
rs2020936,	p(adjusted)/	Depression	score	HADS:	
Trend:	0.903;	Genotype:	0.966	
Lin	et	al,	(2011)	
(22)	
Observational	
study	
n=84:	Non-MBL	-deficient	
genotypes	(27	Male,	21%,	
66.5±10.9	yrs)	
Smoking	status:	Ex/current:	60/24	
Pack-years:	46	
FEV1	(%pred):	46	
COPD	grades(I/II/III/IV):	2/28/39/17	
n=12:	MBL-deficient	genotypes		
(6	Male,50%,68.9±10.3	yrs)		
Smoking	status:	Ex/current:	10/2	
Pack-years:	50	
FEV1	(%pred):	41	
COPD	grades(I/II/III/IV):	1/4/6/1	
Exacerbation	
frequency	
	
Patient	interviews	 MBL2	 rs11003125	
rs7096206	
rs1800451	
rs5030737	
rs1800450	
Frequency	of	infective	exacerbation	(times)	in:	
Non-MBL-Deficient	genotypes	(n=84):	3.52±0.78	
Total	episodes:	296				
MBL-Deficient	Genotypes	(n=12):	4.75±1.22		
Total	episodes:	57	
p˂0.0001	
	
Mandal	et	al,	
(2015)	(14)	
Observational	
study	
n=277	(190	Male,	84%,	67.8	±	9.5	
yrs)	
Smoking	status:	Ex/current:	203/74	
Pack-years:	Median	50	IQR	(35-80)	
FEV1	(%pred):	48.2±17.5	
Exacerbation	
frequency	
Contacting	the	
patients	
MBL2	 HL	(-550	G>C;	
rs11003125)	
YX	(-221	G>C;	
rs7096206)	
MBL2	haplotype:	HYPA	
Infrequent	exacerbation	(n=87):	Frequency:	0.282;	
Frequent	exacerbation	(n=85):	Frequency:	0.346;	
p=0.13	
MBL2	haplotype:	LYQA	
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COPD	grades(I/II/III/IV):	
0/129/104/40	
	
PQ	(+4	C>T;	
rs7095891)	
A/D	(+223	C>T;	
rs5030737)	
A/B	(+230	G>A;	
rs1800450)	
A/C	(+239	G>A;	
rs1800451)	
	
Infrequent	exacerbation	(n=75):	Frequency:	0.243;	
Frequent	exacerbation	(n=53):	Frequency:	0.215;	
p=0.49	
MBL2	haplotype:	LYPA	
Infrequent	exacerbation	(n=30):	Frequency:	0.097;	
Frequent	exacerbation	(n=15):	Frequency:	0.061;	
p=0.16	
MBL2	haplotype:	LXPA	
Infrequent	exacerbation	(n=71):	Frequency:	0.230	
Frequent	exacerbation	(n=50):	Frequency:	0.303;	
p=0.50	
MBL2	haplotype:	LYPB	
Infrequent	exacerbation	(n=27):	Frequency:	0.087;	
Frequent	exacerbation	(n=19):	Frequency:	0.077;	
p=0.77	
MBL2	haplotype:	HYPD	
Infrequent	exacerbation	(n=10):	Frequency:	0.032	
Frequent	exacerbation	(n=21):	Frequency:	0.085;	
p=0.01	
MBL2	haplotype:	LYQC	
Infrequent	exacerbation	(n=8):	Frequency:	0.026;	
Frequent	exacerbation	(n=3):	Frequency:	0.012;	
p=0.39	
Pillai	et	al,		
(2010)	(15)	
Observational	
study	
n=1,609	(1086	Male,	67.5%,	63.8±	
7.1	yrs)	
Smoking	Status:	Ex/Current,	%:	
64.5/35.5	
Pack-years:	50.9±28	
Exacerbation	
Frequency	
Retrospective	
exacerbations:	
questionnaires	
HHIP,	
FAM13A	
CHRNA3/5	
rs13118928	
rs8034191	
rs7671167	
Prior	Exacerbations:	
rs13118928(HHIP):	IRR:	0.877;	95%	IC:	0.78-0.975;	
p=0.015	
rs8034191(CHRNA):	IRR:	0.971;	95%	IC:	0.869-1.084;	
p=0.598	
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FEV1:	48.1±15.6	
COPD	grades(I/II/III/IV):	n.	a	
Prospective	
exacerbations:	
telephone	calls.	
rs7671167(FAM13A):	IRR:	1.081;	95%	IC:	0.978-
1.195;	p=	0.129	
Prospective	exacerbations		
rs13118928(HHIP):	IRR:	0.906;	95	IC:	0.832-0.987;	
p=0.024	
rs8034191(CHRNA):	IRR:	1.017;	95%	IC:	0.930-1.113;	
p=0.709	
rs7671167(FAM13A):	IRR:	1.028;	95%	IC:	0.943-1.22;	
p=0.528.	
Quint	et	al,	
(2011)	(23)	
Observational	
study	
n=204	(119	Male,	58%,	70.7	±11.1	
yrs)	
Smoking	status:	Ex/current:	152/52	
Pack-years:	51.6±38.7	
FEV1	(l):	48.2±19.9	
COPD	grades(I/II/III/IV):	
14/83/73/34	
Exacerbation	
frequency	
Diary	 SERPINA1	
	
11478G>A	
polymorphism	
Exacerbation	α1-antitrypsin:		
(GG):	Median=2.01	IQR	(1.54-2.99);		
(GA/AA):	Median=1.98	IQR	(1.67-2.12);	
	GG	vs.	GA/AA:	p=0.75	
baseline	vs.	exacerbation:	(GG):	p=0.87;	(GA/AA):	
p=0.92	
	
Quint	et	al,	
(2012)	(24)	
Observational	
study	
n=97	(61	Male,	62.9%,	71.8±8.8	yrs)	
Smoking	status:	Ex/current:	72/25	
Pack-years:	50.7±34.2	
FEV1	:(%pred):	50.3±19.7		
COPD	grades(I/II/III/IV):	n.a	
Exacerbation	
frequency	
Diary	 VDR	 rs1544410	
rs731236	
rs2228570	
rs1544410(Bsml):		
Frequent	exacerbators	(n=28):		
3	(10.7%)	–	BB	genotype;		
12	(42.9%)	–	Bb	genotype;		
13	(46.4%)	–	Bb	genotype.	
Infrequent	exacerbators	(n=68):		
15	(22.1%)	–	BB	genotype;		
26	(38.2%)	–	Bb	genotype;		
27	(39.7%)	–	Bb	genotype	
p=0.43	
rs731236(Taql):		
Frequent	exacerbators	(n=28):		
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10	(38.5%)	–	TT	genotype;		
13	(50%)	–	Tt	genotype;		
3	(11.5%)	–	Tt	genotype.	
Infrequent	exacerbators	(n=68):		
24	(36.4%)	–	TT	genotype;		
29	(43.9%)	–	Tt	genotype;		
13	(19.7%)	–	Tt	genotype	
p=0.64	
rs2228570(Fokl):		
Frequent	exacerbators	(n=28):		
10	(35.7%)	–	FF	genotype;		
14	(50,0%)	–	Ff	genotype;		
4	(14.3%)	–	Ff	genotype.	
Infrequent	exacerbators	(n=68):		
21	(30.9%)	–	FF	genotype;		
38	(55.9%)	–	Ff	genotype;		
9	(13.2%)	–	Ff	genotype	
p=0.87	
Takabatake	et	
al,	(2006)	(19)	
Observational	
study	
n=276	(276	Male,	100%,	72.9	±	1.6	
yrs)	
Smoking	status:	Ex/current:	276/0	
Pack-years:	n.a.	
FEV1:	(%pred)	n.a.	
COPD	grades(I+II/III+IV):	n.a.	
	
Exacerbation	
severity	
Questionnaire	 CCL1	 rs2282691	 Kaplan-Meier.	
Genotype:	AA;	No.	of	patients:60	
No.	of	events:	9		
Survival	Time,	mo	(95%	CI):	28	(27-30)	
Log-Rankk	Statistic:	AA	vs	AT:	1.51	(0.2189)	
Genotype:	AT;	No.	of	patients:	132	
No.	of	events:12	
Survival	Time,	mo	(95%	CI):	29	(28-30)	
Log-Rankk	Statistic:	AA	vs	TT:	7.67	(0.0056)	
Genotype:	TT;	No.	of	patients:	84	
	
	
100	
No.	of	events:2	
Survival	Time,	mo	(95%	CI):	30	(29-30)	
Log-Rankk	Statistic:	AT	vs	TT:	3.54	(0.0600)	
	
Cox	Proportional	Hazards	Regression	Model	
TT:	n=84;	p=n.a.;	OR	(95%	CI)	=	1	
AT:	n=132;	p=0.066;	OR	(95%	CI)	=	4.09	(0.91-18.32)	
AA:	n=60;	p=0.023;	OR	(95%	CI)	=	5.93	(1.28-27.48)	
Umeda	et	al,	
(2008)	(17)	
Intervention	
pre/post	
study	
n=	44:	
n=22:	Arg/Arg	(21	Male,	95%,	73±8	
yrs)	
Smoking	status:	Ex/current:	21/1	
Pack-years:	n.a	
FEV1:	(%pred)	Median	50.7	
Interquartile	range	(38.1-67.2)	
COPD	grades(I/II/III/IV):	n.a	
n=22:	non-Arg/Arg	(19	Male,	86%,	
68±8	yrs)	
Smoking	status:	Ex/current:	21/1	
Pack-years:	n.a	
FEV1	(%pred)	Median	63.9	
Interquartile	range	(42.3-89.0)	
COPD	grades(I/II/III/IV):	n.a	
	
Quality	of	life	 SGRQ	 ADRB2	 rs1042713	 Total	Score:		
Arg/Arg:	-16.9;	non-Arg/Arg:	-8.1	
P=0.05	
Impact	score:	
Arg/Arg:	-19.8;	non-	Arg/Arg:	22	
p<0.001	
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Yang	et	al,	
(2003)	(20)	
Observational	
study	
n=82	(52	Male,63	%,69±8	yrs)	
Smoking	status:	Ex/current:	n.a/n.	a	
Pack-years:	Median	54	IQR	(39-66)	
FEV1:(%pred):	41±14	
COPD	grades(I/II/III/IV):	n.a	
Exacerbation	
frequency	
Telephone	call	 MBL2	 rs1800450	 OR	4.9;	95%	IC:	1.7-14.4;	p=0.0037,		
pcorrected=	0.011	
Zhang	et	al,	
(2015)	(26)	
Intervention	
pre/post	
study	
n=219	(194	Male,	88.6%,70.2±7.2	
yrs)	
Smoking	status:	n.a.	
Pack-years:	28.1±7.2	
FEV1:(%pred):	51.8±15.9	
COPD	grades(I/II/III/IV):	n.a	
Respiratory	
Health	status	
SGRQ	 EPHX1	 rs1051740	(slow	
allele)	
rs2234922	(fast	
allele)	
	
	Total	score	
											Slow	activity	group:		
Baseline:	36.9±12.1;	After	NAC:	35.1±12.7	
p>0.05	
											Fast	activity	group:		
Baseline:	38.0±13.1;	After	NAC:	35.8±14.8	
p>0.05	
Symptom	score	
											Slow	activity	group:		
Baseline:	40.9±12.3;	After	NAC:	37.8±13.1	
p=0.033	
											Fast	activity	group:		
Baseline:	41.7±13.5;	After	NAC:	38.7±15.4	
P>0.05	
Activity	score	
											Slow	activity	group:		
Baseline:	47.2±12.1;	After	NAC:	45.8±12.8	
p>0.05	
											Fast	activity	group:		
Baseline:	48.7±13.3;	After	NAC:	49.1±14.0	
p>0.05	
Impact	score	
											Slow	activity	group:		
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Baseline:	26.3±10.9;	After	NAC:	24.9±11.5	
p>0.05	
											Fast	activity	group:	
Baseline:	28.1±11.7;	After	NAC:	26.5±12.1	
p>0.05	
	
Zhang	et	al,	
(2015)	(18)	
Intervention	
pre/post	
study	
n=368	
L+:	n=154	(140	Male,	90.9%,	
68.7±6.3	yrs)	
Smoking	status:	Ex/current:	123/31	
Pack-years:	24.5±6.6	
FEV1:	(%pred):	56.4±14.8	
COPD	grades(I/II/III/IV):	n.a	
L-:	n=214	(193	Male,90.2%,69.3±5	
yrs)	
Smoking	status:	Ex/current:	170/44	
Pack-years:	24.7±5.6	
FEV1:	(%pred)	56.6±19.2	
COPD	grades(I/II/III/IV):	n.a	
	
	
Respiratory	
health	status			
SGRQ	 HO-1	 (GT)n	
polymorphism:	
Total	score	
				Baseline	–	L+	group:35.0±11.6;	L-	group:	35.1±10.7	
				16	weeks	–	L+	group:35.7±9.6;	L-	group:	35.9±11.3	
				32	weeks	–	L+	group:36.2±11.2;	L-	group:36.4±12.4	
				48	weeks	–	L+	group:37.4±10.4;	L-	group:	37.8±9.0	
p=	0.18	
Activity	score	
				Baseline	–	L+	group:46.7±13.9;	L-	group:46.2±14.5	
				16	weeks	–	L+	group:46.5±14.1;	L-	group:	
46.3±11.0	
				32	weeks	–	L+	group:46.8±8.3;	L-	group:	46.7±12.2	
				48	weeks	–	L+	group:46.3±11.5;	L-	group:	
47.4±15.5	
p=	0.02	
Symptom	score	
				Baseline	–	L+	group:40.5±10.8;	L-	group:	40.1±12.3	
				16	weeks	–	L+	group:40.8±8.4;	L-	group:	40.8±15.1	
				32	weeks	–	L+	group:41.1±6.9;	L-	group:	41.6±10.3	
				48	weeks	–	L+	group:41.7±13.7;	L-	group:	41.6±9.7	
p=	0.86	
Impact	score	
				Baseline	–	L+	group:25.6±10.1;	L-	group:	26.0±11.4	
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				16	weeks	–	L+	group:25.9±7.1;	L-	group:	26.5±8.6	
				32	weeks	–	L+	group:25.7±11.3;	L-	group:	
26.9±10.5	
				48	weeks	–	L+	group:25.9±8.9;	L-	group:	26.7±13.4	
p=	0.09	
Legend:	All	values	are	presented	as	mean	±	standard	error,	unless	otherwise	stated.	
M-	male;	yrs-	years;	SNP-	single	nucleotide	polymorphism;	FEV1-		forced	expiratory	volume	in	1	second;	l-	liters;	%pred-	%	predicted;	COPD-	chronic	obstructive	pulmonary	disease	n.a-	not	applicable;	SE-	
standard	error;	IRR-	Incidence	rate	ratio;	IC-	Confidence	interval;	OR-	Odds	ratio;	SGRQ-	St.	George	Respiratory	Questionnaire;	BCSS-	Breathlessness,	cough	and	sputum	scale;	HADS	-	Hospital	anxiety	and	
depression	scale.	´	
Significant	results	presented	in	bold.	
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Discussion	
This	is	the	first	systematic	review	to	explore	associations	between	genetics	and	PROs	in	patients	
with	COPD.	The	13	studies	included	reported	on	12	genetic	variations	positively	associated	with	
5	distinct	PROs,	i.e.,	exacerbation	frequency	and	severity,	depression,	health	related	quality	of	
life	and	symptoms	(breathlessness,	cough	and	sputum).	
Most	studies	 (n=7/13)	assessed	the	association	of	specific	genetic	variants	with	exacerbation	
frequency.	 This	 is	 an	 important	 remark	 since	 the	 frequency	 of	 exacerbations	 is	 strongly	
associated	with	patients’	functional	and	physiological	deterioration	(27),	reduced	health	related	
quality	 of	 life	 (28)	 and	 substantial	morbidity	 and	mortality	 (29).	MBL2	was	 the	 gene	mostly	
associated	with	frequency	of	exacerbations	(3/13)	(14,	20,	22).	Several	polymorphisms	of	MBL2	
gene	play	important	roles	in	the	innate	immunity	as	it	encodes	for	mannose-binding	lectine.	The	
mannose-binding	 lectine	 is	 a	 pattern-recognition	 receptor	 that	 binds	 to	 the	 sugar	 structure	
presented	in	various	microorganisms(30).	Specific	polymorphisms	of	the	MBL2	gene	have	been	
found	responsible	for	causing	a	decreased	production	of	MBL	(MBL-deficient	genotype),	and	this	
has	been	associated	with	an	increased	risk	of	exacerbations.	In	fact,	high	MBL	levels	presented	
in	serum	have	been	associated	with	increased	survival	in	COPD	(14).	Thus,	MBL2	polymorphisms	
seem	to	be	promising	biomarkers	to	detect	those	with	more	susceptibility	to	exacerbations	and	
good	candidates	for	assessment	with	PRO-based	approaches.		
Polymorphisms	in	the	GC	and	VDR	genes	causing	deficits	of	vitamin	D	(associated	with	several	
comorbidities,	such	as	osteoporosis	or	skeletal	muscle	dysfunction,	in	patients	with	COPD(31)),	
have	 also	 been	 connected	 to	 the	 frequency	 of	 exacerbations.	 Nevertheless,	 a	 careful	
interpretation	of	the	literature	is	needed	since	both	significant	and	non-significant	associations	
between	GC	polymorphisms	rs4588	and	rs7041	or	VDR	(Bsm,	Taql,	Fokl)	polymorphisms	with	
frequency	of	exacerbations	and	lack	of	vitamin	D	have	been	reported	(25,	32,	33).	Additionally,	
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many	non-genetic	 factors	may	also	 lead	 to	 vitamin	D	deficiency,	 namely	 the	absence	of	 sun	
exposure,	vitamin	D	retention	on	body	fat	or	other	social/cultural	factors(31).	Therefore,	future	
studies	 are	 yet	 needed	 to	 enhance	 our	 understanding	 of	 the	 relationship	 between	 these	
polymorphisms,	vitamin	D	deficiency	and	PRO	in	COPD.	
Exacerbation	severity	has	been	significantly	associated	with	a	CCL1	allele	for	rs2282691	in	one	
study	(19).	However,	the	authors’	definition	of	exacerbation	severity	can	be	arguable,	as	they	
used	 death	 as	 endpoint.	 It	 is	 known	 that	 the	 severity	 of	 an	 exacerbation	 is	 not	 defined	 by	
mortality	but	rather	by	symptoms	and	number	and	length	of	hospitalizations	in	the	most	severe	
cases(34).	Since	the	authors	have	recorded	patients’	main	symptoms,	it	would	be	interesting	to	
assess	if	the	reported	A	allele	for	rs2282691	was	also	associated	with	those	and	if	the	T	allele	
actually	conferred	protection	to	acute	exacerbations	of	COPD,	as	suggested.	Other	option	would	
be	to	explore	the	correlations	between	rs2282691	variant	with	specific	instruments,	such	as	the	
Exacerbations	 of	 Chronic	 Pulmonary	 Disease	 Tool	 (EXACT-PRO)(35)	 to	 assess	 the	 severity	 of	
exacerbations.	This	analysis	would	be	essential	to	identify	patients	with	higher	predisposition	
for	more	 severe	 exacerbations	which	would	 allow	 them	 to	be	 targeted	 for	more	 timely	 and	
directed	monitoring	and	intervention.	
Depression	 was	 found	 to	 be	 associated	 with	 the	 rs3794808	 variant,	 affecting	 the	 SLC6A4	
gene(21).	It	is	known	that	depression	presents	a	strong	linkage	to	nicotine	dependence(36)	and	
SLC6A4	is	strongly	associated	with	the	pathophysiology	of	tobacco	use,	namely	at	the	level	of	
serotonin	reuptake.	Therefore,	it	would	be	expected	that	specific	genetic	variants	of	this	gene	
would	 play	 an	 important	 role	 on	 nicotine	 dependence	 and	 consequently	 depression	 in	
ex/current	smokers(37).	However,	different	SNPS	of	the	SLC6A4	gene	(38)	and	other	genes	such	
as	THSD4,	CHRNA,	CYP2A6(3)	have	also	been	associated	with	depression	in	COPD.	Thus,	it	would	
be	 valuable	 to	 confirm	 those	 associations	 populations	 patients	 with	 COPD	 with	 different	
characteristics,	 such	 as	 smokers	 and	 non-smokers,	 to	 decide	 if	 future	 therapies	 should	 take	
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these	genes	 into	consideration.	Currently,	 the	most	effective	 therapy	 to	combat	anxiety	and	
depression	in	patients	with	COPD	is	pulmonary	rehabilitation	(PR),	which	has	been	shown	to	be	
significantly	 	effective	by	reducing	the	 levels	of	depression	and	anxiety	symptoms	 in	patients	
with	this	disease	(39).	However,	PR	is	an	expensive	therapy	and	access	to	it	is	highly	limited	(40).	
Therefore,	genetics	may	be	used	to	signal	priority	patients	to	PR,	and	thus	optimize	human	and	
financial	resources	in	managing	COPD.	
Four	 studies	 investigated	 ADRB2(16,	 17),	 Ho-1(18)	 and	 EPHX1(26)	 association	 with	 health	
related	quality	of	life.	The	Gly16Arg	polymorphism	of	ADRB2	has	been	indicated	as	a	risk	factor	
for	COPD(41).	However,	different	results	regarding	its	association	with	health-related	quality	of	
life	emerged	from	our	systematic	review.	Umeda	et	al.,	showed	that	patients	with	COPD	and	the	
Arg/Arg	 genotype	 presented	 better	 health	 related	 quality	 of	 life	 in	 treatments	 with	
tiotropium(17)	whereas	no	significant	associations	was	found	in	the	study	of	Bleecker	et	al.	for	
the	 same	 polymorphism	 and	 budesonide/formoterol	 treatment	 (16).	 The	 most	 obvious	
explanation	is	the	substance	used	in	the	treatments,	since	other	studies	using	other	LABAs	(long-
acting	 b2-agonists)	 and	 LAMAs	 (long-acting	muscarinic	 antagonists)	 have	 also	 presented	 no	
associations	 (42).	 As	 for	 Ho-1	 and	 EPHX1	 polymorphisms,	 both	 genes	 presented	 significant	
associations	 with	 SGRQ	 activity	 and	 symptoms	 sub-scores	 in	 patients	 with	 COPD	 that	 were	
treated	 with	 N-acetylcysteine	 (NAC)(18,	 26).	 Pharmacogenetics	 studies	 are	 of	 significantly	
importance,	 since	 they	 investigate	 how	 genes	 affect	 a	 patient’s	 response	 to	 drugs.	 This	
knowledge	 facilitates	 health-care	 by	 identifying	 patients	 that	 will	 respond	 differently	 to	
treatments.	Future	studies	assessing	health	related	quality	of	life	may	also	include	these	genetic	
variants	reported	as	being	protective	against	COPD(43,	44),	since	they	may	play	an	important	
role	on	patients’	quality	of	life.	
PROs	 are	 increasingly	 being	 understood	 as	 excellent	 instruments	 to	 translate	 a	 range	 of	
outcomes	 that	 spirometry	 cannot	 express,	 such	 as	 symptoms	 and	 patients’	 perspective	 of	
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treatment(45).	 However,	 there	 is	 a	 massive	 number	 of	 PROMs	 (patient-reported	 outcomes	
measures)	 that	 were	 not	 found	 in	 this	 systematic	 review,	 and	 yet	 allow	 to	 assess	 other	
fundamental	PROs	such	as	mood,	social	and	sexual	life	(6).	Also,	it	was	shown	that	genetics	play	
a	 key	 role	 not	 only	 in	 the	 predisposition	 to	 the	 disease	 but	 also	 in	 common	 COPD-related	
comorbidities.	Thus,	further	studies	should	be	conducted	to	re-enforce	the	present	knowledge	
and	to	assess	the	genetic	influence	on	other	dimensions	of	patients’	lives.	
	
Limitations	
This	review	has	some	limitations	that	need	to	be	acknowledged.	Firstly,	the	definition	of	PROs	
(although	published)	has	not	been	used	as	a	primary	outcome	in	some	of	the	included	studies.	
Thus,	few	studies	gave	emphasis	to	it,	giving	priority	to	clinical	outcomes	which	may	have	led	to	
significant	loss	of	studies	and	information.	However,	to	minimize	this	problem	we	performed	a	
meticulous	choice	of	keywords	to	diminish	the	number	of	missed	studies.	Secondly,	the	constant	
changes	in	the	definition	of	exacerbation	in	the	GOLD(1)	may	also	result	in	loss	of	studies	over	
the	 years.	We	 overcome	 this	 drawback	 by	 enclosing	 studies	which	 include	 participants	 that	
reported	exacerbations	independently	of	the	definition	used	at	that	time.	Thirdly,	studies	used	
different	methodologies	 to	assess	similar	or	different	PROs	and	consequently,	prevented	the	
realization	of	a	meta-analysis.		
	
Conclusion	
This	was	the	first	systematic	review	to	explore	associations	between	genetics	and	PROs	in	COPD.	
Although	a	limited	number	of	PROs	have	been	successfully	related	to	genetic	variations,	findings	
suggest	that	a	significant	association	between	specific	genetic	variants	and	the	frequency	and	
severity	 of	 exacerbations,	 health-related	 quality	 of	 life	 and	 depressive	 symptoms	may	 exist.	
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Thus,	 further	 research	 is	 needed	 to	 confirm	 these	 results	 and	 to	 assess	 the	 possibility	 of	
association	 of	 other	 genetic	 variants	with	 other	 PROs	 in	 patients	with	 COPD,	 since	 this	may	
enhance	our	understanding	and	management	of	this	disease.	
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Table	S	1-	Targeted	gene	sequencing	panel	for	microarray	genotyping	
Code	 Gene	 rs	code	 Chromosome	 Location	 Functional	consequence	 Allele	
1	
ABCC1	
rs4148382	 16	 -	 -	 A/G	
2	 rs212093	 16	 16237704	 -	 A/G	
3	 rs35621	 16	 -	 intron	variant	 C/T	
4	
	 rs1045642	 16	 -	 synonymous	codon	 A/C/T	
5	 ABLIM3	 rs3839234	 5	 148596694	 intron	variant	 -/C	
840	 ACE	 rs4646994	 17	 61565900	 -	 (289BPALU)/-	
6	 ADAM19	 rs113897301	 5	 156929077	 intron	variant	 -/T	or	AT/A	
7	 	 rs11134779	 5	 156936766	 intron	variant	 C/T	
8	 ADAM33	 rs612709	 20	 	3652207	 intron	variant	 A/G	
9	 	 rs3918396	 20	 3651765	 Downstream	variant	500B,	missense,	nc	transcript	variant	 A/G	
10	 	 rs528557	 20	 3651742	
Downstream	variant	500B,nc	
transcript	variant,	synonymous	
codon	
C/G	
11	 	 rs543749	 20	 3649679	 intron	variant	 G/T	
12	 	 rs2787094	 20	 3649161	
downstream	variant	500B,nc	
transcript	variant,utr	variant	3	
prime	
C/G	
13	 	 rs2280090	 20	 3650205	 Intron	variant,missense,nc	transcript	variant	 A/G	
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14	 	 rs2280091	 20	 3650234	 intron	variant,missense,nc	transcript	variant	 A/G	
15	 ADRB2	 rs1042713	 5	 148206440	 missense	 A/G	
16	 	 rs1042714	 5	 148206473	 missense	 C/G/T	
17	 	 rs1042717	 5	 148206646	 synonymous	codon	 A/C/G	
18	 	 rs1042718	 5	 148206917	 synonymous	codon	 A/C	
19	 AGER	 rs2070600	 6	 32151443	 missense,nc	transcript	variant	 A/G	
20	 ADGRG6	 rs9399401	 6	 142668901	 intron	variant	 C/T	
21	 AHNAK	 rs2509961	 11	 62310909	 intron	variant	 A/G/T	
22	 AQP5	 rs3736309	 12	 50358054	
downstream	variant	500B,	
intron	variant,	
upstream	variant	2KB	
A/G	
23	 	 rs2878771	 12	 50352393	
intron	variant,utr	variant	3	
prime	
	
C/G	
24	 	 rs296763	 12	 50363014	 intron	variant,nc	transcript	variant	 C/G	
25	 ARL15	 rs2441026	 5	 53444498	 Intron	variant	 C/T	
26	 ARMC2	 rs2798641	 6	 109268050	 intron	variant,nc	transcript	variant	 C/T	
27	 	 rs2806356	 6	 109266255	 intron	variant	 C/G/T	
28	 BCL2	 rs1564483	 18	 60794654	 utr	variant	3	prime	 A/G	
29	 	 rs4987835	 18	 60806215	 intron	variant	 A/G	
30	 	 rs1531697	 18	 60806606	 intron	variant	 A/T	
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31	 	 rs3943258	 18	 60813636	 intron	variant	 A/G	
32	 BICD1	 rs10844154	 12	 32380501	 intron	variant	 A/C/T	
33	 C1GALT1	 rs10246303	 7	 7286445	 utr	variant	3	prime	 A/T	
34	 C5orf56	 rs7713065	 5	 131788334	 intron	variant	 A/C	
35	 C10orf11	 rs11001819	 10	 78315224	 intron	variant	 A/G	
36	 CACNA2D3	 rs1458979	 3	 55150677	 -	 A/G	
37	 CASC20	 rs6140050	 20	 6632901	 -	 A/C	
38	 CAT	 rs1001179	 11	 34460231	 upstream	variant	2KB	 A/G	
39	 CCDC38	 rs1036429	 12	 96271428	 intron	variant	 C/T	
40	 	 rs7957346	 12	 96260474	 downstream	variant	500B	 A/C	
41	 CCDC101	 rs17707300	 16	 28593347	 intron	variant	 A/G	
401	 CCL1	 rs2282691	 17	 32688309	 intron	variant	 A/T	
42	 CCL5	 rs2107538	 17	 34207780	 intron	variant,	upstream	variant	2KB	 C/T	
43	 	 rs2280788	 17	 34207405	 intron	variant,	upstream	variant	2KB	 C/G	
44	 	 rs2280789	 17	 34207003	
intron	variant,	
nc	transcript	
variant	
C/T	
45	 CDC123	 rs7068966	 10	 12277992	 intron	variant	 C/T	
46	 CD14	 rs2569190	 5	 140012916	
intron	variant,	
utr	variant	5	prime	
	
A/G	
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47	 CD40	 rs1883832	 20	 44746982	 nc	transcript	variant,	utr	variant	5	prime	 C/T	
48	 CD86	 rs1129055	 3	 121838319	 missense	 A/G	
49	 CDC6	 rs2077464	 17	 38446564	 intron	variant	 C/T	
50	 	 rs13706	 17	 38457151	 missense	 A/C/G	
51	 	 rs7217852	 17	 38470021	 Intron	variant	 A/G	
52	 	 rs9904270	 17	 38479831	 intron	variant,	upstream	variant	2KB	 C/T	
53	 CDC7	 rs1192404	 1	 92068967	 -	 A/G	
54	 CDH13		 rs4783244	 16	 82662268	 intron	variant	 G/T	
55	 	 rs12922394	 16	 82672327	 intron	variant	 C/T	
56	 CDKN1A	 rs1801270	 6	 36651971	 missense	 A/C/T	
57	 CDON	 rs567508	 11	 126008910	 intron	variant	 A/C/T	
58	 CELSR1	 rs9615358	 22	 46788781	 intron	variant	 A/G/T	
59	 CFDP1	 rs2865531	 16	 75390316	 intron	variant	 A/T	
60	 	 rs7186831	 16	 75473155	 -	 A/G	
61	 CHRM3	 rs6688537	 1	 239850588	 intron	variant	 A/C	
62	 CHRNA3/5	 rs1051730	 15	 78894339	 nc	transcript	variant,	synonymous	codon	 C/T	
63	 	 rs8034191	 15	 78806023	 intron	variant	 C/T	
64	 	 rs578776	 15	 78888400	 intron	variant,	utr	variant	3	prime	 C/T	
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65	 	 rs16969968	 15	 78882925	 intron	variant,	missense,nc	transcript	variant	 A/G	
66	 	 rs6495309	 15	 78915245	 downstream	variant	500B,	upstream	variant	2KB	 C/T	
67	 	 rs12910984	 15	 78819627	 intron	variant	 A/G	
68	 CHRNB4	 rs56218866	 15	 78922229	 intron	variant,missense,	utr	variant	5	prime	 A/G	
838	 CLCA1	 rs2145412	 1	 86939130	 missense	 A/C/T	
839	 	 rs1321694	 1	 86947975	 synonymous	codon	 A/T	
69	 CISD3	 rs11658500	 17	 36886828	 intron	variant	 A/G	
70	 CNTN4	 rs41526344	 3	 2985142	 intron	variant	 C/T	
71	 COL4A3	 rs11677877	 2	 228131169	 intron	variant,	missense,nc	transcript	variant	 A/G	
72	 CRP	 rs1205	 1	 159682233	 utr	variant	3	prime	 C/T	
73	 CSF2	 rs25882	 5	 131411460	 missense	 C/T	
74	 CSF3	 rs1042658	 17	 38173902	 nc	transcript	variant,	utr	variant	3	prime	 C/T	
75	 	 rs2227319	 17	 38170845	 upstream	variant	2KB	 A/G	
76	 	 rs2227316	 17	 38170007	 upstream	variant	2KB	 C/T	
77	 CTLA4	 rs231775	 2	 204732714	 missense	 A/G/T	
78	 	 rs926169	 2	 204722752	 -	 C/G/T	
79	 	 rs11571316	 2	 204731089	 upstream	variant	2KB	 C/T	
80	 	 rs3087243	 2	 204738919	 downstream	variant	500B	 A/G	
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81	 	 rs231725	 2	 204740675	 -	 A/G	
82	 CTSS	 rs7534124	 1	 150739073	 upstream	variant	2KB	 C/T	
83	 	 rs35989725	 1	 150738967:150738968	 -	 (CA)11/12		
84	 	 rs16827671	 1	 150738759	 upstream	variant	2KB	 C/T	
85	 	 rs34495036	 1	 150738484:150738487	 upstream	variant	2KB	 -/TCCC	
86	 	 rs3754212	 1	 150738200	 utr	variant	5	prime	 C/T	
87	 	 rs1136774	 1	 150738197	 utr	variant	5	prime	 A/G	
88	 CYBA	 rs9932581	 16	 88718353	 upstream	variant	2KB,	utr	variant	3	prime	 C/T	
89	 	 rs4673	 16	 88713236	 missense	 C/T	
90	 CYFIP2	 rs10515750	 5	 156810072	 intron	variant	 C/T	
91	 CYP1A1	 rs1048943	 15	 75012985	 missense	 A/C/G/T	
92	 	 rs464624		 5	 102103919	 intron	variant	 C/T	
93	 CYP1A2	 rs762551	 15	 75041917	 intron	variant	 A/C	
94	 	 rs35694136	 15	 75039613	 upstream	variant	2KB	 -/T	
95	 CYP2A6	 rs12459249	 19	 41339896	 -	 C/T	
96	 CYP2E1	 rs2031920	 10	 135339845	 nc	transcript	variant,	upstream	variant	2KB	 C/T	
97	 CYP2R1	 rs11819875	 11	 14917297	 utr	variant	5	prime	 G/T	
98	 DNAH5	 rs114929486	 5	 13887980	 intron	variant	 A/G	
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99	 DNLZ	 rs10870202	 9	 139257411	 intron	variant	 C/T	
100	 DSP	 rs2076295	 6	 7563232	 intron	variant	 G/T	
101	 EDN1	 rs5370	 6	 12296255	 missense	 G/T	
402	 EDNRB	 rs5351	 13	 78475313	 intron	variant,	synonymous	codon	 A/C/G	
102	 EEFSEC	 rs2955083	 3	 127961178	 Intron	variant	 A/T	
103	 EFCAB5	 rs62070270	 17	 28263980	 Intron	variant	 A/G	
104	 ELN	 rs41511151	 7	 73482987	 missense	 A/G	
105	 EPHX1	 rs2234922	 1	 226026406	 missense	 A/G/T	
106	 	 rs1051740	 1	 226019633	 missense	 C/T	
107	 F2R	 rs2227744	 5	 76010349	 upstream	variant	2KB	 A/G	
108	 FAM13A	 rs7671167	 4	 89883979	 Intron	variant	 C/T	
109	 	 rs2045517	 4	 89870964	 intron	variant,	upstream	variant	2KB	 C/T	
110	 	 rs2609264	 4	 89828080	 Intron	variant	 A/G	
111	 	 rs2609261	 4	 89835485	 Intron	variant	 C/T	
112	 	 rs2609260	 4	 89836819	 Intron	variant	 A/G	
113	 	 rs6830970	 4	 89777081	 Intron	variant	 A/G	
114	 	 rs2869966	 4	 89869078	 intron	variant	 C/T	
115	 	 rs2869967	 4	 89869332	 Intron	variant	 C/T	
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116	 FAM19A2	 rs348644	 12	 62463703	 Intron	variant	 G/T	
117	 FGD6	 rs113745635	 12	 95554771	 Intron	variant	 C/T	
118	 FGF7	 rs10519225	 15	 49720778	 Intron	variant	 A/G	
119	 FGF10	 rs2973644	 5	 44384183	 Intron	variant	 A/C/T	
120	 	 rs10473352	 5	 44308252	 Intron	variant	 A/G	
121	 FZD8	 rs663700	 10	 35916372	 -	 A/G	
122	 GALNT13	 rs6751439	 2	 154731287	 Intron	variant	 A/G	
123	 GC	 rs7041	 4	 72618334	 intron	variant,	missense	 G/T	
124	 	 rs4588	 4	 72618323	 intron	variant,	missense	 A/C/T	
125	 	 rs17467825	 4	 72605517	 intron	variant	 A/G	
126	 	 rs1155563	 4	 72643488	 Intron	variant	 C/T	
127	 GCLC	 rs17883901	 6	 53410037	 upstream	variant	2KB	 A/C/T	
128	 GCLM	(DNTTIP2)	 rs2235970	 1	 94345137	 upstream	variant	2KB	 C/T	
129	 GDNF-AS1	 rs10461985	 5	 37874409	 intron	variant	 A/G	
130	 GLIS3	 rs7872188	 9	 4124377	 intron	variant	 C/T	
131	 GSTCD	 rs10516526	 4	 106688904	 intron	variant	 A/G	
132	 	 rs11727735	 4	 106631870	 intron	variant,	upstream	variant	2KB	 A/G	
421	 GSTM1	 	 	 Null	genotype	 	 	
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133	 GSTO1	 rs4925	 10	 106022789	 intron	variant,	missense	 A/C	
134	 GSTO2	 rs156697	 10	 106039185	 intron	variant,	missense	 C/T	
135	 	 rs156699	 10	 106053641	 intron	variant	 C/T	
136	 GSTP1	 rs1695	 11	 67352689	 missense	 A/G	
137	 	 rs1138272	 11	 67353579	 missense	 C/T	
420	 GSTT1	 	 GSTT1	null		genotype	 	 	 	
138	 HCRTR1	 rs1056526	 1	 32084904	 synonymous	codon	 C/T	
139	 HDAC4	 rs12477314	 2	 239877148	 -	 C/T	
140	 HHIP	 rs13118928	 4	 145486389	 -	 A/G	
141	 	 rs12504628	 4	 145436324	 intron	variant	 C/T	
142	 	 rs1828591	 4	 145480780	 intron	variant	 A/G	
143	 	 rs1980057	 4	 145485738	 -	 C/T	
144	 	 rs10519717	 4	 145480340	 intron	variant	 C/T	
145	 	 rs11938704	 4	 145443370	 intron	variant	 A/C	
146	 	 rs10013495	 4	 145505638	 -	 C/T	
147	 HLA-DQB1	 rs114229351	 6	 32648418	 -	 C/T	
403	 HMOXI	 rs3074372	 22	 35776887:35776888	 upstream	variant	2KB	 -/GT	
148	 HTR4	 rs3995090	 5	 147845815	 Intron	variant	 A/C	
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149	 	 rs11168040	 5	 139711031	 -	 A/G	
150	 	 rs6889822	 5	 147846707	 intron	variant	 A/G	
151	 IDH3B	 rs6107100	 20	 2644685	 intron	variant	 A/C/T	
152	 IFIT3	 rs140549288	 10	 91099466	 intron	variant,	missense	 C/G	
153	 IFNG	 rs2069732	 12	 68554461	 upstream	variant	2KB	 C/T	
154	 	 rs2069707	 12	 68554288	 upstream	variant	2KB	 C/G	
155	 	 rs2430561	 12	 68552522	 intron	variant	 A/T	
156	 	 rs1861493	 12	 68551196	 intron	variant	 A/G	
157	 	 rs2069718	 12	 68550162	 intron	variant	 A/C/T	
158	 	 rs2069727	 12	 68548223	 downstream	variant	500B	 A/G	
159	 IL1A		 rs1800587	 2	 113542960	 utr	variant	5	prime	 C/G/T	
160	 IL1B	 rs1143634	 2	 113590390	 synonymous	codon	 C/T	
161	 	 rs16944		 2	 113594867	 upstream	variant	2KB	 A/G	
807	 IL1RN	 rs2234663	 2	 113888106:113888191	 -	
(ATCCTGGGGAAAGTGAGGGAAATA	
TGGACATCACATGGAACAACATCCA	
GGAGACTCAGGCCTCTAGGAGTAAC	
TGGGTAGTGTGC)2/3/4/5/6	
162	 IL2	 rs2069762	 4	 123377980	 upstream	variant	2KB	 G/T	
163	 IL27	 rs153109	 16	 28519096	 intron	variant,upstream	variant	2KB	 C/T	
164	 	 rs17855750	 16	 28515228	 missense	 G/T	
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165	 IL4	 rs2070874	 5	 132009710	 utr	variant	5	prime	 C/T	
404	 	 rs2243248	 5	 132008644	 upstream	variant	2KB	 G/T	
405	 IL4R	 rs1801275	 16	 27374400	 downstream	variant	500B,	missense	 A/G	
166	 IL6		
rs1800795	
	 7	 22766645	
intron	variant,	
upstream	variant	2KB	 C/G	
167	 	 rs1800797	 7	 22766221	
intron	variant,	
nc	transcript	variant,	
upstream	variant	2KB	
A/G	
168	 	 rs1800796	 7	 22766246	
intron	variant,	
nc	transcript	variant,	
upstream	variant	2KB	
C/G	
169	 	 rs2069825	 7	 22765337:22765338	 nc	transcript	variant,upstream	variant	2KB	 -/CT/TC	
170	 IL6R	 rs4129267	 1	 154426264	 intron	variant	 C/T	
171	 IL8	 rs4073	 4	 74606024	 upstream	variant	2KB	 A/T	
172	 IL8RB	 rs2230054	 2	 219000310	 synonymous	codon	 C/T	
173	 IL10	 rs1800871	 1	 206946634	 upstream	variant	2KB	 C/T	
174	 	 rs1518110	 1	 206944861	 intron	variant	 G/T	
175	 	 rs1800896	 1	 206946897	 upstream	variant	2KB	 A/G	
176	 	 rs1878672	 1	 206943713	 intron	variant	 C/G/T	
177	 	 rs3024496	 1	 206941864	 utr	variant	3	prime	 C/T	
178	 	 rs3024498	 1	
	
206941529	
	
utr	variant	3	prime	 A/G	
179	 IL12A	 rs2243115	 3	 159706280	 intron	variant,	upstream	variant	2KB	 G/T	
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180	 IL13	 rs2066960	 5	 131994435	 intron	variant	 A/C	
182	 	 rs20541	 5	 131995964	 missense	 C/T	
182	 	 rs1295685	 5	 131996445	 utr	variant	3	prime	 C/T	
183	 	 rs1800925	 5	 131992809	 upstream	variant	2KB	 C/T	
184	 IL13RA1	 rs2250747	 X	 117863748	 intron	variant	 A/G	
185	 IL16	 rs11556218	 15	 81598269	 missense,	nc	transcript	variant	 G/T	
186	 IL17F	 rs763780	 6	 52101739	 missense	 C/T	
187	 IREB2	 rs2568494	 15	 78740964	 intron	variant	 A/G	
188	 	 rs2656069	 15	 78745707	 intron	variant	 A/G	
189	 	 rs12593229	 15	 78765290	 intron	variant	 G/T	
190	 	 rs10851906	 15	 78774676	 intron	variant	 A/G	
191	 	 rs13180	 15	 78789488	 synonymous	codon	 C/T	
192	 	 rs1964678	 15	 78754000	 intron	variant	 C/T	
193	 	 rs965604	 15	 78789223	 intron	variant	 C/T	
194	 ITGA1	 rs1551943	 5	 52195033	 intron	variant	 A/G	
195	 KCNE2	 rs9978142	 21	 35652239	 -	 A/G/T	
196	 KCNMB1		
rs11739136	
	 5	 169810796	
intron	variant,	
missense	 C/T	
197	 	 rs2301149	 5	 169805956	 intron	variant,	missense	 A/C/G	
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198	 	 rs2656842	 5	 169805630	 intron	variant,	utr	variant	3	prime	 G/T	
199	 	 rs314156	 5	 169805411	 intron	variant,	utr	variant	3	prime	 C/T	
200	 KCNQ5	 rs141651520	 6	 73670096:73670101	 intron	variant	 -/TTCTAT	
201	 KEAP1	 rs11085735	 19	 10602180	 intron	variant	 A/C	
202	 LEP	 rs7799039	 7	 127878783	 upstream	variant	2KB	 A/C/G	
817	 LEPR	 rs1137100	 1	 66036391	 missense	 A/G	
818	 	 rs1805096	 1	 66102257	 synonymous	codon	 C/T	
819	 	 rs7531867	 1	 66107546	 -	 A/G	
820	 	 rs1892535	 1	 66097181	 intron	variant	 C/T	
821	 	 rs6588153	 1	 66092017	 downstream	variant	500B,intron	variant	 A/T	
822	 	 rs1938484	 1	 66081282	 intron	variant	 A/C	
823	 	 rs12564626	 1	 66056542	 intron	variant	 A/G	
824	 	 rs10443259	 1	 66051350	 intron	variant	 A/G	
825	 	 rs6691346	 1	 66046397	 intron	variant	 A/G	
826	 	 rs4655680	 1	 66041469	 intron	variant	 G/T	
827	 	 rs6702028	 1	 66019891	 intron	variant	 C/T	
828	 	 rs1782763	 1	 66007900	 intron	variant	 C/T	
829	 	 rs1171265	 1	 66003252	 intron	variant	 A/G	
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830	 	 rs1171271	 1	 65998790	 intron	variant	 C/T	
831	 	 rs1782754	 1	 65993348	 intron	variant	 A/G	
832	 	 rs1171274	 1	 65980838	 intron	variant	 C/T	
833	 	 rs10889558	 1	 65976966	 intron	variant	 A/G	
834	 	 rs1327121	 1	 65957337	 intron	variant	 C/T	
835	 	 rs17412682	 1	 65952293	 intron	variant	 C/T	
836	 	 rs2025804	 1	 65946121	 intron	variant	 C/T	
837	 	 rs9436740	 1	 65891901	 intron	variant	 A/T	
203	 LRP1	 rs11172113	 12	 57527283	 intron	variant	 C/T	
204	 LTA	 rs909253	 6	 31540313	 intron	variant	 C/T	
205	 LTBP4	 rs2077407	 19	 41119829	 synonymous	codon	 A/C/T	
206	 	 rs2303729	 19	 41111069	 missense,utr	variant	5	prime	 C/T	
207	 	 rs1131620	 19	 41117869	 missense	 A/G	
208	 	 rs1051303	 19	 41118056	 missense	 A/G	
209	 LOC105377462	 rs11100860	 4	 145479139	 intron	variant	 A/G	
210	 LOC153910	 rs262129	 6	 142853144	 intron	variant	 A/G	
211	 LOC101928765	 rs16825116	 2	 229406685	 intron	variant	 A/G/T	
212	 LST1	 rs28986170	 6	 31556156:31556157	 intron	variant	 -/AA	
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213	 MAGI2	 rs10251504	 7	 77689888	 intron	variant	 A/G	
406	 MBL2	 rs11003125	 10	 54532014	 intron	variant,upstream	variant	2KB	 C/G	
407	 	 rs7096206	 10	 54531685	 intron	variant,upstream	variant	2KB	 C/G	
408	 	 rs1800450	 10	 54531235	 missense	 A/G	
409	 	 rs5030737	 10	 54531242	 missense	 C/T	
410	 	 rs7095891	 10	 54531461	 intron	variant,upstream	variant	2KB	 A/G	
214	 ME3	 rs145729347	 11	 86442733	 intron	variant	 C/G	
215	 MECOM	 rs1344555	 3	 169300219	 intron	variant	 A/G	
216	 MFAP2	 rs2284746	 1	 17306675	 intron	variant	 C/G	
217	 MICAL3	 rs11704827	 22	 18450287	 intron	variant	 A/T	
218	 MGA	 rs72724130	 15	 41977690	 intron	variant	 A/T	
219	 MIR146A	 rs2910164	 5	 159912418	 nc	transcript	variant	 C/G	
220	 MIR169A2	 rs11614913	 12	 54385599	 nc	transcript	variant	 C/T	
221	 MIR499A	 rs3746444	 20	 33578251	 intron	variant,nc	transcript	variant	 C/T	
222	 MMP1	 rs1799750	 11	 102670496	 intron	variant,upstream	variant	2KB	 -/G	
223	 MMP2	 rs243865	 16	 55511806	 upstream	variant	2KB	 C/T	
224	 MMP9	 rs3918242	 20	 44635976	 upstream	variant	2KB	 C/T	
225	 MMP12	 rs2276109	 11	 102745791	 upstream	variant	2KB	 A/G	
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226	 	 rs652438	 11	 102736642	 missense	 A/C/G	
227	 MMP14	 rs1003349	 14	 23305663	 upstream	variant	2KB	 G/T	
228	 	 rs1042703	 14	 23306048	 missense	 C/T	
229	 	 rs2236302	 14	 23312554	 synonymous	codon	 C/G	
230	 	 rs2236307	 14	 23312923	 synonymous	codon	 A/C/G/T	
231	 MMP15	 rs12447804	 16	 58075282	 intron	variant	 C/T	
232	 MN1	 rs2283847	 22	 28181399	 intron	variant	 A/C/G/T	
233	 MOCS3	 rs7269297	 20	 49576664	 missense,upstream	variant	2KB	 G/T	
234	 MSR1	 rs3747531	 8	 16012648	 missense	 C/G/T	
235	 MSRB3	 rs1494502	 12	 65824670	 intron	variant	 A/G	
236	 MTCL1	 rs647097	 18	 8808464	 intron	variant	 A/G	
237	 MYPN	 rs7095607	 10	 69957350	 intron	variant	 A/G	
238	 NAT2	 rs1799929	 8	 18257994	 synonymous	codon	 C/T	
239	 	 rs1799930	 8	 18258103	 missense	 A/G	
240	 	 rs1208	 8	 18258316	 missense	 A/G	
241	 	 rs1799931	 8	 18258370	 missense	 A/G	
242	 NCR3	 rs2857595	 6	 31568469	 -	 C/T	
243	 NFE2L2	 rs2364723	 2	 178126546	 intron	variant	 C/G/T	
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244	 NFKB1B	 rs2241704	 19	 39396335	 intron	variant	 A/T	
245	 NOS3	 rs1799983	 7	 150696111	 missense	 G/T	
246	 	 rs3918161	 7	 150690009	 intron	variant,	upstream	variant	2KB	 C/T	
247	 	 rs1800779	 7	 150689943	 intron	variant,	upstream	variant	2KB	 A/G	
411	 	 4B/4A	 7	 150694144:150694644	 -	 -	
248	 	 rs1549758	 7	 150695726	 synonymous	codon	 C/T	
249	 NQO1	 rs1800566	 16	 69745145	 missense	 C/T	
250	 NR3C1	 rs6195	 5	 142779317	 missense	 A/G/T	
251	 NT5C3B	 rs4796712	 17	 39987130	 nc	transcript	variant,synonymous	codon	 A/C/T	
252	 NTSDC1	 rs1052443	 6	 116568773	 -	 A/C	
253	 ODZ2	 rs516732	 5	 165107100	 -	 C/T	
254	 OGG1	 rs1052133	 3	 9798773	
downstream	variant	500B,	
intron	variant,missense,	
utr	variant	3	prime	
C/G	
255	 OLIG3	 rs473892	 6	 137951047	 	 A/G	
256	 OR4X1	 rs10838851	 11	 48286231	
stop	gained,	
synonymous	codon	
	
A/C/T	
257	 PARK2	 rs577876	 6	 161923155	 intron	variant	 A/G	
258	 	 rs6455728	 6	 161849789	 intron	variant	 A/G/T	
259	 	 rs9346917	 6	 162914986	 intron	variant	 C/T	
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260	 PCDH9	 rs17490056	 13	 66726903	 -	 C/T	
261	 PDE4D	 rs829259	 5	 58267976	 utr	variant	3	prime	 A/T	
262	 	 rs159497	 5	 58208218	 -	 A/G	
263	 	 rs16878037	 5	 59709752	 intron	variant	 C/T	
264	 PLAUR	 rs2302524	 19	 44156472	 intron	variant,missense	 C/T	
265	 	 rs2283628	 19	 44163061	 intron	variant	 C/T	
266	 	 rs740587	 19	 44196668	 intron	variant,upstream	variant	2KB	 C/T	
267	 	 rs11668247	 19	 44194362	 intron	variant	 C/T	
268	 	 rs344779	 19	 44194362	 -	 G/T	
269	 PPARG	 rs3856806	 3	 12475557	
intron	variant,	
synonymous	codon,	
utr	variant	3	prime	
C/T	
270	 PPT2	 rs10947233	 6	 32124424	 -	 C/G/T	
271	 PRDX5	 rs9787810	 11	 64085298	 upstream	variant	2KB,	utr	variant	5	prime	 C/T	
272	 PTCH1	 rs16909859	 9	 98204792	 downstream	variant	500B	 A/G	
273	 PTEN	 rs701848	 10	 89726745	 utr	variant	3	prime	 C/T	
841	 	 rs1903858		 10	 89653686	 intron	variant	 C/T	
274	 PTGS2	 rs20417	 1	 186650321	 nc	transcript	variant,	upstream	variant	2KB	 C/G	
275	 RAB4B	 rs7937	 19	 41302706	 intron	variant,nc	transcript	variant,utr	variant	3	prime	 A/C/T	
276	 	 rs2604894	 19	 41292404	 intron	variant	 C/T	
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277	 RIN3	 rs754388	 14	 93115410	 intron	variant	 C/G	
278	 RARB	 rs1529672	 3	 25520582	 intron	variant	 A/C	
279	 SATB1	 rs6577641	 3	 18397849	 intron	variant	 C/T	
800	 SERPINA1	 rs8004738	 14	 94856914	 upstream	variant	2KB,utr	variant	5	prime	 A/G	
801	 	 rs17751769	 14	 94856657	 intron	variant,	upstream	variant	2KB	 A/G	
802	 	 rs709932	 14	 94849201	 missense	 A/G	
803	 	 rs11832	 14	 94843565	 utr	variant	3	prime	 A/G	
804	 	 rs1303	 14	 94844843	 missense	 G/T	
805	 	 rs28929474	 14	 94844947	 missense	 A/G	
806	 	 rs17580	 14	 94847262	 missense	 A/T	
280	 SERPINA3	 rs1800463	 14	 95081011	 missense	 A/C/T	
281	 	 rs17473	 14	 95085642	 missense	 C/G/T	
282	 SERPINE2	 rs6754561	 2	 224839696	 downstream	variant	500B	 C/T	
283	 	 rs6734100	 2	 224841995	 intron	variant	 C/G	
284	 	 rs729631	 2	 224844919	 intron	variant	 C/G/T	
285	 	 rs975278	 2	 224847707	 intron	variant	 A/G/T	
286	 	 rs6436449	 2	 224848333	 intron	variant	 C/T	
287	 	 rs7608941	 2	 224854068	 intron	variant	 A/C	
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288	 	 rs1371028	 2	 224879450	 intron	variant	 C/T	
289	 SERPINA12	 rs140198372	 14	 94953832	 intron	variant,splice	acceptor	variant	 A/C	
290	 SETD7	 rs17050782	 4	 140423134	 intron	variant	 A/G	
291	 SFTPA1	 rs1136450	 10	 81371729	 intron	variant,missense	 C/G	
292	 STFTPA2	 rs17886395	 10	 81318663	 missense	 C/G	
293	 SFTPB	 rs3024791	 2	 85895704	 intron	variant,upstream	variant	2KB	 A/G	
294	 	 rs2118177	 2	 85890293	 intron	variant	 C/T	
295	 	 rs2304566	 2	 85890758	 intron	variant	 A/G	
296	 	 rs1130866	 2	 85893741	 missense	 C/T	
297	 SFTPD	 mrs721917	 10	 81706324	 missense	 C/T	
298	 	 rs10887199	 10	 81702834	 intron	variant	 C/T	
299	 	 rs2245121	 10	 81699238	 intron	variant	 A/G	
300	 	 rs911887	 10	 81701523	 intron	variant	 A/G	
301	 	 rs6413520	 10	 81706281	 synonymous	codon	 C/T	
302	 	 rs7078012	 10	 81705433	 intron	variant	 C/T	
303	 	 rs3088308	 10	 81697868	 missense	 A/T	
304	 SH3GL3	 rs66650179	 15	 84261690	 intron	variant	 -/A	
305	 SIRT1	 rs7895833	 10	 69623057	 -	 A/C/G	
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306	 	 rs2273773	 10	 69666598	 synonymous	codon	 C/T	
307	 	 rs7069102	 10	 69663120	 intron	variant	 C/G	
308	 SLC6A4	 rs2020936	 17	 28550814	 intron	variant	 C/T	
309	 	 rs3794808	 17	 28531793	 intron	variant	 A/G	
310	 SLC11A1	 rs3731865	 2	 219250003	 intron	variant	 A/C/G	
311	 	 rs17235409	 2	 219259732	 missense,nc	transcript	variant	 A/C/G	
312	 	 rs1059823	 2	 219259844	 nc	transcript	variant,utr	variant	3	prime	 A/G	
313	 SMAD3	 rs28683050	 15	 67378336	 intron	variant	 C/T	
314	 SMOC2	 rs1402	 6	 168943376	 intron	variant	 G/T	
315	 	 rs747995	 6	 168930816	 intron	variant	 A/G	
316	 SOD2	 rs2842958	 6	 160108425	 intron	variant	 A/G	
317	 	 rs4880	 6	 160113872	 missense,utr	variant	5	prime	 C/T	
318	 SOD3	 rs1799895	 4	 24801834	 missense,nc	transcript	variant	 C/G	
319	 	 rs8192288	 4	 24796678	 upstream	variant	2KB	 A/G/T	
320	 	 rs8192287	 4	 24796568	 upstream	variant	2KB	 G/T	
321	 SOX5	 rs11046966	 12	 23677692	 -	 C/T	
322	 SPAG17	 rs200154334	 1	 118862071:118862072	 -	 -/AT	
323	 SPATA9	 rs153916	 5	 95036700	 intron	variant	 A/G	
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324	 STAT1	 rs13010343	 2	 191843445	 intron	variant	 A/G	
325	 SUCLG2	 rs1490265	 3	 67452043	 intron	variant	 A/C	
326	 SVIL	 rs3847402	 10	 30267810	 -	 A/G	
327	 TET2	 rs2047409	 4	 106137033	 intron	variant	 C/T	
328	 TBX3	 rs35506	 12	 115500691	 intron	variant	 A/T	
329	 TERT	 rs2736100	 5	 -	 intron	variant	 G/T	
330	 TGFB	 rs1800469	 19	 41860296	 downstream	variant	500B,upstream	variant	2KB	 C/T	
331	 	 rs1800470	or	rs1982073	 19	 41858921	 missense	 C/G/T	
332	 	 rs1800471	 19	 41858876	 missense	 C/G	
333	 	 rs11083616	 19	 41865643	 intron	variant	 A/G	
334	 	 rs11466321	 19	 41854916	 intron	variant	 C/G/T	
335	 	 rs2241712	 19	 41869756	
intron	variant,	
upstream	variant	2KB,	
utr	variant	5	prime	
A/G	
336	 	 rs2241718	 19	 41829606	 utr	variant	3	prime	 C/T	
337	 	 rs6957	 19	 41830606	 utr	variant	3	prime	 A/G	
808	 TGFBR3	 rs2296621	 1	 92163786	 intron	variant	 A/C	
809	 	 rs2291477	 1	 92178335	 intron	variant	 C/G	
810	 	 rs284170	 1	 92214628	 intron	variant	 C/G/T	
811	 	 rs10874996	 1	 92300084	 intron	variant	 A/G	
	
137	
812	 	 rs2129972	 1	 92305250	 intron	variant	 A/G	
813	 	 rs2634028	 1	 92320853	 intron	variant	 A/C	
814	 	 rs2046737	 1	 92326636	 intron	variant	 A/G	
815	 	 rs12727153	 1	 92331518	 intron	variant	 A/C	
816	 	 rs1805110	 1	 92327045	 missense,nc	transcript	variant	 C/T	
338	 THSD4	 rs8033889	 15	 71680080	 intron	variant	 G/T	
339	 	 rs1441358	 15	 71612514	 intron	variant	 G/T	
340	 	 rs12591467	 15	 71788387	 intron	variant	 C/T	
341	 	 rs12899618	 15	 71645120	 intron	variant	 A/G	
342	 TIMP1	 rs4898	 X	 47444985	
intron	variant,	
synonymous	codon,	
upstream	variant	2KB	
C/T	
343	 	 rs11551797	 X	 47445940	
downstream	variant	500B,	
intron	variant,	
synonymous	codon,	
upstream	variant	2KB	
C/T	
344	 TIMP2	 rs2277698	 17	 76867017	 synonymous	codon	 A/G	
345	 	 rs8179090	 17	 76921889	 upstream	variant	2KB	 C/G	
346	 TLR4	 rs4986791	 9	 120475602	 missense	 C/T	
347	 TLR9	 rs187084	 3	 52261031	 upstream	variant	2KB	 C/T	
348	 TMEM176A	 rs2888674	 7	 150510915	 -	 A/G/T	
349	 TNF	 rs1800629	 6	 31543031	 upstream	variant	2KB	 A/G	
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350	 	 rs769178	 6	 31547514	 -	 A/C	
351	 	 rs3091257	 6	 31546850	 -	 C/T	
352	 	 rs361525	 6	 31543101	 upstream	variant	2KB	 A/G	
353	 	 rs1800630	 6	 31542476	 downstream	variant	500B,	upstream	variant	2KB	 A/C	
354	 	 rs56036015	 6	 31543064	 upstream	variant	2KB	 A/G	
355	 TNS1	 rs2571445	 2	 218683154	 missense	 C/T	
356	 TP53	 rs1042522	 17	 7579472	 missense,	upstream	variant	2KB	 A/C/G	
357	 TRPV4	 rs12578401	 12	 110233500	 intron	variant	 C/T	
358	 	 rs12579553	 12	 110235632	 intron	variant	 A/G	
359	 	 rs16940583	 12	 110238265	 intron	variant	 A/G	
360	 	 rs3742030	 12	 110252547	 missense	 C/G/T	
361	 TSLP	 rs3806933	 5	 110406742	 nc	transcript	variant,	upstream	variant	2KB	 A/C/T	
362	 	 rs2289276	 5	 110407507	
intron	variant,	
upstream	variant	2KB,	
utr	variant	5	prime	
C/T	
363	 TSPYL4	 rs3749893	 6	 116571695	 utr	variant	3	prime	 A/G	
364	 VDR	 rs10735810	or	rs2228570	 12	 48272895	 missense	 A/C/G/T	
365	 	 rs1544410	 12	 48239835	 intron	variant	 A/G	
412	 	 rs731236	 12	 48238757	 synonymous	codon	 C/T	
366	 VEGFR1	 rs7326277	 13	 28876214	 utr	variant	3	prime	 C/T	
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367	 XRCC1	 rs25487	 19	 44055726	 missense	 A/G	
368	 XRCC5	 rs828922	 2	 216956668	 intron	variant	 C/T	
369	 	 rs3821104	 2	 217057846	 intron	variant	 C/T	
370	 	 rs207936	 2	 217040033	 intron	variant	 C/T	
371	 ZGPAT	 rs72448466	 20	 62363641:62363642	 intorn	variant	 -/GT	
372	 ZKSCAN1	 rs72615157	 7	 99635967	
intron	variant,	
nc	transcript	variant,	
utr	variant	3	prime	
A/C/G	
373	 ZKSCAN3	 rs6903823	 6	 28322296	
intron	variant,	
upstream	variant	2KB,	
utr	variant	5	prime	
A/G	
374	 ZMAT	 rs13278529	 8	 40333321	 -	 G/T	
375	 WNT16	 rs2707469	 7	 120976886	 intron	variant	 C/T	
376	 WWOX	 rs383362	 16	 79245820	 missense,nc	transcript	variant,utr	variant	3	prime	 G/T	
377	 	 rs2857595	 -	 -	 -	 -	
378	 	 rs2571445	 -	 -	 -	 -	
379	 	 rs9978142	 -	 -	 -	 -	
380	 	 rs993925	 -	 -	 -	 -	
381	 	 rs12477314	 -	 -	 -	 -	
382	 	 rs9296092	 -	 -	 -	 -	
383	 	 rs950063	 -	 -	 -	 -	
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384	 	 rs734556	 -	 -	 -	 -	
385	 	 rs10795108	 -	 -	 -	 -	
387	 	 rs8102683	 -	 -	 -	 -	
388	 	 rs11878604	 -	 -	 -	 -	
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Table	S	2-Characteristics	(DNA	concentration	and	ratios	from	Denovix	and	DNA	concentration	from	Qubit)	
of	the	60	samples	selected	for	microarray	genotyping	
Patient	Code	
Denovix	
Mean	DNA	conc	
(ng/μl)	
	
	
	
Mean	±	SD	260/280	
	
	
	
Mean	±	SD	260/230	
	
Qubit	
Mean	DNA	conc	
(ng/μl)	
	
AO_E4	
	
37,784	 1,75	 1,47	 30,6	
AO_S24	
	 22,049	 2	 1,32	 11,3	
AO_S3	
	 30,015	 1,86	 1,38	 23,4	
AO_E22	
	 10,459	 1,86	 1,99	 12,2	
AO_E46	
	 7,999	 1,8	 0,89	 7,2	
AO_147	
	 28,671	 2,01	 0,73	 24,4	
500	
	 25,766	 1,96	 	1.04	 16,1	
503	
	 29,798	 1,88	 1,24	 52,6	
508	
	 24,637	 1,93	 1,03	 11,1	
516	
	 14,903	 1,75	 0,93	 9,2	
520	
	 50,832	 1,93	 1,18	 23,4	
523	
	 40,138	 1,81	 1,86	 27,4	
526	
	 21,359	 1,86	 1,44	 8,12	
529	
	 14,217	 1,86	 2,18	 9,42	
535	
	 8,657	 1,77	 2,09	 6,98	
536	
	 21,245	 1,82	 1,84	 16,9	
543	
	 34,487	 1,86	 1,92	 24,6	
546	
	 29,659	 1,81	 1,98	 17,2	
554	
	 16,401	 1,88	 0,96	 8,44	
556	
	 192,784	 1,82	 1,8	 153	
558	
	 59,103	 1,79	 1,82	 64	
563	 91,474	 1,83	 1,71	 82	
572	
	 12,645	 1,91	 2,4	 9,24	
579	
	 55,533	 1,88	 2,14	 26,6	
583	
	 19,637	 2,01	 2,11	 18,1	
607	
	 93,105	 1,92	 1,62	 65	
609	
	 39,219	 1,84	 1,63	 39,4	
616	
	 19,121	 2,23	 1,51	 9,26	
623	
	 31,302	 1,95	 1,72	 35,8	
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644	
	 49,901	 1,84	 1,51	 46,4	
646	
	 30,955	 1,9	 1,6	 18,1	
647	
	 18,896	 1,92	 1,37	 8,16	
661	
	 16,183	 1,98	 1,82	 14,1	
671	
	 28,148	 1,94	 2,09	 18,7	
672	
	 24,838	 1,98	 1,72	 15,2	
674	
	 12,69	 1,97	 1,03	 5,54	
678	
	 18,386	 1,99	 1,79	 13,9	
686	
	 22,228	 2,01	 1,4	 16,7	
696	
	 35,341	 1,84	 1,27	 34,4	
698	
	 47,488	 1,87	 1,57	 31,4	
713	
	 35,945	 1,98	 1,14	 24,6	
716	
	 41,274	 1,79	 1,08	 49,2	
736	
	 20,686	 1,96	 1,19	 21,6	
744	
	 35,203	 1,94	 1,91	 29,6	
746	
	 45,765	 1,84	 1,09	 48,8	
758	 14,488	 2,13	 1,61	 14,9	
765	
	 83,485	 1,78	 1,66	 106	
766	
	 15,653	 1,92	 1,29	 13,6	
768	
	 30,024	 2,02	 1,76	 24,4	
774	
	 71,259	 1,83	 1,47	 11,6	
783	
	 23,394	 1,85	 1,33	 12,8	
784	
	 13,028	 1,82	 1	 9,6	
791	
	 38,938	 1,93	 1,35	 46,4	
795	
	 15,611	 1,86	 1	 13	
796	
	 17,244	 2,18	 0,8	 9,98	
542	
	 10,728	 1,78	 1,71	 8,18	
687	
	 17,417	 1,78	 1,41	 13,3	
777	
	 16,393	 1,73	 0,69	 13	
787	
	 11,839	 1,7	 0,87	 12,4	
666	
	 128,526	 1,9	 1,89	 114	
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• respiratory muscle training in the improvement of
functional capacity in patients with COPD with
respiratory muscle weakness.
Background
Aim
Methods
Results
Conclusions
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Genetic profile and patient-reported outcomes (PROs) in COPD:
a systematic review
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• Chronic Obstructive Pulmonary Disease (COPD) may
impact differently on patients with similar lung function
impairment1, suggesting that factors other than lung
function may influence patients’ experience of the
disease.
• Recent studies have found associations between genetic
variations and patient-reported outcomes (PROs).
• PROs are defined as a set of health outcomes directly
reported by patients.
• Identifying these associations might be fundamental to
predict the disease progression and develop tailored
interventions.
• This systematic review aimed to identify the genetic
variations associated with PROs in COPD.
• Search Strategy: Pubmed, Scopus and Web of Science
were searched until May 2017 (PROSPERO Reg.
CRD42016041639). Additional searches were conducted
scanning the reference list of the articles.
• Eligibility Criteria: Studies were eligible if included
patients diagnosed with COPD and associated a genetic
variant to one or more PROs.
• Quality assessment: 2 independent reviewers assessed
the quality of studies using the Q-Genie checklist2. This
checklist is composed of 11 questions, each with 7
possible answers from “1-poor” to “7-excelent”
• The most reported PRO was frequency of exacerbations
(n=7/13), which was often associated with MBL2 gene
variants (n=3/7). Other PRO’s reported were health-
related quality of life (n=4/13), depressive symptoms
(n=1/13), exacerbation severity (n=1/13) and
breathlessness, cough and sputum (n=1/13), which were
commonly associated with other gene variants (Fig. 2).
Fig. 2 – Significant correlations between PROs and specific genetic variants in COPD.
• A limited number of PRO’s have been explored and
related to genetic variations.
• Findings suggest significant associations between specific
gene variants and the number/severity of exacerbations,
depressive symptoms and health-related quality of life.
• Further research is needed to confirm these findings and
assess the genetic influence on other dimensions of
patients’ lives, since it may enhance our understanding
and management of COPD.
Results
• 13 reporting on associations between 5 PROs and 12
genetic variants studies were included (Fig. 1). Quality of
studies were rated as “good” (n=8) and “moderate”
(n=5).
1Brien, S.B., G.T. Lewith, and M. Thomas, Patient coping strategies in
COPD across diseas severity and quality of life: a qualitative study.
NPJ Primary Care Respiratory Medicine, 2016. 26: p. 16051.
2Sohani, Z.N., et al., Assessing the quality of published genetic
association studies in meta-analyses: the quality of genetic studies
(Q-Genie) tool. BMC genetics, 2015. 16(1): p. 50.
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under the project UID/BIM/04501/2013.
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Fig. 1 –Flow diagram for study selection according to the preferred reporting items for
systematic review and meta-analysis (PRISMA) guidelines.
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Appendix	V:	Associations	between	SNPs	and	
PROS/clinical	outcomes	(Results)	
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Table	S	3-Associations	between	modified	medical	research	council	and	genetic	variants	
SNP	 Genotype	 N	 Median	 IQR	 Chi-Square	 p-value*	
rs10011792	
	
CC	 37	 2.0000	 1	to	3	 	 	
CT	 22	 3.0000	 1.75	to	3	 1.342	 .247	
TT	 -	 -	 -	 	 -	
rs1042522	 CC	 5	 2.000	 1	to	3	 	 	
	 CG	 25	 2.0000	 1	to	3	 .805	 .669	
	 GG	 30	 2.5000	 1.75	to	3	 	 	
rs1042713	 CC	 21	 2.5000	 2	to	3	 	 	
	 TC	 24	 2.5000	 1	to	3	 1.260	 .533	
	 TT	 14	 2.0000	 1	to	3	 	 	
rs1042714	 GG	 30	 2.0000	 1	to	3	 	 	
	 CG	 24	 3.0000	 2	to	3	 6.003	 .050	
	 CC	 5	 2.0000	 1.50	to	3	 	 	
rs1042717	 CC	 31	 3.0000	 1	to	3	 	 	
	 CT	 25	 2.0000	 1.25	to	3	 .990	 .610	
	 TT	 4	 1.5000	 1	to	2.75	 	 	
rs10461985	 GG	 56	 2.0000	 1	to	3	 	 	
	 GA	 4	 3.0000	 .75	to	3	 .127	 .721	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 3.0000	 1.25	to	3.75	 	 	
	 CT	 35	 2.0000	 1	to	3.0	 1.962	 .375	
	 TT	 16	 3.0000	 1.25	to	3	 	 	
rs10516526	 GG	 50	 3.0000	 1	to	3	 	 	
	 GA	 10	 2.0000	 2	to	2.5	 4.061	 .044	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 3.0000	 1.25	to	3	 	 	
	 AG	 16	 2.0000	 1	to	3	 2.925	 .232	
	 GG	 2	 1.5000	 1	to	-	 	 	
rs1059823	 TT	 14	 2.5000	 1	to	3	 	 	
	 TC	 26	 3.0000	 2	to	3	 2.195	 .334	
	 CC	 20	 2.0000	 1	to	3	 	 	
rs10844154	 TT	 10	 2.5000	 1	to	3	 	 	
	 TG	 35	 2.5000	 1	to	3	 .245	 .885	
	 GG	 15	 2.0000	 1	to	3	 	 	
rs11001819	 GG	 23	 2.0000	 1	to	3	 	 	
	 GA	 27	 3.0000	 2	to	3	 2.254	 .324	
	 AA	 10	 1.0000	 1	to	3	 	 	
rs11046966	 AA	 30	 3.0000	 1	to	3	 	 	
	 AG	 23	 2.0000	 1.75	to	3	 3.579	 .167	
	 GG	 7	 1.0000	 1	to	2	 	 	
rs11172113	 AA	 9	 2.0000	 1	to	3.5	 	 	
	 AG	 22	 2.0000	 1	to	3	 3.832	 .147	
	 GG	 29	 3.0000	 2	to	3	 	 	
rs1129055	 GG	 37	 2.0000	 1.25	to	3	 	 	
	 GA	 19	 3.0000	 1	to	3	 .323	 .851	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 3.0000	 2	to	3	 	 	
	 TC	 37	 2.0000	 1	to	3	 .427	 .808	
	 CC	 10	 2.5000	 1	to	3	 	 	
rs1131620	 CC	 9	 3.0000	 1.50	to	3.50	 	 	
	 CT	 35	 2.0000	 1	to	3	 1.660	 .436	
	 TT	 16	 3.0000	 1.25	to	3	 	 	
rs1138272	 CC	 53	 2.0000	 1	to	3	 	 	
	 CT	 5	 3.0000	 1.5	to	3.5	 .789	 .375	
	 TT	 -	 -	 -	 	 	
rs1143634	 			GG†	 36	 2.0000	 1	to	3	 	 	
	 GA	 19	 3.0000	 2	to	3	 9.352	 .009	
	 AA	 5	 3.0000	 3	to	3.5	 	 	
rs1155563	 CC	 2	 3.0000	 -	 	 	
	 CT	 25	 3.0000	 1	to	3	 2.357	 .308	
	 TT	 30	 2.0000	 1	to	3	 	 	
rs11556218	 TT	 46	 2.0000	 .2	to	3	 	 	
	 TG	 14	 1.5000	 1	to	3	 1.549	 .213	
	 GG	 -	 -	 -	 	 	
 
 
152	
rs11614913	 CC	 30	 2.0000	 1	to	3	 	 	
	 CT	 24	 2.5000	 1	to	3	 2.895	 .235	
	 TT	 6	 3.0000	 2.50	to	3.25	 	 	
rs11677877	 TT	 53	 2.0000	 1	to	3	 	 	
	 TG	 6	 2.5000	 1.75	to	3	 .062	 .803	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 2.0000	 1	to	3	 	 	
	 GA	 13	 2.0000	 1.25	to	3	 .007	 .933	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 3.0000	 1	to	3	 	 	
	 GA	 19	 3.0000	 1	to	3	 .309	 .857	
	 AA	 2	 2.0000	 1	to	-		 	 	
rs12504628	 TT	 31	 2.0000	 1	to	3	 	 	
	 TC	 25	 3.0000	 2	to	3	 4.124	 .127	
	 CC	 4	 2.5000	 1.25	to	3.75	 	 	
rs12899618	 CC	 46	 2.0000	 1	to	3	 	 	
	 CT	 14	 2.5000	 2	to	3	 .634	 .426	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 2.0000	 1	to	3	 	 	
	 GA	 4	 1.5000	 1	to	2.75	 .956	 .328	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 2.0000	 1	to	3	 	 	
	 TC	 27	 3.0000	 1	to	3	 1.252	 .535	
	 CC	 5	 2.0000	 		1	to	2.5	 	 	
rs1800450	 CC	 44	 2.0000	 1	to	3	 	 	
	 CT	 15	 2.0000	 1	to	3.25	 .680	 .712	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 52	 2.0000	 1	to	3	 	 	
	 GA	 8	 2.5000	 1	to	3	 .005	 .946	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 2.0000	 2	to	3	 	 	
	 GT	 29	 3.0000	 1	to	3	 6.549	 .038	
	 TT	 9	 3.0000	 2.50	to	2.50	 	 	
	
	
	
	
	
	
	
	
*Calculated	using	Kruskal-Wallis	test	
†	Significant	different	from	GA		
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
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Table	S	4-Associations	between	frequency	of	exacerbations	and	genetic	variants	
SNP	 Genotype	 N	 Median	 IQR	 Chi-Square	 p-value*	
rs10011792	
	
CC	 37	 1.0000	 0	to	3	 	 	
CT	 22	 2.0000	 0	to	3	 .403	 .526	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 2.0000	 1	to	4	 	 	
	 CG	 25	 1.0000	 0	to	3		 .701	 .704	
	 GG	 30	 1.0000	 0	to	2.25	 	 	
rs1042713	 CC	 21	 2.5000	 1	to	4.75	 	 	
	 TC	 24	 1.0000	 0	to	2	 4.350	 .114	
	 TT	 14	 1.5000	 0	to	5.25	 	 	
rs1042714	 GG	 30	 1.0000	 0	to	3	 	 	
	 CG	 24	 2.0000	 1	to	3	 2.233	 .327	
	 CC	 5	 1.0000	 0	to	2.5	 	 	
rs1042717	 CC	 31	 1.0000	 0	to	3	 	 	
	 CT	 25	 2.5000	 1	to	4.50	 4.323	 .115	
	 TT	 4	 1.0000	 0.25	to	1	 	 	
rs10461985	 GG	 56	 1.0000	 0	to	3	 	 	
	 GA	 4	 1.5000	 0	to	5.25	 .002	 .964	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 0.5000	 0	to	4.50	 	 	
	 CT	 35	 1.0000	 0	to	3	 2.308	 .315	
	 TT	 16	 2.5000	 1	to	4.50	 	 	
rs10516526	 GG	 50	 1.0000	 0	to	3	 	 	
	 GA	 10	 .0000	 0	to	2	 2.959	 .085	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 1.0000	 0	to	3	 	 	
	 AG	 16	 1.5000	 0	to	3	 .010	 .995	
	 GG	 2	 2.5000	 0	to	-	 	 	
rs1059823	 TT	 14	 1.0000	 0	to	5	 	 	
	 TC	 26	 2.0000	 1	to	4.50	 4.506	 .105	
	 CC	 20	 1.0000	 0	to	2	 	 	
rs10844154	 TT	 10	 2.5000	 0.75	to	3	 	 	
	 TG	 35	 1.0000	 0	to	3	 1.057	 .589	
	 GG	 15	 1.0000	 1	to	3	 	 	
rs11001819	 GG	 23	 1.0000	 0	to	3	 	 	
	 GA	 27	 1.0000	 0	to	3	 .029	 .985	
	 AA	 10	 1.5000	 0	to	4.50	 	 	
rs11046966	 AA	 30	 2.0000	 1	to	3	 	 	
	 AG	 23	 1.0000	 0	to	5	 4.022	 .134	
	 GG	 7	 .0000	 0	to	1	 	 	
rs11172113	 AA	 9	 3.0000	 1	to	5	 	 	
	 AG	 22	 1.0000	 0	to	2	 4.471	 .107	
	 GG	 29	 1.0000	 0	to	3.75	 	 	
rs1129055	 GG	 37	 1.0000	 0	to	3	 	 	
	 GA	 19	 1.0000	 0	to	2	 4.610	 .100	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 1.0000	 .5	to	2	 	 	
	 TC	 37	 1.0000	 0	to	3	 .857	 .652	
	 CC	 10	 2.0000	 0	to	5.25	 	 	
rs1131620	 CC	 9	 0.	 0	to	4	 	 	
	 CT	 35	 1.0000	 0	to	3	 2.861	 .239	
	 TT	 16	 2.5000	 1	to	4.50	 	 	
rs1138272	 CC	 53	 1.0000	 0	to	3	 	 	
	 CT	 5	 3.0000	 2	to	3	 2.359	 .125	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 1.0000	 0	to	3	 	 	
	 GA	 19	 2.5000	 1	to	3.25	 1.821	 .402	
	 AA	 5	 3.0000	 0	to	7.50	 	 	
rs1155563	 CC	 2	 3.0000	 1	to	-	 	 	
	 CT	 25	 1.0000	 0	to	4	 .844	 .656	
	 TT	 30	 1.0000	 0	to	3	 	 	
rs11556218	 TT	 46	 1.0000	 0	to	3	 	 	
	 TG	 14	 1.5000	 0	to	5.25	 .063	 .0.802	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 30	 1.0000	 0	to	2.50	 	 	
	 CT	 24	 1.5000	 1	to	3	 4.335	 .114	
	 TT	 6	 3.0000	 0.75	to	7	 	 	
rs11677877	 TT	 53	 1.000	 0	to	3	 	 	
	 TG	 6	 3.5000	 0.75	to	5.25	 1.964	 .161	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 1.0000	 0	to	3	 	 	
	 GA	 13	 1.0000	 0.25	to	2.75	 .037	 .847	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 1.0000	 0	to	3.50	 	 	
	 GA	 19	 1.0000	 0	to	3	 1.754	 .416	
	 AA	 2	 1.0000	 0	to	3	 	 	
rs12504628	 TT	 31	 1	 0	to	3	 	 	
	 TC	 25	 2.0000	 0	to	4.50	 1.860	 .395	
	 CC	 4	 0.50	 0	to	2.50	 	 	
rs12899618	 CC	 46	 1.0000	 0	to	3	 	 	
	 CT	 14	 1.0000	 0	to	3	 .163	 .685	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 1.0000	 0	to	3	 	 	
	 GA	 4	 1.0000	 0.25	to	1	 1.007	 .316	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 2.0000	 0	to	4.75	 	 	
	 TC	 27	 1.0000	 0	to	3	 1.186	 .553	
	 CC	 5	 1.0000	 0	to	2.5	 	 	
rs1800450	 CC	 44	 2.0000	 0	to	2.75	 	 	
	 CT	 15	 2.0000	 0.75	to	3.25	 5.100	 .078	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 52	 1.0000	 0	to	3	 	 	
	 GA	 8	 2.5000	 1	to	5	 3.148	 .076	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 1.0000	 0	to	3.25	 	 	
	 GT	 29	 1.0000	 0	to	3	 .889	 .638	
	 TT	 9	 3.0000	 0.5	to	4	 	 	
	
	
	
*Calculated	using	Kruskal-Wallis	test		
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
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Table	S	5-Associations	between	Borg	scale	(Dyspnoea)	and	genetic	variants	
SNP	 Genotype	 N	 Median	 IQR	 Chi-Square	 p-value*	
rs10011792	
	
CC	 36	 1	 0	to	3.75	 	 	
CT	 22	 0.5	 0	to	2.25	 1.126	 .289	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 3.0000	 0	to	4.5	 	 	
	 CG	 24	 0.7500	 0	to	3	 .659	 .719	
	 GG	 30	 1.0000	 0	to	3	 	 	
rs1042713	 CC	 20	 1.5000	 0	to	3.75	 	 	
	 TC	 24	 2.0000	 0	to	4	 5.268	 .072	
	 TT	 14	 0.0000	 0	to	1	 	 	
rs1042714	 GG	 30	 0.0000	 0	to	3	 	 	
	 CG	 23	 3.0000	 0	to	4	 4.111	 .128	
	 CC	 5	 0.0000	 0	to	3	 	 	
rs1042717	 CC	 31	 0.0000	 0	to	3	 	 	
	 		CT†	 24	 3.0000	 0.25	to	4	 11.147	 .004	
	 TT	 4	 0.0000	 0	to	0	 	 	
rs10461985	 GG	 55	 1.0000	 0	to	3	 	 	
	 GA	 4	 .0000	 0	to	2.25	 2.194	 .13	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 3.0000	 0.1250	to	4	 	 	
	 CT	 34	 0.0000	 0	to	3	 2.351	 .309	
	 TT	 16	 1.0000	 0	to	3	 	 	
rs10516526	 GG	 50	 1.0000	 0	to	3	 	 	
	 GA	 9	 1.0000	 0	to	3.50	 .084	 .772	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 40	 0.1250	 0	to	3	 	 	
	 AG	 16	 1.0000	 0	to	3.75	 .755	 .685	
	 GG	 2	 2.5000	 2	to	-	 	 	
rs1059823	 TT	 14	 3.0000	 0	to	4	 	 	
	 TC	 25	 0.0000	 0	to	3	 3.668	 .160	
	 CC	 20	 0.7500	 0	to	2.75	 	 	
rs10844154	 TT	 10	 0.5000	 0	to	3.25	 	 	
	 TG	 34	 2.0000	 0	to	4	 3.666	 .160	
	 GG	 15	 .0000	 0	to	1	 	 	
rs11001819	 GG	 23	 1.0000	 0	to	3	 	 	
	 GA	 26	 1.0000	 0	to	3	 .206	 .902	
	 AA	 10	 1.7500	 0	to	3.25	 	 	
rs11046966	 AA	 30	 1.5000	 0	to	3	 	 	
	 AG	 22	 .0000	 0	to	4	 .513	 .774	
	 GG	 7	 3.000	 0	to	3	 	 	
rs11172113	 AA	 9	 1.0000	 .5	to	3	 	 	
	 AG	 22	 .0000	 0	to	3	 1.379	 .502	
	 GG	 28	 1.0000	 0	to	4	 	 	
rs1129055	 GG	 36	 1.5000	 0	to	3	 	 	
	 GA	 19	 0.0000	 0	to	3	 .524	 .769	
	 AA	 -	 -	 .	 	 	
rs1130866	 TT	 13	 0.0000	 0	to	3	 	 	
	 TC	 36	 0.7500	 0	to	3.75	 .673	 .714	
	 CC	 10	 3.0000	 0	to	3	 	 	
rs1131620	 CC	 9	 3.0000	 0.25	to	4	 	 	
	 CT	 34	 .0000	 0	to	3	 2.233	 .327	
	 TT	 16	 1.0000	 0	to	3	 	 	
rs1138272	 CC#	 52	 .0000	 0	to	3	 	 	
	 CT	 5	 3.0000	 2.5	to	4	 4.924	 .026	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 1.0000	 0	to3	 	 	
	 GA	 18	 .0000	 0	to	3.25	 1.057	 .589	
	 AA	 5	 2.0000	 0.5	to	4	 	 	
rs1155563	 CC	 2	 2.5000	 0	to	-	 	 	
	 CT	 25	 2.0000	 0	to	4	 3.586	 .166	
	 TT	 29	 .0000	 0	to	2.5	 	 	
rs11556218	 TT	 45	 .0000	 0	to	3	 	 	
	 TG	 14	 1.5000	 0	to	3	 .904	 .342	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 1.0000	 0	to	3	 	 	
	 CT	 24	 0.5000	 0	to	4	 .992	 .609	
	 TT	 6	 2.5000	 0	to	4	 	 	
rs11677877	 TT	 52	 .7500	 0	to	3	 	 	
	 TG	 6	 2.0000	 0	to	3.25	 .176	 .675	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 1.0000	 0	to	3	 	 	
	 GA	 12	 0.2500	 0	to	2.75	 .766	 .381	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 38	 1.0000	 0	to	3	 	 	
	 GA	 19	 1.0000	 0	to	3	 2.117	 .347	
	 AA	 2	 .0000	 0	to	3	 	 	
rs12504628	 		TT‡	 30	 .0000	 0	to	1.50	 	 	
	 TC	 25	 3.0000	 0	to	4	 9.092	 .011	
	 CC	 4	 1.0000	 0	to	2	 	 	
rs12899618	 CC	 45	 1.0000	 0	to	3	 	 	
	 CT	 14	 1.0000	 0	to	3.25	 .000	 .992	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 55	 1.0000	 0	to	3	 	 	
	 GA	 4	 1.75000	 0.1250	to	3.75	 .260	 .610	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 1.0000	 0	to	3	 	 	
	 TC	 26	 1.0000	 0	to	4	 .684	 .711	
	 CC	 5	 .0000	 0	to	4	 	 	
rs1800450	 CC	 44	 .7500	 0	to	3	 	 	
	 CT	 14	 2.0000	 0	to	4	 1.324	 .516	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 51	 1.0000	 0	to	3	 	 	
	 GA	 8	 3.0000	 0	to	3.75	 .749	 .387	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 .0000	 0	to	3	 	 	
	 GT	 29	 .2500	 0	to	3	 4.420	 .110	
	 TT	 9	 3.0000	 1	to	4.50	 	 	
	 	
	
	
	
	
	
*Calculated	using	Kruskal-Wallis	test	
	†Significant	different	from	CC	and	TT	
#Significant	different	from	CT	
‡Significant	different	from	TC		
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
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Table	S	6-Associations	between	Borg	scale	(fatigue)	and	genetic	variants	
SNP	 Genotype	 N	 Median	 IQR	 F.	 p-value*	
rs10011792	
	
CC	 36	 0.2500	 0	to	3.75	 	 	
CT	 22	 .0000	 0	to	2.25	 .793	 .373	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 .0000	 0	yo	3	 	 	
	 CG	 24	 .5000	 0	to	3	 .402	 .818	
	 GG	 30	 .0000	 0	to	3.25	 	 	
rs1042713	 CC	 20	 1.2500	 0	to	3.75	 	 	
	 TC	 24	 .0000	 0	to	4	 2.632	 .268	
	 TT	 14	 .0000	 0	to	1	 	 	
rs1042714	 			GG†	 30	 .0000	 0	to	1.25	 	 	
	 GC	 23	 3.0000	 0	to	4	 6.784	 .034	
	 CC	 5	 .0000	 0	to	3	 	 	
rs1042717	 CC	 31	 .0000	 0	to	3	 	 	
	 CT	 24	 2.5000	 0	to	4	 6.500	 .039	
	 TT	 4	 .0000	 0	to	0	 	 	
rs10461985	 GG	 55	 .0000	 0	to	3	 	 	
	 GA	 4	 .0000	 0	to	2.25	 .691	 .359	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 1.7500	 0	to	4.50	 	 	
	 CT	 34	 .0000	 0	to	3	 1.306	 .520	
	 TT	 16	 .5000	 0	to	3.75	 	 	
rs10516526	 GG	 50	 .5000	 0	to	3	 	 	
	 GA	 9	 .0000	 0	to	0.50	 2.214	 .137	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 40	 0.0000	 0	to	3	 	 	
	 AG	 16	 1.2500	 0	to	3.75	 2.520	 .284	
	 GG	 2	 2.5000	 2	to	-	 	 	
rs1059823	 TT	 14	 0.0000	 0	to	3	 	 	
	 TC	 25	 0.0000	 0	to	3.50	 .173	 .917	
	 CC	 20	 0.2500	 0	to	2.75	 	 	
rs10844154	 TT	 10	 1.0000	 0	to	3.25	 	 	
	 TG	 34	 .0000	 0	to	3.25	 1.009	 .604	
	 GG	 15	 .0000	 0	to	2	 	 	
rs11001819	 GG	 23	 .0000	 0	to	3	 	 	
	 GA	 26	 .000	 0	to	3	 .970	 .616	
	 AA	 10	 1.7500	 0	to	4	 	 	
rs11046966	 AA	 30	 .2500	 0	to	3	 	 	
	 AG	 22	 .2500	 0	to	4.25	 1.335	 0.513	
	 GG	 7	 .0000	 0	to	3	 	 	
rs11172113	 AA	 9	 3.0000	 0.5	to	4.5	 	 	
	 AG	 22	 .0000	 0	to	3	 3.564	 .168	
	 GG	 28	 .0000	 0	to	3	 	 	
rs1129055	 GG	 36	 1.5000	 0	to	3	 	 	
	 GA	 19	 .0000	 0	to	3	 1.865	 .394	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 0.0000	 0	to	3	 	 	
	 TC	 36	 0.2500	 0	to	3	 .076	 .963	
	 CC	 10	 1.5000	 0	to	3	 	 	
rs1131620	 CC	 9	 3.0000	 0	to	4	 	 	
	 CT	 34	 .0000	 0	to	3	 1.824	 .402	
	 TT	 16	 .5000	 0	to	3.75	 	 	
rs1138272	 			CC#	 52	 .0000	 0	to	3	 	 	
	 CT	 5	 3.0000	 1.75	to	4	 5.443	 .020	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 .0000	 0	to	3	 	 	
	 GA	 18	 .7500	 0	to	3	 .306	 .858	
	 AA	 5	 .0000	 0	to	3	 	 	
rs1155563	 CC	 2	 .5000	 0	to	-	 	 	
	 CT	 25	 .0000	 0	to	3	 .100	 .971	
	 TT	 29	 .0000	 0	to	3	 	 	
rs11556218	 TT	 45	 0.5000	 0	to	3	 	 	
	 TG	 14	 .0000	 0	to	3	 .725	 .395	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 .0000	 0	to	3	 	 	
	 CT	 24	 .2500	 0	to	3	 .724	 .696	
	 TT	 6	 1.5000	 0	to	4	 	 	
rs11677877	 TT	 52	 .0000	 0	to	3	 	 	
	 TG	 6	 3.0000	 0	to	4.75	 1.465	 .226	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 .0000	 0	to	3	 	 	
	 GA	 12	 .0000	 0	to	3	 .121	 .728	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 38	 .0000	 0	to	3	 	 	
	 GA	 19	 2.0000	 0	to	4	 4.075	 .130	
	 AA	 2	 .0000	 .00000	 	 	
rs12504628	 TT	 30	 .0000	 0	to	3	 	 	
	 TC	 25	 .5000	 0	to	3.50	 2.562	 .278	
	 CC	 4	 2.5000	 	0.50	to	3.75	 	 	
rs12899618	 CC	 45	 .0000	 0	to	3	 	 	
	 CT	 14	 .0000	 0	to	2.25	 .775	 .379	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 55	 .0000	 0	to	3	 	 	
	 GA	 4	 2.2500	 .1250	to	8.50	 1.630	 .202	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 .0000	 0	to	3	 	 	
	 TC	 26	 1.0000	 0	to	4	 2.455	 .293	
	 CC	 5	 .0000	 0	to	6.5	 	 	
rs1800450	 CC	 44	 .0000	 0	to	3	 	 	
	 CT	 14	 .2500	 0	to	3.25	 .942	 .624	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 51	 .0000	 0	to	3	 	 	
	 GA	 8	 1.5000	 0	to	3	 .033	 .857	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 .25000	 0	to	3.25	 	 	
	 GT	 28	 .0000	 0	to	3	 2.608	 .271	
	 TT	 9	 3.0000	 0	to	4	 	 	
	
	
	
	
	
	
	
*Calculated	using	Kruskal-Wallis	test	
†Significant	different	from	GC	
#Significant	different	from	CT		
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
	
	
 
 
159	
Table	S	7-Associations	between	Chronic	Obstructive	Pulmonary	Disease	Assessment	Test	and	genetic	
variants	
SNP	 Genotype	 N	 Median	 IQR	 Chi-Square	 p-value*	
rs10011792	
	
CC	 37	 21	 14.25	to	25.75	 	 	
CT	 22	 19	 11.75	to	25.50	 .285	 .594	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 17.0000	 10	to	27.50	 	 	
	 CG	 25	 17.5000	 12.25	to	26.25	 .717	 .699	
	 GG	 5	 21.0000	 15.50	to	25	 	 	
rs1042713	 CC	 21	 21.5000	 15.25	to	25.75	 	 	
	 TC	 24	 20.5000	 11.75	to	26.75	 .801	 .670	
	 TT	 14	 16.5000	 10.25	to	24.25	 	 	
rs1042714	 GG	 30	 16.5000	 10.75	to	24.25	 	 	
	 CG	 24	 21.0000	 17	to	27	 3.250	 .197	
	 CC	 5	 25.0000	 19	to	27	 	 	
rs1042717	 CC	 31	 21.0000	 15	to	25	 	 	
	 CT	 25	 21.0000	 13.25	to	26.75	 1.060	 .589	
	 TT	 4	 14.0000	 13	to	21.75	 	 	
rs10461985	 			GG†	 56	 21.0000	 14	to	26	 	 	
	 GA	 4	 12.0000	 7.50	to	16.50	 3.893	 .048	
	 AA	 -	 -	 -	 	 	
rS1051303	 CC	 8	 18.5000	 11.75	to	26.50	 	 	
	 CT	 35	 17.5000	 13	to	24.25	 2.209	 .331	
	 TT	 16	 23.5000	 17.25	to	26.75	 	 	
rs10516526	 GG	 50	 21.0000	 14.75	to	25	 	 	
	 GA	 10	 18.0000	 12	to	26.50	 .663	 .416	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 21.0000	 14.25	to	25.75	 	 	
	 AG	 16	 17.5000	 13	to	23.75	 2.037	 .361	
	 GG	 2	 26.0000	 23	to	-	 	 	
rs1059823	 TT	 14	 19.0000	 14.75	to	25.	 	 	
	 TC	 26	 21.0000	 13	to	23.50	 .947	 .623	
	 CC	 20	 20.5000	 13	to	27.50	 	 	
rs10844154	 TT	 10	 21.0000	 9	to	26.75	 	 	
	 TG	 35	 17.0000	 14.75	to	24.25	 .732	 .694	
	 GG	 15	 23.0000	 14	to	26	 	 	
rs11001819	 GG	 23	 17.0000	 11	to	25	 	 	
	 GA	 27	 21.0000	 16.50	to	26.25	 .868	 .648	
	 AA	 10	 17.5000	 12.50	to	27.25	 	 	
rs11046966	 AA	 30	 23.0000	 15.50	to	27	 	 	
	 AG	 23	 17.0000	 14.40	to	24.25	 3.716	 .156	
	 GG	 7	 14.0000	 10	to	22	 	 	
rs11172113	 		AA#	 9	 23.0000	 20.50	to	28.50	 	 	
	 AG	 22	 15.0000	 8.75	to	21.25	 9.668	 .008	
	 GG	 29	 22.0000	 15.25	to	26.75	 	 	
rs1129055	 GG	 37	 21.0000	 15.25	to	24.75	 	 	
	 GA	 19	 17.0000	 10	to	27	 .393	 .822	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 23.0000	 15.50	to	27	 	 	
	 TC	 37	 17.5000	 14	to	25.50	 1.558	 .459	
	 CC	 10	 20.0000	 10.50	to	25.25	 	 	
rs1131620	 CC	 9	 19.5556	 12.50	to	26	 	 	
	 CT	 35	 18.1429	 13	to	24.25	 2.267	 .322	
	 TT	 16	 21.4375	 17.25	to	26.25	 	 	
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rs1138272	 CC	 53	 20.5000	 13.25	to	25	 	 	
	 CT	 5	 21.0000	 19.50	to	26.50	 .889	 .346	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 18.0000	 13	to	23.75	 	 	
	 GA	 19	 25.0000	 15.25	to	29	 .1.971	 .0.373	
	 AA	 5	 20.0000	 16	to	22.50	 	 	
rs1155563	 CC	 2	 23.0000	 17	to	-	 	 	
	 CT	 25	 21.0000	 §3.50	to	26	 .129	 .720	
	 TT	 30	 20.0000	 12.50	to	24.50	 	 	
rs11556218	 TT	 46	 21.0000	 13.50	to	25	 	 	
	 TG	 14	 20.0000	 14.75	to	27	 .063	 .803	
	 GG	 -	 -	 -	 	 	
rs11614913	 CC	 30	 21.0000	 13	to	26	 	 	
	 CT	 24	 18.5000	 14.25	to	25.75	 .002	 .999	
	 TT	 6	 19.0000	 14.25	to	26	 	 	
rs11677877	 TT	 53	 20.5000	 13	to	25	 	 	
	 TG	 6	 25.0000	 17	to	29.25	 2.542	 .111	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 20.0000	 14	to	26	 	 	
	 GA	 13	 22.5000	 12.25	to	25	 .029	 .864	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 20.5000	 13	to	26	 	 	
	 GA	 19	 21.0000	 16	to	25	 1.150	 .563	
	 AA	 2	 14.0000	 9	to	-	 	 	
rs12504628	 TT	 31	 17.0000	 12.75	to	24	 	 	
	 TC	 25	 22.0000	 15	to	26.50	 3.798	 .150	
	 CC	 4	 25.000	 17.25	to	29	 	 	
rs12899618	 CC	 46	 21.0000	 13.75	to	25	 	 	
	 CT	 14	 17.0000	 10.75	to	27.50	 .344	 .558	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 20.0000	 14	to	25	 	 	
	 GA	 4	 23.0000	 13.50	to	31	 .528	 .467	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 17.5000	 13	to	23.75	 	 	
	 TC	 27	 21.0000	 15.75	to	26.25	 1.491	 .475	
	 CC	 5	 8.0000	 6.50	to	29.50	 	 	
rs1800450	 CC	 44	 21.0000	 14	to	26	 	 	
	 CT	 15	 17.5000	 12.75	to	22	 1.864	 .394	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 52	 20.0000	 14	to	26	 	 	
	 GA	 8	 22.0000	 14	to	24.75	 .034	 .853	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 19.0000	 13	to	24.25	 	 	
	 GT	 29	 20.0000	 13.25	to	26	 1.014	 .602	
	 TT	 9	 21.0000	 17	to	27	 	 	
	
	
	
	
	
	
*Calculated	using	Kruskal-Wallis	test	
†Significant	different	from	GA	
#Significant	different	from	AG		
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
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Table	S	8-Associations	between	Hospital	Anxiety	and	Depression	scale	(Anxiety	score)	and	genetic	variants	
SNP	 Genotype	 N	 Median	 IQR	 Chi-Square	 p-value*	
rs10011792	
	
CC	 37	 8	 5	to	13	 	 	
CT	 22	 7	 5.50	to	9.25	 .645	 .422	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 8.0000	 4.50	to	10.50	 	 	
	 CG	 25	 7.5000	 5.25	to	9.75	 .280	 .870	
	 GG	 30	 7.0000	 5	to	13	 	 	
rs1042713	 CC	 21	 8.0000	 6	to	10.50	 	 	
	 TC	 24	 7.0000	 5	to	10.75	 1.784	 .410	
	 TT	 14	 6.0000	 2.75	to	10.50	 	 	
rs1042714	 GG	 30	 8.0000	 5	to	11	 	 	
	 CG	 24	 6.0000	 5	to	11	 .497	 .780	
	 CC	 5	 8.0000	 4	to	14.50	 	 	
rs1042717	 CC	 31	 6.0000	 3	to	11	 	 	
	 CT	 25	 8.0000	 6	to	13	 3.696	 .158	
	 TT	 4	 9.0000	 8.25	to	10.50	 	 	
rs10461985	 GG	 56	 8.0000	 5	to	11	 	 	
	 GA	 4	 7.0000	 1.75	to	7.75	 .622	 .430	
	 AA	 -	 -	 -	 	 	
rS1051303	 		CC†	 8	 11.0000	 7.50	to	13.75	 	 	
	 CT	 35	 6.0000	 4	to	9.25	 6.199	 .045	
	 TT	 16	 8.0000	 6	to	13	 	 	
rs10516526	 GG	 50	 7.0000	 5	to	11	 	 	
	 GA	 10	 8.0000	 6.50	to	12	 .219	 .640	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 6.0000	 4.25	to	10	 	 	
	 AG	 16	 8.0000	 6.25	to	12.50	 3.147	 .207	
	 GG	 2	 6.0000	 6	to	-	 	 	
rS1059823	 TT	 14	 10.0000	 5.75	to	13	 	 	
	 TC	 26	 7.0000	 6	to	9	 1.757	 .415	
	 CC	 20	 6.5000	 3.50	to	10.75	 	 	
rs10844154	 TT	 10	 7.0000	 3.59629	 	 	
	 TG	 35	 8.0000	 4.95831	 .536	 .765	
	 GG	 15	 7.0000	 4.46681	 	 	
rs11001819	 GG	 10	 7.0000	 6	to	10	 	 	
	 GA	 35	 7.5000	 5	to	11	 .538	 .764	
	 AA	 15	 7.0000	 4.50	to	14	 	 	
rs11046966	 AA	 30	 8.0000	 6	to	10.25	 	 	
	 AG	 23	 6.0000	 4.75	to	13	 .701	 .704	
	 GG	 7	 9.0000	 5	to	11	 	 	
rs11172113	 AA	 9	 6.0000	 5.50	to	12	 	 	
	 AG	 22	 6.5000	 4.75	to	9	 1.117	 .572	
	 GG	 29	 8.0000	 6	to	13	 	 	
rs1129055	 GG	 37	 8.0000	 6	to	10.75	 	 	
	 GA	 19	 7.0000	 4	to	13	 .678	 .713	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 9.0000	 5	to	12	 	 	
	 TC	 37	 7.0000	 5.25	to	10.75	 .512	 .774	
	 CC	 10	 7.5000	 4.75	to	11.50	 	 	
rS1131620	 		CC‡	 9	 13.0000	 8	to	13.50	 	 	
	 CT	 35	 6.0000	 4	to	9.25	 7.429	 .024	
	 TT	 16	 8.0000	 6	to	13	 	 	
rs1138272	 CC	 53	 7.6038	 4.72041	 	 	
	 CT	 5	 9.2000	 3.03315	 .545	 .463	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 7.0000	 5	to	10.75	 	 	
	 GA	 19	 8.0000	 5.50	to	11.50	 1.253	 .534	
	 AA	 5	 6.0000	 2.50	to	9.50	 	 	
rs1155563	 CC	 2	 3.5000	 1	to	-	 	 	
	 CT	 25	 8.0000	 5	to	12	 2.617	 .270	
	 TT	 30	 7.0000	 5	to	9	 	 	
rs11556218	 TT	 46	 7.0000	 5	to	11	 	 	
	 TG	 14	 7.5000	 5.50	to	11.50	 .031	 .861	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 30	 7.0000	 5	to	10.50	 	 	
	 CT	 24	 8.0000	 5.25	to	12.50	 .868	 .648	
	 TT	 6	 6.5000	 5	to	14.25	 	 	
rs11677877	 TT	 53	 7.0000	 5	to	11	 	 	
	 TG	 6	 7.0000	 4.25	to	9.75	 .057	 .811	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 8.0000	 5	to	11	 	 	
	 GA	 13	 6.0000	 4.25	to	13	 .469	 .493	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 8.0000	 5	to	11.50	 	 	
	 GA	 19	 7.0000	 6	to	9	 1.229	 .541	
	 AA	 2	 4.0000	 1	to	-	 	 	
rs12504628	 TT	 31	 7.0000	 4.50	to	9.25	 	 	
	 TC	 25	 8.0000	 6	to	13	 3.183	 .204	
	 CC	 4	 6.0000	 4.50	to	9	 	 	
rs12899618	 CC	 46	 7.5000	 5	to	13	 	 	
	 CT	 14	 6.000	 2.75	to	9	 1.532	 .216	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 7.0000	 5	to	11	 	 	
	 GA	 4	 11.0000	 5.75	to	14.75	 1.418	 .234	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 8.0000	 6	to	10.75	 	 	
	 TC	 27	 6.0000	 5	to	11.50	 .236	 .790	
	 CC	 5	 4.0000	 2.50	to	12.50	 	 	
rs1800450	 			CC#	 44	 8.0000	 6	to	12.50	 	 	
	 CT	 15	 6.0000	 2	to	6.50	 8.093	 .017	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 52	 7.0000	 5	to	11	 	 	
	 GA	 8	 9.5000	 6.75	to	12.50	 2.720	 .099	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 7.5000	 5	to	10	 	 	
	 GT	 29	 7.5000	 5	to	11	 .014	 .993	
	 TT	 9	 6.0000	 3.50	to	13	 	 	
	
	
	
	
	
	
	
	 	
*Calculated	using	Kruskal-Wallis	test	
	†Significant	different	from	CT	
#Significant	different	from	CT	
‡Significant	different	from	CT		
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
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Table	S	9-Associations	between	Hospital	Anxiety	and	Depression	scale	(Depression	score)	and	genetic	
variants	
SNP	 Genotype	 N	 Median	 IQR	 Chi-Square	 p-value*	
rs10011792	
	
CC	 37	 8.0000	 3.79070	 	 	
CT	 22	 8.0000	 4.35766	 .897	 .344	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 7.0000	 4.5	to	10	 	 	
	 CG	 25	 6.5000	 3	to	9	 1.530	 .465	
	 GG	 30	 8.0000	 4.75	to	10.50	 	 	
rs1042713	 CC	 21	 8.0000	 5	to	9	 	 	
	 TC	 24	 7.5000	 3	to	10.75	 .088	 .957	
	 TT	 14	 8.0000	 4	to	9	 	 	
rs1042714	 GG	 30	 8.0000	 4	to	9	 	 	
	 CG	 24	 8.0000	 3	to	14	 .075	 .963	
	 CC	 5	 6.0000	 4	to	10	 	 	
rs1042717	 CC	 31	 8.0000	 3	to	9	 	 	
	 CT	 25	 7.5000	 5	to	10.50	 .356	 .837	
	 TT	 4	 9.0000	 4	to	9	 	 	
rs10461985	 GG	 56	 8.0000	 4	to	9		 	 	
	 GA	 4	 3.0000	 2.50	to	9	 2.050	 .152	
	 AA	 -	 -	 -	 	 	
rS1051303	 CC	 8	 8.0000	 3.75	to	9	 	 	
	 TC	 35	 8.0000	 3	to	9	 .428	 .807	
	 TT	 16	 7.5000	 4.25	to	12	 	 	
rS10516526	 GG	 50	 8.0000	 3.75	to	9.25	 	 	
	 GA	 10	 7.0000	 3.50	to	8	 .687	 .407	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 8.0000	 4.25	to	10	 	 	
	 AG	 16	 8.0000	 6.25	to	12.50	 .166	 .920	
	 GG	 2	 8.0000	 6	to	-	 	 	
rs1059823	 TT	 14	 6.0000	 2.75	to	8	 	 	
	 TC	 26	 8.0000	 4	to	10.50	 2.641	 .267	
	 CC	 20	 8.0000	 5.25	to	9	 	 	
rs10844154	 TT	 10	 8.5000	 2.75	to	9.75	 	 	
	 TG	 35	 8.0000	 4	to	11	 1.243	 .537	
	 GG	 15	 6.0000	 4	to	8	 	 	
rs11001819	 GG	 23	 6.0000	 3	to	11	 	 	
	 GA	 27	 8.0000	 3.75	to	9	 .793	 .673	
	 AA	 10	 8.0000	 4.50	to	9.75	 	 	
rs11046966	 AA	 30	 8.0000	 3	to	9	 	 	
	 AG	 23	 8.0000	 4	to	11.25	 1.987	 .370	
	 GG	 7	 5.0000	 3	to	9	 	 	
rs11172113	 AA	 9	 9.0000	 4	to	14	 	 	
	 AG	 22	 7.5000	 3	to	8.25	 2.454	 .293	
	 GG	 29	 8.0000	 4.25	to	11.75	 	 	
rs1129055	 GG	 37	 8.0000	 4.25	to	9	 	 	
	 GA	 19	 6.0000	 3	to	9	 2.009	 .366	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 8.0000	 4	to	9.50	 	 	
	 TC	 37	 8.0000	 3.25	to	9	 .058	 .972	
	 CC	 10	 7.5000	 3.75	to	9.75	 	 	
rs1131620	 CC	 9	 8.0000	 4.50	to	9	 	 	
	 CT	 35	 8.0000	 3	to	9	 .350	 .839	
	 TT	 16	 7.5000	 4.25	to	12	 	 	
rs1138272	 CC	 53	 7.0000	 5	to	11	 	 	
	 CT	 5	 8.0000	 7	to	12	 .1.059	 .303	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 7.0000	 3.25	to	9	 	 	
	 GA	 19	 8.0000	 4	to	11	 1.959	 .376	
	 AA	 5	 6.0000	 3	to	10.50	 	 	
rs1155563	 CC	 2	 7.5000	 6	to	-	 	 	
	 CT	 25	 8.0000	 3	to	10.50	 .145	 .930	
	 TT	 30	 8.0000	 3.5	to	9	 	 	
rs11556218	 TT	 46	 8.0000	 3.50	to	9	 	 	
	 TG	 14	 7.0000	 3.75	to	11.25	 .011	 .916	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 30	 7.0000	 3	to	10	 	 	
	 CT	 24	 8.0000	 5.25	to	9	 2.584	 .275	
	 TT	 6	 5.5000	 2.75	to	10.50	 	 	
rs11677877	 TT	 53	 8.0000	 3	to	9	 	 	
	 TG	 6	 9.5000	 6.50	to	12	 1.757	 .185	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 8.0000	 3	to	9	 	 	
	 GA	 13	 8.0000	 4	to	9	 .094	 .759	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 7.5000	 3	to	9.50	 	 	
	 GA	 19	 8.0000	 5	to	9	 .096	 .908	
	 AA	 2	 8.5000	 3	to	-	 	 	
rs12504628	 TT	 31	 7.0000	 3	to	9	 	 	
	 TC	 25	 8.0000	 5	to	11	 .890	 .641	
	 CC	 4	 6.5000	 3.25	to	10.50	 	 	
rs12899618	 CC	 46	 8.0000	 3	to	9.25	 	 	
	 CT	 14	 7.0000	 4.75	to	9	 .020	 .888	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 8.0000	 3	to	9	 	 	
	 GA	 4	 8.0000	 5.75	to	11	 .356	 .551	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 7.5000	 3.50	to	9	 	 	
	 TC	 27	 8.0000	 3	to	9	 .338	 .844	
	 CC	 5	 8.0000	 4	to	12	 	 	
rs1800450	 CC	 44	 7.5000	 4	to	9	 	 	
	 CT	 15	 8.0000	 3	to	10.50	 1.674	 .433	
	 TT	 -	 -	 .	 	 	
rs5030737	 GG	 52	 7.0000	 3	to	9	 	 	
	 GA	 8	 8.5000	 6.50	to	9	 1.346	 .246	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 8.0000	 3	to	9.50	 	 	
	 GT	 29	 7.5000	 4	to	9	 .805	 .669	
	 TT	 9	 9.0000	 6	to	10.50	 	 	
	
	
	
	
	
	
	 	
*Calculated	using	Kruskal-Wallis	test	
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
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Table	S	10-Associations	between	St.	George	Respiratory	Questionnaire	(Symptoms	score)	and	genetic	
variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 34	 52.5979	 20.80043	 	 	
CT	 22	 54.5625	 19.84468	 .123	 .727	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 55.0720	 29.48990	 	 	
	 CG	 23	 51.3709	 21.33971	 .132	 .877	
	 GG	 29	 53.9994	 18.27664	 	 	
rs1042713	 CC	 18	 50.6439	 15.89985	 	 	
	 TC	 24	 56.8910	 21.93412	 .625	 .539	
	 TT	 14	 50.8379	 22.72766	 	 	
rs1042714	 GG	 29	 55.4126	 21.92192	 	 	
	 CG	 23	 52.4630	 19.08857	 .610	 .547	
	 CC	 4	 43.7725	 14.36144	 	 	
rs1042717	 CC	 30	 49.8437	 20.83650	 	 	
	 CT	 24	 57.8843	 19.70921	 1.247	 .296	
	 TT	 3	 46.1133	 14.53889	 	 	
rs10461985	 GG	 53	 53.9788	 19.41973	 	 	
	 GA	 4	 40.5000	 29.86188	 1.668	 .202	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 7	 46.5500	 27.09478	 	 	
	 TC	 33	 53.7813	 20.47939	 .482	 .620	
	 TT	 16	 55.5044	 17.06751	 	 	
rs10516526	 GG	 48	 52.6736	 20.39925	 	 	
	 GA	 9	 54.9489	 20.50653	 .094	 .760	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 39	 52.4969	 20.35840	 	 	
	 AG	 15	 53.2249	 20.80802	 .829	 .442	
	 GG	 2	 71.4750	 10.11870	 	 	
rs1059823	 TT	 13	 56.2123	 19.53700	 	 	
	 TC	 24	 50.1577	 18.78003	 .440	 .646	
	 CC	 20	 54.4165	 22.82791	 	 	
rs10844154	 TT	 10	 50.4914	 24.79301	 	 	
	 TG	 32	 54.1163	 20.45977	 .127	 .881	
	 GG	 15	 52.4160	 17.61633	 	 	
rs11001819	 GG	 23	 53.5750	 19.54653	 	 	
	 GA	 25	 53.9952	 21.47041	 .211	 .810	
	 AA	 9	 48.9744	 20.35422	 	 	
rs11046966	 AA	 29	 54.5288	 18.73832	 	 	
	 AG	 22	 52.0214	 23.49962	 .192	 .826	
	 GG	 6	 49.5117	 16.56080	 	 	
rs11172113	 				AA	†	 9	 66.9278	 18.39889	 	 	
	 AG	 20	 42.5840	 19.78069	 5.996	 .004	
	 GG	 28	 56.0301	 17.89509	 	 	
rs1129055	 GG	 34	 55.3632	 19.22733	 	 	
	 GA	 19	 47.7986	 18.72939	 .984	 .380	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 57.9423	 23.55151	 	 	
	 TC	 35	 51.0106	 19.20872	 .554	 .578	
	 CC	 9	 53.8060	 20.30511	 	 	
rs1131620	 CC	 8	 45.0025	 25.46389	 	 	
	 CT	 33	 53.7813	 20.47939	 .764	 .471	
	 TT	 16	 55.5044	 17.06751	 	 	
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rs1138272	 CC	 50	 52.3809	 20.41150	 	 	
	 CT	 5	 66.3880	 16.14998	 2.203	 .144	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 35	 52.9329	 20.53516	 	 	
	 GA	 17	 52.2955	 22.53929	 .072	 .931	
	 AA	 5	 56.2400	 10.42320	 	 	
rs1155563	 CC	 2	 53.1300	 26.43165	 	 	
	 CT	 24	 56.7996	 19.82614	 .585	 .561	
	 TT	 28	 50.5430	 21.34634	 	 	
rs11556218	 TT	 44	 51.7340	 19.86672	 	 	
	 TG	 13	 57.4292	 21.72641	 .791	 .378	
	 GG	 -	 -	 -	 	 	
rs11614913	 CC	 29	 47.9128	 17.30064	 	 	
	 CT	 23	 60.2597	 21.79640	 2.611	 .083	
	 TT	 5	 49.4860	 22.93741	 	 	
rs11677877	 TT	 50	 53.1941	 19.94553	 	 	
	 TG	 6	 54.8333	 24.86572	 .034	 .854	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 45	 53.3390	 20.86103	 	 	
	 GA	 12	 51.8850	 18.57023	 .048	 .827	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 37	 54.7838	 19.41736	 	 	
	 GA	 18	 50.7058	 20.09206	 .568	 .570	
	 AA	 2	 41.5850	 45.30433	 	 	
rs12504628	 TT	 29	 52.0157	 19.80469	 	 	
	 TC	 24	 54.3704	 21.59501	 .088	 .916	
	 CC	 4	 52.3825	 19.82074	 	 	
rs12899618	 CC	 44	 54.3651	 19.28426	 	 	
	 CT	 13	 48.5238	 23.50194	 .833	 .366	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 53	 52.6725	 20.18728	 	 	
	 GA	 4	 57.8075	 23.60813	 .236	 .629	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 52.9012	 21.22131	 	 	
	 TC	 24	 54.0875	 15.45051	 .143	 .867	
	 CC	 5	 48.7080	 36.02415	 	 	
rs1800450	 CC	 43	 53.4133	 20.62229	 	 	
	 CT	 13	 51.3023	 20.44694	 .098	 .907	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 49	 51.4292	 20.40153	 	 	
	 GA	 8	 62.8555	 17.25806	 2.238	 .140	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 52.5550	 21.19238	 	 	
	 GT	 27	 54.0374	 22.15838	 .076	 .927	
	 TT	 9	 51.1344	 11.98335	 	 	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	test	
†Significant	different	from	AG	
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	11-Associations	between	St.	George	Respiratory	Questionnaire	(Activity	score)	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 34	 70.2118	 19.37017	 	 	
CT	 22	 66.7077	 23.16256	 .374	 .543	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 65.3880	 21.04737	 	 	
	 CG	 23	 68.5491	 21.03862	 .101	 .904	
	 GG	 29	 69.8234	 20.90495	 	 	
rs1042713	 	.	CC†	 18	 79.0311	 15.91436	 	 	
	 TC	 24	 63.2325	 22.08733	 3.526	 .036	
	 TT	 14	 65.3307	 20.54955	 	 	
rs1042714	 GG	 29	 65.8476	 20.97003	 	 	
	 CG	 23	 70.5243	 21.55962	 1.035	 .362	
	 CC	 4	 80.7825	 11.22677	 	 	
rs1042717	 CC	 30	 64.7257	 20.09562	 	 	
	 CT	 24	 75.2208	 20.95140	 2.067	 .136	
	 TT	 3	 60.4600	 12.89910	 	 	
rs10461985	 GG	 53	 70.0085	 20.04660	 	 	
	 GA	 4	 54.5000	 26.10092	 2.145	 .149	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 7	 75.7657	 20.64956	 	 	
	 TC	 33	 63.5048	 19.50543	 2.817	 .069	
	 TT	 16	 76.7969	 21.27762	 	 	
rs10516526	 GG	 48	 69.9683	 21.31517	 	 	
	 GA	 9	 63.3300	 16.38430	 .782	 .380	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 39	 68.2987	 21.72775	 	 	
	 AG	 15	 68.8500	 19.98075	 .253	 .777	
	 GG	 2	 79.1850	 7.61554	 	 	
rs1059823	 TT	 13	 69.0154	 24.09696	 	 	
	 TC	 24	 69.7317	 20.86936	 .042	 .959	
	 CC	 20	 67.8845	 18.93595	 	 	
rs10844154	 TT	 10	 66.5920	 28.35055	 	 	
	 TG	 32	 69.8572	 20.32893	 .097	 .908	
	 GG	 15	 68.4733	 16.26797	 	 	
rs11001819	 GG	 23	 67.8448	 22.38554	 	 	
	 GA	 25	 68.8240	 19.07342	 .124	 .884	
	 AA	 9	 71.9356	 22.27987	 	 	
rs11046966	 AA	 29	 70.9169	 20.22739	 	 	
	 AG	 22	 67.5673	 21.28586	 .330	 .720	
	 GG	 6	 64.2300	 22.70032	 	 	
rs11172113	 AA	 9	 75.9400	 18.66911	 	 	
	 		AG#	 20	 58.7865	 22.24360	 4.175	 .021	
	 GG	 28	 73.9021	 17.69496	 	 	
rs1129055	 GG	 34	 71.7609	 19.86770	 	 	
	 GA	 19	 65.9058	 21.03647	 .978	 .383	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 67.0238	 20.88121	 	 	
	 TC	 35	 70.1123	 20.78886	 .147	 .864	
	 CC	 9	 67.0233	 21.73759	 	 	
rs1131620	 CC	 8	 75.5050	 19.13199	 	 	
	 CT	 33	 63.5048	 19.50543	 2.894	 .064	
	 TT	 16	 76.7969	 21.27762	 	 	
rs1138272	 		CC‡	 50	 66.3212	 20.23950	 	 	
	 CT	 5	 89.2400	 13.98030	 6.068	 .017	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 35	 65.5640	 21.28671	 	 	
	 GA	 17	 73.3806	 20.42301	 1.280	 .286	
	 AA	 5	 77.2480	 13.00318	 	 	
rs1155563	 CC	 2	 82.7800	 13.76030	 	 	
	 CT	 24	 64.5321	 25.44051	 .974	 .384	
	 TT	 28	 70.0450	 16.06988	 	 	
rs11556218	 TT	 44	 70.1861	 20.14395	 	 	
TG	 13	 64.6354	 22.50498	 .723	 .399	
GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 68.2883	 17.47859	 	 	
	 CT	 23	 68.4187	 23.17694	 .223	 .800	
	 TT	 5	 74.8920	 28.58279	 	 	
rs11677877	 TT	 50	 68.0170	 21.45566	 	 	
	 TG	 6	 75.6533	 13.73316	 .718	 .401	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 45	 69.3709	 20.03877	 	 	
	 GA	 12	 67.2300	 23.59438	 .100	 .753	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 37	 70.4795	 21.16130	 	 	
	 GA	 18	 68.7511	 18.98916	 1.922	 .156	
	 AA	 2	 41.5950	 .85560	 	 	
rs12504628	 TT	 29	 64.9393	 20.82707	 	 	
	 TC	 24	 72.7921	 19.87723	 1.116	 .335	
	 CC	 4	 74.5500	 23.49718	 	 	
rs12899618	 CC	 44	 68.9209	 20.40090	 	 	
	 CT	 13	 68.9177	 22.24653	 .000	 1.000	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 53	 68.4591	 21.16911	 	 	
	 GA	 4	 75.0300	 11.13478	 .373	 .544	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 67.3643	 20.08433	 	 	
	 TC	 24	 73.4629	 19.33415	 1.711	 .190	
	 CC	 5	 55.8280	 27.04807	 	 	
rs1800450	 CC	 43	 70.2458	 19.66751	 	 	
	 CT	 13	 64.1600	 24.48699	 .454	 .638	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 49	 67.7618	 21.06921	 	 	
	 GA	 8	 76.0150	 17.15133	 1.103	 .298	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 71.3471	 14.27988	 	 	
	 GT	 27	 63.2856	 23.00992	 2.633	 .081	
	 TT	 9	 80.1611	 22.00300	 	 	
	
	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CT	
#Significant	different	from	GG	
‡Significant	different	from	CT		
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	12-Associations	between	St.	George	Respiratory	Questionnaire	(Impact	Score)	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 34	 45.2656	 18.62708	 	 	
CT	 22	 42.3900	 21.09715	 .287	 .594	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 38.3660	 15.39285	 	 	
	 CG	 23	 44.7643	 17.00941	 .241	 .786	
	 GG	 29	 44.7200	 21.88894	 	 	
rs1042713	 CC	 18	 50.0578	 18.76757	 	 	
	 TC	 24	 43.1163	 19.95268	 1.525	 .227	
	 TT	 14	 38.2700	 18.86203	 	 	
rs1042714	 GG	 29	 20.98933	 3.89762	 	 	
	 CG	 23	 18.79014	 3.91802	 .735	 .484	
	 CC	 4	 8.94930	 4.47465	 	 	
rs1042717	 CC	 30	 39.7777	 15.92838	 	 	
	 CT	 24	 51.3600	 21.72833	 3.431	 .040	
	 TT	 3	 30.7733	 13.02492	 	 	
rs10461985	 GG	 53	 44.8728	 19.55990	 	 	
	 GA	 4	 35.0075	 14.79869	 .969	 .329	
	 AA	 -	 -	 -	 	 	
rS1051303	 CC	 7	 52.5300	 23.80603	 	 	
	 TC	 33	 40.6036	 18.48712	 1.491	 .234	
	 TT	 16	 47.7487	 19.07243	 	 	
rs10516526	 GG	 48	 45.3219	 19.19479	 	 	
	 GA	 9	 38.0933	 20.00299	 1.062	 .307	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 39	 42.6892	 20.05267	 	 	
	 AG	 15	 46.1080	 18.81363	 .649	 .526	
	 GG	 2	 57.5550	 13.10269	 	 	
rs1059823	 TT	 13	 46.3362	 23.35305	 	 	
	 TC	 24	 43.7308	 19.49193	 .104	 .902	
	 CC	 20	 43.3190	 17.09208	 	 	
rs10844154	 TT	 10	 37.8120	 18.49690	 	 	
	 TG	 32	 46.6250	 19.32087	 .812	 .449	
	 GG	 15	 43.2113	 20.09151	 	 	
rs11001819	 GG	 23	 40.2809	 18.57520	 	 	
	 GA	 25	 48.1748	 17.88285	 1.018	 .368	
	 AA	 9	 43.0511	 24.71737	 	 	
rs11046966	 AA	 29	 47.1769	 19.04418	 	 	
	 AG	 22	 43.5845	 19.33900	 1.608	 .210	
	 GG	 6	 31.8833	 18.59641	 	 	
rs11172113	 AA	 9	 52.7144	 17.03475	 	 	
	 AG	 20	 35.6425	 20.13032	 3.547	 .036	
	 GG	 28	 47.5361	 17.70555	 	 	
rs1129055	 GG	 34	 46.6491	 18.64518	 	 	
	 GA	 19	 39.8668	 20.52576	 .745	 .479	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 45.8315	 18.91883	 	 	
	 TC	 35	 44.0257	 19.33429	 .084	 .920	
	 CC	 9	 42.3978	 21.92031	 	 	
rs1131620	 CC	 8	 51.7988	 22.13694	 	 	
	 CT	 33	 40.6036	 18.48712	 1.485	 .236	
	 TT	 16	 47.7487	 19.07243	 	 	
rs1138272	 			CC†	 50	 42.2744	 18.97115	 	 	
	 CT	 5	 60.6500	 20.15434	 4.224	 .045	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 35	 40.8691	 18.98948	 	 	
	 GA	 17	 47.7900	 19.76881	 1.644	 .203	
	 AA	 5	 55.0880	 17.32199	 	 	
rs1155563	 CC	 2	 55.4050	 8.40750	 	 	
	 CT	 24	 44.8196	 22.71234	 .520	 .597	
	 TT	 28	 41.7521	 17.38502	 	 	
rs11556218	 TT	 44	 44.4593	 19.36247	 	 	
	 TG	 13	 43.2369	 19.95354	 .039	 .843	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 43.3938	 18.88644	 	 	
	 CT	 23	 43.2970	 18.23409	 .537	 .587	
	 TT	 5	 52.8080	 28.29946	 	 	
rs11677877	 TT	 50	 43.2586	 19.42261	 	 	
	 TG	 6	 51.4467	 20.31481	 .944	 .336	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 45	 43.4233	 16.27253	 	 	
	 GA	 12	 47.0200	 28.82566	 .324	 .571	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 37	 44.4222	 20.29817	 	 	
	 GA	 18	 44.8211	 18.48005	 .286	 .753	
	 AA	 2	 33.9450	 7.50240	 	 	
rs12504628	 		TT#	 29	 37.0803	 16.61336	 	 	
	 TC	 24	 50.2713	 18.72004	 4.957	 .011	
	 CC	 4	 59.1125	 25.04178	 	 	
rS12899618	 CC	 44	 44.4118	 18.58080	 	 	
	 CT	 13	 43.3977	 22.46800	 .027	 .870	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 53	 44.1387	 19.32656	 	 	
	 GA	 4	 44.7350	 22.28217	 .003	 .953	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 43.0389	 19.42410	 	 	
	 TC	 24	 47.0058	 17.39732	 .641	 .531	
	 CC	 5	 37.0120	 28.63704	 	 	
rs1800450	 CC	 43	 44.9816	 19.06801	 	 	
	 CT	 13	 40.9985	 21.28339	 .270	 .764	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 49	 43.5278	 19.45506	 	 	
	 GA	 8	 48.1788	 19.26104	 .394	 .533	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 42.3200	 15.50570	 	 	
	 GT	 27	 41.7267	 21.02765	 2.038	 .140	
	 TT	 9	 55.8833	 19.81484	 	 	
	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CT	
#Significant	different	from	TC	
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	13-Associations	between	St.	George	Respiratory	Questionnaire	(Total	Score)	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 34	 53.9150	 16.79465	 	 	
CT	 22	 51.7823	 19.66819	 .188	 .666	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 49.2640	 18.69689	 	 	
	 CG	 23	 53.0039	 16.97328	 .136	 .873	
	 GG	 29	 53.7972	 18.58202	 	 	
rs1042713	 CC	 18	 58.8878	 16.07853	 	 	
	 TC	 24	 51.3442	 18.26215	 1.544	 0.223	
	 TT	 14	 48.5771	 18.52970	 	 	
rs1042714	 GG	 29	 50.9462	 19.53534	 	 	
	 CG	 23	 55.2074	 16.81341	 .426	 .655	
	 CC	 4	 56.2775	 10.17319	 	 	
rs1042717	 CC	 30	 48.8740	 15.44293	 	 	
	 CT	 24	 59.7158	 19.01201	 3.393	 .041	
	 TT	 3	 42.0433	 12.44685	 	 	
rs10461985	 GG	 53	 53.9223	 17.42378	 	 	
	 GA	 4	 41.9125	 19.74256	 1.740	 .193	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 7	 58.4929	 22.24824	 	 	
	 TC	 33	 49.6070	 16.93087	 1.555	 .221	
	 TT	 16	 57.8650	 17.08802	 	 	
rs10516526	 GG	 48	 53.9335	 17.77584	 	 	
	 GA	 9	 48.5244	 17.39081	 .706	 .404	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 39	 51.9641	 18.29773	 	 	
	 AG	 15	 54.2107	 17.39855	 .646	 .528	
	 GG	 2	 66.2800	 10.74802	 	 	
rs1059823	 TT	 13	 54.7692	 21.56489	 	 	
	 TC	 24	 52.5471	 17.19216	 .075	 .928	
	 CC	 20	 52.6200	 16.32813	 	 	
rs10844154	 TT	 10	 48.6650	 20.86285	 	 	
	 TG	 32	 54.7756	 17.43008	 .461	 .633	
	 GG	 15	 52.4040	 16.61153	 	 	
rs11001819	 GG	 23	 50.8313	 18.44772	 	 	
	 GA	 25	 55.2424	 16.03978	 .366	 .695	
	 AA	 9	 52.8167	 21.20415	 	 	
rs11046966	 AA	 29	 55.6352	 17.20112	 	 	
	 AG	 22	 52.0941	 18.39924	 1.074	 .349	
	 GG	 6	 44.3400	 16.90871	 	 	
rs11172113	 AA	 9	 62.1211	 14.38634	 	 	
	 AG#	 20	 43.5285	 18.32917	 5.566	 .006	
	 GG	 28	 56.9954	 15.47263	 	 	
rs1129055	 GG	 34	 55.6129	 16.65029	 	 	
	 GA	 19	 49.0768	 18.47931	 .873	 .423	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 53.8685	 17.23610	 	 	
	 TC	 35	 53.1357	 17.70014	 .038	 .962	
	 CC	 9	 51.7211	 20.15723	 	 	
rs1131620	 CC	 8	 57.8325	 20.68237	 	 	
	 CT	 33	 49.6070	 16.93087	 1.542	 .223	
	 TT	 16	 57.8650	 17.08802	 	 	
rs1138272	 CC	 50	 51.1408	 17.48064	 	 	
	 		CT†	 5	 70.3940	 13.48814	 5.688	 .021	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 35	 50.2094	 17.21339	 	 	
	 GA	 17	 56.3082	 19.00697	 1.431	 .248	
	 AA	 5	 62.1920	 13.75839	 	 	
rs1155563	 CC	 2	 63.6900	 4.76590	 	 	
	 CT	 24	 52.5529	 21.17344	 .401	 .672	
	 TT	 28	 51.7786	 15.50849	 	 	
rs11556218	 TT	 44	 53.3700	 17.41088	 	 	
	 TG	 13	 52.0962	 19.23777	 .051	 .822	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 51.6714	 16.16983	 	 	
	 CT	 23	 53.5513	 18.14183	 .379	 .686	
	 TT	 5	 59.0760	 25.92389	 	 	
rs11677877	 TT	 50	 52.3184	 17.97764	 	 	
	 TG	 6	 59.4000	 16.65586	 .842	 .363	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 45	 52.8447	 15.77574	 	 	
	 GA	 12	 53.9600	 24.36484	 .037	 .848	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 37	 54.0508	 18.66852	 	 	
	 GA	 18	 52.8461	 15.86391	 .859	 .429	
	 AA	 2	 37.2100	 11.31371	 	 	
rs12504628	 TT	 29	 47.9672	 16.38147	 	 	
	 TC	 24	 57.6562	 17.19982	 2.774	 .071	
	 CC	 4	 62.6825	 22.69210	 	 	
rs12899618	 CC	 44	 53.4361	 16.85865	 	 	
	 CT	 13	 51.8723	 20.90974	 .077	 .782	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 53	 52.8525	 17.85170	 	 	
	 GA	 4	 56.0875	 17.14547	 .123	 .728	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 51.9846	 18.16920	 	 	
	 TC	 24	 56.1262	 14.39423	 .987	 .379	
	 CC	 5	 44.5860	 28.26926	 	 	
rs1800450	 CC	 43	 54.0272	 17.61712	 	 	
	 CT	 13	 49.4646	 18.72979	 .387	 .681	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 49	 52.1210	 17.77384	 	 	
	 GA	 8	 58.9500	 16.93674	 1.027	 .315	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 52.8248	 14.42236	 	 	
	 GT	 27	 50.0619	 19.52526	 1.785	 .178	
	 TT	 9	 62.7267	 17.08540	 	 	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CT	
#Significant	different	from	AA	and	GG		
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	14-Associations	between	Fev1pp	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 37	 34.7081	 9.00723	 	 	
CT	 22	 32.0773	 7.84905	 1.291	 .261	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 34.0000	 6.08276	 	 	
	 CG	 25	 34.2680	 7.84298	 .039	 .962	
	 GG	 30	 33.6067	 9.83414	 	 	
rs1042713	 		CC†	 21	 29.8190	 8.97260	 	 	
	 TC	 24	 36.4583	 7.80735	 3.836	 .027	
	 TT	 14	 34.9071	 7.73886	 	 	
rs1042714	 GG	 30	 34.6967	 7.63108	 	 	
	 CG	 24	 33.3333	 9.64440	 .727	 .488	
	 CC	 5	 29.8000	 9.65401	 	 	
rs1042717	 CC	 31	 35.3129	 8.03462	 	 	
	 CT	 25	 32.2400	 9.70945	 .869	 .425	
	 TT	 4	 33.5500	 5.90000	 	 	
rs10461985	 GG	 56	 34.0750	 8.83065	 	 	
	 GA	 4	 31.6750	 6.44121	 .283	 .597	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 31.8750	 10.60239	 	 	
	 TC	 35	 34.1114	 7.15767	 .214	 .808	
	 TT	 16	 33.8125	 10.79641	 	 	
rs10516526	 GG	 50	 33.6580	 8.78250	 	 	
	 GA	 10	 35.2000	 8.40370	 .260	 .612	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 33.8780	 8.77267	 	 	
	 AG	 16	 33.2438	 8.94867	 .038	 .963	
	 GG	 2	 34.5000	 4.94975	 	 	
rs1059823	 TT	 14	 35.2143	 11.03267	 	 	
	 TC	 26	 32.3808	 7.43548	 .714	 .494	
	 CC	 20	 35.0000	 8.46665	 	 	
rs10844154	 TT	 10	 33.1000	 8.81224	 	 	
	 TG	 35	 35.7114	 8.47803	 2.211	 .119	
	 GG	 15	 30.2667	 8.33638	 	 	
rs11001819	 GG	 23	 32.0304	 9.30999	 	 	
	 GA	 27	 35.7852	 8.47438	 1.214	 .304	
	 AA	 10	 33.2000	 7.29992	 	 	
rs11046966	 AA	 30	 32.1067	 8.67954	 	 	
	 AG	 23	 35.3783	 8.68489	 1.402	 .254	
	 GG	 7	 36.8571	 7.98809	 	 	
RS11172113	 AA	 9	 36.3333	 10.73546	 	 	
	 AG	 22	 33.3727	 7.32440	 .407	 .668	
	 GG	 29	 33.5759	 9.11018	 	 	
rs1129055	 GG	 37	 33.2946	 8.44906	 	 	
	 GA	 19	 35.0526	 8.72718	 .255	 .776	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 32.0769	 7.54389	 	 	
	 TC	 37	 34.1324	 8.84226	 .462	 .632	
	 CC	 10	 35.5000	 9.81212	 	 	
rs1131620	 CC	 9	 33.3333	 10.83974	 	 	
	 CT	 35	 34.1114	 7.15767	 .029	 .971	
	 TT	 16	 33.8125	 10.79641	 	 	
rs1138272	 CC	 53	 33.8660	 8.72924	 	 	
	 CT	 5	 32.8000	 9.14877	 .068	 .796	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 35.4167	 8.33024	 	 	
	 GA	 19	 30.2053	 8.18783	 2.799	 .069	
	 AA	 5	 37.2000	 10.03494	 	 	
rs1155563	 CC	 2	 34.0000	 9.89949	 	 	
	 CT	 25	 33.8880	 9.39842	 .001	 .999	
	 TT	 30	 33.9900	 7.85886	 	 	
rs11556218	 TT	 46	 33.2000	 8.63944	 	 	
	 TG	 14	 36.2643	 8.66164	 1.349	 .250	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 30	 33.8067	 9.45428	 	 	
	 CT	 24	 34.4042	 7.83296	 .117	 .890	
	 TT	 6	 32.5000	 9.09395	 	 	
rs11677877	 TT	 53	 33.6453	 8.77669	 	 	
	 TG	 6	 34.4500	 7.75725	 .046	 .831	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 33.8277	 8.61613	 	 	
	 GA	 13	 34.2308	 9.21189	 .022	 .884	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 33.4333	 8.99679	 	 	
	 GA	 19	 34.4737	 8.36905	 .314	 .732	
	 AA	 2	 38.0000	 7.07107	 	 	
rs12504628	 TT	 39	 33.4333	 8.99679	 	 	
	 TC	 19	 34.4737	 8.36905	 .314	 .732	
	 CC	 2	 38.0000	 7.07107	 	 	
rs12899618	 CC	 46	 34.0413	 8.64645	 	 	
	 CT	 14	 33.5000	 9.06175	 .041	 .840	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 33.9982	 8.68680	 	 	
	 GA	 4	 32.7500	 9.63933	 .076	 .784	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 34.1750	 9.54225	 	 	
	 TC	 27	 33.1481	 8.56515	 .350	 .706	
	 CC	 5	 36.6000	 1.94936	 	 	
rs1800450	 CC	 44	 33.3614	 8.28052	 	 	
	 CT	 15	 34.5333	 9.41023	 1.679	 .196	
	 TT	 -	 -	 -	 	 	
rs5030737	 		GG#	 52	 33.8596	 8.73023	 	 	
	 GA	 8	 34.2750	 8.83690	 .016	 .901	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 32.6227	 8.37615	 	 	
	 GT	 29	 34.8000	 8.07925	 .393	 .677	
	 TT	 9	 34.2222	 11.58423	 	 	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CT	
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	15-Associations	between	FVCpp	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 37	 62.4757	 16.49056	 	 	
CT	 22	 63.8818	 15.37291	 .105	 .747	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 1.8820	 .80732	 	 	
	 CG	 25	 2.3700	 .64972	 1.325	 .274	
	 GG	 30	 2.1543	 .70556	 	 	
rs1042713	 CC	 21	 60.0762	 18.70620	 	 	
	 CT	 24	 62.7917	 15.27140	 .971	 .385	
	 TT	 14	 67.7429	 12.15931	 	 	
rs1042714	 GG	 30	 65.4000	 14.71467	 	 	
	 CG	 24	 57.7500	 16.44556	 2.970	 .059	
	 CC	 5	 73.8000	 14.68673	 	 	
rs1042717	 		CC†	 31	 67.2710	 12.99164	 	 	
	 CT	 25	 57.0000	 17.65408	 3.436	 .039	
	 TT	 4	 68.6500	 14.92503	 	 	
rs10461985	 GG	 56	 62.7071	 16.17527	 	 	
	 GA	 4	 68.3500	 9.92421	 .469	 .496	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 63.6250	 16.54377	 	 	
	 TC	 35	 65.4000	 14.52009	 1.392	 .257	
	 TT	 16	 57.4375	 18.25000	 	 	
rs10516526	 GG	 50	 61.6800	 15.11102	 	 	
	 GA	 10	 70.1000	 18.33303	 2.411	 .126	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 62.0244	 15.45071	 	 	
	 AG	 16	 66.6875	 17.28459	 .853	 .431	
	 GG	 2	 53.5000	 17.67767	 	 	
rs1059823	 TT	 14	 61.0714	 18.68963	 	 	
	 TC	 26	 60.0000	 14.82150	 1.824	 .171	
	 CC	 20	 68.5000	 14.29207	 	 	
rs10844154	 TT	 10	 55.8000	 13.41475	 	 	
	 TG	 35	 63.5429	 14.77140	 1.526	 .226	
	 GG	 15	 66.8667	 18.92416	 	 	
rs11001819	 GG	 23	 58.4957	 15.95777	 	 	
	 GA	 27	 66.5778	 14.93106	 1.685	 .195	
	 AA	 10	 64.2000	 16.92992	 	 	
rs11046966	 AA	 30	 62.2200	 16.83562	 	 	
	 AG	 23	 61.1043	 14.91538	 1.717	 .189	
	 GG	 7	 73.2857	 11.89838	 	 	
rs11172113	 AA	 9	 60.5556	 18.62868	 	 	
	 AG	 22	 64.7545	 16.47254	 .244	 .784	
	 GG	 29	 62.6000	 14.88566	 	 	
rs1129055	 GG	 37	 62.0541	 17.68695	 	 	
	 GA	 19	 65.5789	 12.76852	 .349	 .707	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 70.1538	 11.66795	 	 	
	 TC	 37	 62.3243	 16.40971	 2.240	 .116	
	 CC	 10	 56.7000	 16.32347	 	 	
rs1131620	 CC	 9	 64.1111	 15.54384	 	 	
	 CT	 35	 65.4000	 14.52009	 1.430	 .248	
	 TT	 16	 57.4375	 18.25000	 	 	
rs1138272	 CC	 53	 63.4717	 15.48394	 	 	
	 CT	 5	 57.2000	 23.00435	 .690	 .410	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 63.8056	 15.94960	 	 	
	 GA	 19	 62.3158	 15.89204	 .108	 .898	
	 AA	 5	 60.8000	 18.01943	 	 	
rs1155563	 CC	 2	 45.5000	 16.26346	 	 	
	 CT	 25	 62.3440	 15.09167	 1.614	 .208	
	 TT	 30	 65.4133	 16.06692	 	 	
rs11556218	 TT	 46	 62.4478	 15.28539	 	 	
	 TG	 14	 65.1714	 17.99775	 .314	 .578	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 30	 63.0533	 16.05258	 	 	
	 CT	 24	 61.9333	 16.07273	 .325	 .724	
	 TT	 6	 67.8333	 15.63863	 	 	
rs11677877	 TT	 53	 62.8415	 16.12787	 	 	
	 TG	 6	 64.4000	 15.75563	 .051	 .823	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 62.4043	 16.14960	 	 	
	 GA	 13	 65.5385	 15.02007	 .395	 .532	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 60.1282	 16.24506	 	 	
	 GA	 19	 69.0000	 14.45683	 2.086	 .134	
	 AA	 2	 64.5000	 2.12132	 	 	
rs12504628	 TT	 39	 60.1282	 16.24506	 	 	
	 TC	 19	 69.0000	 14.45683	 2.086	 .134	
	 CC	 2	 64.5000	 2.12132	 	 	
rs12899618	 CC	 46	 62.6957	 14.70273	 	 	
	 CT	 14	 64.3571	 19.70399	 .116	 .734	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 62.7321	 15.78083	 	 	
	 GA	 4	 68.0000	 18.29390	 .409	 .525	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 62.0000	 16.81261	 	 	
	 TC	 27	 63.8889	 14.90311	 .126	 .882	
	 CC	 5	 64.8000	 18.25377	 	 	
rs1800450	 CC	 44	 62.7955	 15.04186	 	 	
	 CT	 15	 64.1333	 18.98445	 .057	 .944	
	 TT	 -	 -	 -	 	 	
rs5030737#	 GG	 52	 65.2000	 14.88866	 	 	
	 GA	 8	 49.3250	 15.82004	 7.762	 .007	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 66.7909	 16.14488	 	 	
	 GT	 29	 62.5724	 15.82003	 1.639	 .203	
	 TT	 9	 55.6667	 13.77498	 	 	
	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CT	
#Significant	different	from	GA		
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	16-Associations	between	FEV1/FVC	ratio	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 37	 48.0000	 20.88460	 	 	
CT	 22	 40.9595	 8.71506	 2.254	 .139	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 57.0000	 32.57299	 	 	
	 CG	 25	 42.8444	 12.73281	 1.393	 .257	
	 GG	 30	 45.7000	 17.64428	 	 	
rs1042713	 CC	 21	 42.5238	 16.66919	 	 	
	 CT	 24	 50.0000	 20.82223	 1.425	 .249	
	 TT	 14	 41.7221	 11.02700	 	 	
rs1042714	 GG	 30	 45.6037	 18.19077	 	 	
	 CG	 24	 48.0417	 17.46171	 1.961	 .150	
	 CC	 5	 31.2000	 6.97854	 	 	
rs1042717	 CC	 31	 42.6810	 14.26702	 	 	
	 CT	 25	 49.4800	 20.95654	 1.150	 .324	
	 TT	 4	 41.7500	 14.79583	 	 	
rs10461985	 GG	 56	 46.0714	 17.90465	 	 	
	 GA	 4	 36.7775	 3.98807	 1.058	 .308	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 43.0000	 11.42679	 	 	
	 TC	 35	 43.5460	 16.41749	 .955	 .391	
	 TT	 16	 50.5625	 22.07553	 	 	
rs10516526	 GG	 50	 46.4222	 18.46509	 	 	
	 GA	 10	 40.6000	 10.60608	 .925	 .340	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 61.6098	 23.98320	 	 	
	 AG	 13	 70.7692	 25.66500	 1.034	 .362	
	 GG	 2	 97.0000	 2.82843	 	 	
rs1059823	 TT	 14	 51.7857	 23.52798	 	 	
	 TC	 26	 45.8119	 17.85387	 1.757	 .182	
	 CC	 20	 40.5500	 9.70879	 	 	
rs10844154	 TT	 10	 48.5000	 16.44013	 	 	
	 TG	 35	 47.4603	 18.10370	 1.519	 .228	
	 GG	 15	 38.7333	 15.84508	 	 	
rs11001819	 GG	 23	 45.1352	 17.86277	 	 	
	 GA	 27	 45.1481	 16.96309	 .046	 .955	
	 AA	 10	 47.0000	 19.64123	 	 	
rs11046966	 AA	 30	 44.2333	 15.25797	 	 	
	 AG	 23	 48.3961	 21.61847	 .619	 .542	
	 GG	 7	 41.0000	 9.88264	 	 	
rs11172113	 AA	 9	 52.4444	 23.33512	 	 	
	 AG	 22	 43.7727	 14.93775	 .857	 .430	
	 GG	 29	 44.5555	 17.35596	 	 	
rs1129055	 GG	 37	 46.9759	 20.26470	 	 	
	 GA	 19	 42.8421	 11.80519	 .364	 .697	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 13	 36.7692	 9.69668	 	 	
	 TC	 37	 46.1381	 19.21604	 3.094	 .053	
	 CC	 10	 54.2000	 14.21111	 	 	
rs1131620	 CC	 9	 43.7778	 10.94050	 	 	
	 CT	 35	 43.5460	 16.41749	 .932	 .400	
	 TT	 16	 50.5625	 22.07553	 	 	
rs1138272	 CC	 53	 44.8700	 17.32454	 	 	
	 CT	 5	 53.0000	 22.02272	 .964	 .330	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 36	 46.8056	 16.68501	 	 	
	 GA	 19	 39.2689	 11.88860	 3.044	 .055	
	 AA	 5	 59.2000	 31.53094	 	 	
rs1155563	 CC	 2	 75.0000	 52.32590	 	 	
	 CT	 25	 45.3200	 13.13938	 3.075	 .054	
	 TT	 30	 43.8037	 17.77466	 	 	
rs11556218	 TT	 46	 44.0870	 16.17244	 	 	
	 TG	 14	 49.9364	 21.24037	 1.208	 .276	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 30	 44.9667	 15.82334	 	 	
	 CT	 24	 47.0879	 20.31762	 .277	 .759	
	 TT	 6	 41.3333	 14.65151	 	 	
rs11677877	 TT	 53	 45.3208	 17.75774	 	 	
	 TG	 6	 45.8517	 17.78651	 .005	 .945	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 47	 45.5981	 18.73751	 	 	
	 GA	 13	 44.9231	 12.40606	 .015	 .903	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 39	 47.5926	 18.97368	 	 	
	 GA	 19	 41.0526	 14.31966	 .892	 .415	
	 AA	 2	 45.5000	 9.19239	 	 	
rs12504628	 TT	 39	 47.5926	 18.97368	 	 	
	 TC	 19	 41.0526	 14.31966	 .892	 .415	
	 CC	 2	 45.5000	 9.19239	 	 	
rs12899618	 CC	 46	 45.5459	 16.58677	 	 	
	 CT	 14	 45.1429	 20.79148	 .006	 .941	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 56	 45.5020	 16.70114	 	 	
	 GA	 4	 44.7500	 29.76995	 .007	 .935	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 28	 47.7896	 19.92509	 	 	
	 TC	 27	 42.6667	 15.64510	 .617	 .543	
	 CC	 5	 47.4000	 11.58879	 	 	
rs1800450	 CC	 44	 45.3661	 19.27358	 	 	
	 CT	 15	 44.4000	 10.78888	 .646	 .528	
	 TT	 -	 -	 -	 	 	
rs5030737	 		GG†	 52	 42.2713	 13.32253	 	 	
	 GA	 8	 66.1250	 26.73915	 16.278	 .000	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 22	 41.1414	 19.72018	 	 	
	 GT	 29	 46.2759	 12.48970	 1.654	 .200	
	 TT	 9	 53.3333	 23.66432	 	 	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	GA	
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	17-Associations	between	maximum	inspiratory	pressure	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 35	 66.9143	 26.64844	 	 	
CT	 21	 61.8095	 21.66245	 .551	 .461	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 69.2000	 20.96902	 	 	
	 CG	 24	 65.3750	 19.95171	 .079	 .924	
	 GG	 28	 64.3929	 29.20216	 	 	
rs1042713	 CC	 19	 54.1579	 26.25995	 	 	
	 CT	 24	 70.1667	 25.60854	 2.948	 .061	
	 TT	 13	 71.3077	 15.77120	 	 	
rs1042714	 GG	 28	 66.0000	 22.69116	 	 	
	 CG	 24	 65.9583	 28.22654	 .559	 .575	
	 CC	 4	 52.2500	 17.74589	 	 	
rs1042717	 CC	 29	 70.2069	 19.60390	 	 	
	 CT	 25	 61.8000	 29.63950	 1.830	 .170	
	 TT	 3	 45.6667	 4.04145	 	 	
rs10461985	 GG	 53	 65.4906	 25.40792	 	 	
	 GA	 4	 61.7500	 11.78629	 .084	 .773	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 8	 63.8750	 11.06394	 	 	
	 TC	 33	 69.3030	 22.95578	 1.488	 .235	
	 TT	 15	 56.1333	 32.01755	 	 	
rs10516526	 GG	 47	 64.4681	 24.34878	 	 	
	 GA	 10	 68.8000	 27.10392	 .251	 .618	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 61.6098	 23.98320	 	 	
	 AG	 13	 70.7692	 25.66500	 2.530	 .089	
	 GG	 2	 97.0000	 2.82843	 	 	
rs1059823	 TT	 13	 64.0769	 20.91834	 	 	
	 TC	 24	 57.9583	 24.03707	 2.686	 .077	
	 CC	 20	 74.7000	 25.56540	 	 	
rs10844154	 TT	 10	 52.0000	 20.77926	 	 	
	 TG	 32	 66.4063	 21.47145	 2.040	 .140	
	 GG	 15	 71.5333	 31.01812	 	 	
rs11001819	 GG	 23	 64.8261	 24.56467	 	 	
	 GA	 25	 69.9200	 23.49986	 1.553	 .221	
	 AA	 9	 53.2222	 26.59313	 	 	
rs11046966	 AA	 27	 67.0370	 28.91164	 	 	
	 AG	 23	 64.6957	 21.92017	 .229	 .796	
	 GG	 7	 60.0000	 15.53491	 	 	
rs11172113	 AA	 9	 78.3333	 30.72458	 	 	
	 AG	 20	 66.2500	 23.08309	 1.912	 .158	
	 GG	 28	 60.2857	 22.86167	 	 	
rs1129055	 GG	 34	 63.7647	 23.14913	 	 	
	 GA	 19	 68.1053	 28.76320	 .189	 .829	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 12	 60.0000	 17.09864	 	 	
	 TC	 36	 63.2500	 27.41259	 2.106	 .132	
	 CC	 9	 80.1111	 16.04248	 	 	
rs1131620	 CC	 9	 65.4444	 11.37004	 	 	
	 CT	 33	 69.3030	 22.95578	 1.498	 .233	
	 TT	 15	 56.1333	 32.01755	 	 	
rs1138272	 CC	 50	 65.6200	 25.25372	 	 	
	 CT	 5	 63.6000	 22.45662	 .030	 .864	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 35	 67.6571	 24.18306	 	 	
	 GA	 17	 56.0000	 22.78431	 2.314	 .109	
	 AA	 5	 79.6000	 28.11227	 	 	
rs1155563	 CC	 2	 53.0000	 8.48528	 	 	
	 CT	 23	 68.6522	 20.16660	 .476	 .624	
	 TT	 29	 64.3793	 27.82780	 	 	
rs11556218	 TT	 44	 64.1136	 23.83199	 	 	
	 TG	 13	 69.0000	 27.95234	 .390	 .535	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 68.5862	 27.63993	 	 	
	 CT	 24	 62.4167	 18.36565	 .600	 .552	
	 TT	 4	 57.7500	 37.18759	 	 	
rs11677877	 TT	 50	 65.3400	 25.02212	 	 	
	 TG	 6	 62.1667	 25.05527	 .086	 .770	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 44	 64.9318	 26.06021	 	 	
	 GA	 13	 66.2308	 20.03810	 .027	 .869	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 37	 66.5946	 27.49289	 	 	
	 GA	 18	 63.6667	 19.44827	 .293	 .747	
	 AA	 2	 54.0000	 5.65685	 	 	
rs12504628	 TT	 37	 66.5946	 27.49289	 	 	
	 TC	 18	 63.6667	 19.44827	 .293	 .747	
	 CC	 2	 54.0000	 5.65685	 	 	
rs12899618	 CC	 43	 65.7209	 26.37759	 	 	
	 CT	 14	 63.7143	 19.16097	 .069	 .794	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 53	 66.3962	 24.75056	 	 	
	 GA	 4	 49.7500	 19.60230	 1.717	 .195	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 26	 66.8846	 26.23483	 	 	
	 TC	 26	 61.5769	 23.34639	 .780	 .463	
	 CC	 5	 75.6000	 23.71287	 	 	
rs1800450	 CC	 42	 66.8571	 23.92832	 	 	
	 CT	 14	 58.2143	 26.13038	 1.408	 .254	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 50	 66.0000	 24.79302	 	 	
	 GA	 7	 59.7143	 24.75018	 .395	 .532	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 62.4286	 22.60657	 	 	
	 GT	 27	 68.0370	 27.13851	 .329	 .721	
	 TT	 9	 63.3333	 23.07054	 	 	
	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
SNP-	Single	Nucleotide	Polymorphism	
	
	
 
 
181	
Table	S	18-Associations	between	maximum	expiratory	pressure	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 35	 114.2000	 39.00890	 	 	
CT	 21	 105.7619	 42.70820	 .572	 .453	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 116.4000	 45.50604	 	 	
	 CG	 24	 111.5833	 40.84000	 .104	 .902	
	 GG	 28	 108.2143	 40.21089	 	 	
rs1042713	 CC	 19	 98.7895	 49.43636	 	 	
	 CT	 24	 117.8333	 32.95671	 1.353	 .267	
	 TT	 13	 116.3846	 36.34221	 	 	
rs1042714	 GG	 28	 112.1429	 36.18954	 	 	
	 CG	 24	 108.9583	 45.64083	 .068	 .935	
	 CC	 4	 115.7500	 43.40795	 	 	
rs1042717	 CC	 29	 117.0690	 34.20937	 	 	
	 CT	 25	 107.0800	 46.33026	 1.858	 0.166	
	 TT	 3	 72.6667	 16.25833	 	 	
rs10461985	 GG	 53	 109.5472	 40.80609	 	 	
	 GA	 4	 121.0000	 34.51570	 .298	 .588	
	 AA	 -	 -	 -	 	 	
rS1051303	 CC	 8	 114.5000	 28.79980	 	 	
	 TC	 33	 117.0000	 39.98515	 1.452	 .243	
	 TT	 15	 96.0667	 44.36290	 	 	
rs10516526	 GG	 47	 110.8936	 42.26893	 	 	
	 GA	 10	 107.8000	 30.52067	 .048	 .828	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 104.8780	 38.36613	 	 	
	 AG	 13	 127.6923	 44.79097	 1.846	 .168	
	 GG	 2	 129.0000	 19.79899	 	 	
rs1059823	 TT	 13	 111.3846	 23.93581	 	 	
	 TC	 24	 101.8750	 43.90039	 1.098	 .341	
	 CC	 20	 119.8500	 43.47083	 	 	
rs10844154	 TT	 10	 111.7000	 41.62812	 	 	
	 TG	 32	 108.3438	 38.12425	 .095	 .909	
	 GG	 15	 113.7333	 46.04108	 	 	
rs11001819	 GG	 23	 113.6522	 44.96424	 	 	
	 GA	 25	 112.3200	 35.85819	 .637	 .533	
	 AA	 9	 96.4444	 40.65437	 	 	
rs11046966	 AA	 27	 111.1852	 39.86326	 	 	
	 AG	 23	 112.8261	 44.99662	 .320	 .728	
	 GG	 7	 99.0000	 24.92656	 	 	
rs11172113	 AA	 9	 109.2222	 22.87891	 	 	
	 AG	 20	 123.2000	 45.71030	 1.740	 .185	
	 GG	 28	 101.5357	 39.09768	 	 	
rs1129055	 GG	 34	 105.9118	 41.61539	 	 	
	 GA	 19	 116.0526	 40.38904	 .529	 .592	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 12	 103.9167	 33.23596	 	 	
	 		TC†	 36	 104.6667	 41.19015	 3.532	 .036	
	 CC	 9	 141.6667	 32.84433	 	 	
rs1131620	 CC	 9	 109.7778	 30.43755	 	 	
	 CT	 33	 117.0000	 39.98515	 1.418	 .251	
	 TT	 15	 96.0667	 44.36290	 	 	
rs1138272	 CC	 50	 109.7400	 41.25372	 	 	
	 CT	 5	 118.6000	 34.14381	 .215	 .645	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 35	 112.9714	 42.51954	 	 	
	 GA	 17	 106.9412	 40.25151	 .200	 .819	
	 AA	 5	 103.6000	 25.45192	 	 	
rs1155563	 CC	 2	 93.0000	 48.08326	 	 	
	 CT	 23	 119.1739	 30.58171	 .800	 .455	
	 TT	 29	 107.5862	 44.65304	 	 	
rs11556218	 TT	 44	 109.0909	 38.37624	 	 	
	 TG	 13	 114.6154	 47.44741	 .186	 .668	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 112.5172	 46.41553	 	 	
	 CT	 24	 109.7500	 31.61212	 .219	 .804	
	 TT	 4	 98.2500	 46.94234	 	 	
rs11677877	 TT	 50	 113.7800	 40.28687	 	 	
	 TG	 6	 88.1667	 34.95378	 2.216	 .142	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 44	 109.0227	 42.23879	 	 	
	 GA	 13	 114.8462	 33.65473	 .207	 .651	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 37	 107.4865	 42.02025	 	 	
	 GA	 18	 113.1667	 38.42984	 .601	 .552	
	 AA	 2	 138.0000	 1.41421	 	 	
rs12504628	 TT	 37	 107.4865	 42.02025	 	 	
	 TC	 18	 113.1667	 38.42984	 .601	 .552	
	 CC	 2	 138.0000	 1.41421	 	 	
rs12899618	 CC	 43	 111.2093	 40.98464	 	 	
	 CT	 14	 107.7143	 39.19464	 .078	 .781	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 53	 111.1509	 40.67762	 	 	
	 GA	 4	 99.7500	 37.07088	 .295	 .589	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 26	 110.6154	 41.11163	 	 	
	 TC	 26	 102.9615	 33.64578	 2.716	 .075	
	 CC	 5	 147.4000	 54.33507	 	 	
rs1800450	 CC	 42	 111.7381	 38.64350	 	 	
	 CT	 14	 106.2857	 47.31958	 .094	 .911	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 50	 110.3200	 40.76635	 	 	
	 GA	 7	 110.5714	 39.19123	 .000	 .988	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 114.6667	 41.14527	 	 	
	 GT	 27	 110.4815	 39.58474	 .416	 .662	
	 TT	 9	 99.8889	 42.82652	 	 	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CC	
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	19-Associations	between	quadriceps	muscle	strength	(dynamometer)	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 35	 22.9600	 9.57202	 	 	
CT	 21	 20.4091	 9.22109	 .987	 .325	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 5	 21.5200	 8.53710	 	 	
	 CG	 24	 22.5333	 11.02817	 .100	 .905	
	 GG	 28	 21.3793	 8.27912	 	 	
rs1042713	 .	CC†	 19	 17.8737	 9.44051	 	 	
	 CT	 24	 25.0667	 9.76287	 3.346	 .043	
	 TT	 14	 22.2429	 9.43843	 	 	
rs1042714	 GG	 28	 21.4233	 7.09807	 	 	
	 CG	 24	 22.1043	 11.19474	 .305	 .738	
	 CC	 4	 25.3750	 15.43554	 	 	
rs1042717	 			CC#	 29	 25.1967	 9.96883	 	 	
	 CT	 25	 18.3250	 7.57400	 4.363	 .017	
	 TT	 3	 18.1750	 6.74802	 	 	
rs10461985	 GG	 53	 21.4556	 9.48883	 	 	
	 GA	 4	 27.4500	 6.33377	 1.532	 .221	
	 AA	 -	 -	 -	 	 	
rS1051303	 CC	 8	 23.9125	 14.02197	 	 	
	 TC	 33	 23.5061	 8.74325	 2.224	 .118	
	 TT	 15	 17.8500	 7.24127	 	 	
rs10516526	 GG	 47	 21.0673	 9.45748	 	 	
	 GA	 10	 26.2333	 8.13910	 2.356	 .130	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 41	 21.5625	 10.35695	 	 	
	 AG	 13	 22.8533	 7.40809	 .130	 .878	
	 GG	 2	 23.6500	 3.69624	 	 	
rs1059823	 TT	 13	 22.5308	 10.92439	 	 	
	 TC	 24	 20.4840	 8.98279	 .487	 .617	
	 CC	 20	 23.1700	 9.09020	 	 	
rs10844154	 TT	 10	 20.8300	 8.16851	 	 	
	 TG	 32	 21.5818	 9.17410	 .220	 .804	
	 GG	 15	 23.1933	 10.99542	 	 	
rs11001819	 GG	 23	 19.9000	 7.72540	 	 	
	 GA	 25	 24.2115	 10.66330	 1.494	 .233	
	 AA	 9	 20.1333	 8.74343	 	 	
rs11046966	 AA	 27	 21.9103	 8.99942	 	 	
	 AG	 23	 21.2045	 9.55089	 .195	 .823	
	 GG	 7	 23.7857	 11.60021	 	 	
rs11172113	 AA	 9	 19.8556	 8.80158	 	 	
	 AG	 20	 25.2429	 10.92221	 2.216	 .119	
	 GG	 28	 19.9857	 7.80720	 	 	
rs1129055	 GG	 34	 20.6557	 8.46044	 	 	
	 GA	 19	 25.4684	 10.63313	 3.333	 .074	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 12	 25.4000	 11.69622	 	 	
	 TC	 36	 19.6111	 7.95188	 2.935	 .062	
	 CC	 9	 25.8000	 9.26512	 	 	
rs1131620	 CC	 9	 23.0111	 13.39220	 	 	
	 CT	 33	 23.5061	 8.74325	 2.113	 .131	
	 TT	 15	 17.8500	 7.24127	 	 	
rs1138272	 CC	 50	 22.7216	 9.62475	 	 	
	 CT	 5	 16.6600	 3.72733	 1.977	 .171	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 35	 22.0889	 9.73425	 	 	
	 GA	 17	 22.0765	 9.42122	 .158	 .854	
	 AA	 5	 19.5800	 8.07527	 	 	
rs1155563	 CC	 2	 19.1500	 12.51579	 	 	
	 CT	 23	 21.8220	 9.03919	 .194	 .825	
	 TT	 29	 22.8857	 9.86069	 	 	
rs11556218	 TT	 44	 22.0022	 9.79444	 	 	
	 TG	 13	 21.4077	 8.17338	 .040	 .843	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 29	 24.4034	 11.05174	 	 	
	 CT	 24	 19.0375	 6.42582	 2.280	 .112	
	 TT	 4	 20.7600	 8.24154	 	 	
rs11677877	 TT	 50	 21.6902	 9.27244	 	 	
	 TG	 6	 24.4000	 11.40509	 .438	 .511	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 44	 21.4674	 9.06449	 	 	
	 GA	 13	 23.4083	 10.84146	 .402	 .528	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 37	 21.8053	 9.05992	 	 	
	 GA	 18	 21.8722	 10.55818	 .016	 .984	
	 AA	 2	 23.0500	 9.54594	 	 	
rs12504628	 TT	 37	 21.5433	 8.03667	 	 	
	 TC	 18	 21.9333	 10.20199	 .111	 .895	
	 CC	 2	 23.9250	 15.69594	 	 	
rs12899618	 CC	 43	 21.8886	 8.45000	 	 	
	 CT	 14	 21.8071	 12.26568	 .001	 .978	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 53	 21.6389	 9.37855	 	 	
	 GA	 4	 24.9750	 10.37638	 .466	 .498	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 26	 22.3714	 9.55831	 	 	
	 TC	 26	 20.9920	 10.09467	 .213	 .809	
	 CC	 5	 23.4400	 4.33394	 	 	
rs1800450	 CC	 42	 22.1932	 9.10462	 	 	
	 CT	 14	 20.6923	 10.94703	 .249	 .620	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 50	 22.5260	 9.73550	 	 	
	 GA	 7	 17.7625	 5.67550	 1.800	 .185	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 21.1429	 8.15657	 	 	
	 GT	 27	 23.8036	 10.52723	 1.648	 .202	
	 TT	 9	 17.5444	 7.23880	 	 	
	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CT	
#Significant	different	from	CT		
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	20-Associations	between	handgrip	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 26	 38.0962	 9.05982	 	 	
CT	 14	 38.2857	 7.96559	 .004	 .948	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 2	 37.5000	 2.12132	 	 	
	 CG	 17	 37.5588	 8.93358	 .015	 .985	
	 GG	 22	 38.0455	 9.22975	 	 	
rs1042713	 CC	 14	 34.9643	 9.50398	 	 	
	 TC	 19	 40.5789	 8.08507	 1.794	 .180	
	 TT	 7	 38.0000	 6.73300	 	 	
rs1042714	 GG	 18	 40.2222	 7.62006	 	 	
	 CG	 19	 36.3421	 9.41638	 .956	 .394	
	 CC	 3	 37.3333	 8.73689	 	 	
rs1042717	 CC	 19	 38.4211	 7.15942	 	 	
	 CT	 21	 37.2143	 10.33026	 .099	 .906	
	 TT	 1	 39.0000	 .	 	 	
rs10461985	 GG	 37	 37.4730	 8.51139	 	 	
	 GA	 4	 41.0000	 11.83216	 .578	 .452	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 6	 37.7500	 8.04829	 	 	
	 TC	 24	 40.1667	 7.38781	 2.198	 .125	
	 TT	 10	 33.6000	 10.50079	 	 	
rs10516526	 GG	 35	 37.1286	 9.11797	 	 	
	 GA	 6	 41.8333	 5.15429	 1.494	 .229	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 26	 36.4423	 7.26681	 	 	
	 AG	 13	 42.0769	 10.17727	 2.267	 .118	
	 GG	 1	 32.0000	 -	 	 	
rs1059823	 TT	 10	 39.3500	 9.70123	 	 	
	 TC	 18	 35.4444	 8.22637	 1.200	 .312	
	 CC	 13	 39.9231	 8.62614	 	 	
rs10844154	 TT	 8	 37.8750	 10.03476	 	 	
	 TG	 21	 36.5952	 9.08518	 .536	 .590	
	 GG	 12	 39.9167	 7.58537	 	 	
rs11001819	 GG	 19	 35.9737	 9.95891	 	 	
	 GA	 14	 41.3571	 6.22164	 1.804	 .178	
	 AA	 8	 36.0000	 8.60233	 	 	
rs11046966	 AA	 20	 39.8000	 8.25642	 	 	
	 AG	 16	 34.0313	 9.31033	 2.806	 .073	
	 GG	 5	 42.0000	 4.52769	 	 	
rs11172113	 AA	 8	 36.6875	 11.02898	 	 	
	 .	AG†	 17	 42.3529	 7.22791	 5.093	 .011	
	 GG	 16	 33.5625	 7.00446	 	 	
rs1129055	 GG	 23	 37.6087	 7.55428	 	 	
	 GA	 16	 39.3125	 10.10425	 1.464	 .244	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 9	 38.4444	 4.90181	 	 	
	 TC	 25	 36.8200	 10.24581	 .518	 .600	
	 CC	 7	 40.5714	 6.82781	 	 	
rs1131620	 CC	 7	 35.7857	 8.99934	 	 	
	 CT	 24	 40.1667	 7.38781	 2.358	 .108	
	 TT	 10	 33.6000	 10.50079	 	 	
rs1138272	 CC	 35	 38.2143	 9.00922	 	 	
	 CT	 4	 38.7500	 5.73730	 .013	 .909	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 25	 39.2800	 8.60484	 	 	
	 GA	 13	 33.9615	 8.46183	 2.116	 .134	
	 AA	 3	 42.3333	 8.02081	 	 	
rs1155563	 CC	 -	 -	 -	 	 	
	 CT	 15	 38.8333	 7.66175	 .055	 .816	
	 TT	 23	 38.1739	 8.92724	 	 	
rs11556218	 .	TT#	 31	 36.0484	 8.13875	 	 	
	 TG	 10	 43.3000	 8.74389	 5.796	 .021	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 20	 39.8500	 9.90096	 	 	
	 CT	 16	 34.9688	 5.92303	 1.446	 .248	
	 TT	 5	 38.8000	 10.80278	 	 	
rs11677877	 TT	 36	 38.9028	 8.74546	 	 	
	 TG	 4	 31.5000	 1.00000	 2.797	 .103	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 32	 37.7344	 9.79630	 	 	
	 GA	 9	 38.1111	 3.48010	 .013	 .911	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 27	 37.7222	 9.47906	 	 	
	 GA	 12	 38.1667	 8.06602	 .019	 .981	
	 AA	 2	 37.0000	 4.24264	 	 	
rs12504628	 TT	 27	 37.7222	 9.47906	 	 	
	 TC	 12	 38.1667	 8.06602	 .019	 .981	
	 CC	 2	 37.0000	 4.24264	 	 	
rs12899618	 CC	 36	 37.9167	 8.68620	 	 	
	 CT	 5	 37.1000	 10.35857	 .037	 .848	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 37	 38.2568	 9.10862	 	 	
	 GA	 4	 33.7500	 2.06155	 .953	 .335	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 19	 37.7105	 8.98350	 	 	
	 TC	 18	 37.5556	 9.01125	 .079	 .924	
	 CC	 4	 39.5000	 8.69866	 	 	
rs1800450	 CC	 28	 38.2679	 9.72062	 	 	
	 CT	 13	 36.8462	 6.47876	 .229	 .635	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 36	 38.1528	 9.24648	 	 	
	 GA	 5	 35.4000	 3.43511	 .427	 .517	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 19	 37.7632	 9.14143	 	 	
	 GT	 17	 38.8235	 8.06408	 .437	 .649	
	 TT	 5	 34.6000	 10.71448	 	 	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	GG	
#Significant	different	from	TG		
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	21-Associations	between	five	time	sit-to-stand	test	and	genetic	variants	
SNP	 Genotype	 N	 Mean	 Std.	Deviation	 F.	 p-value*	
rs10011792	
	
CC	 32	 9.8131	 5.48420	 	 	
CT	 20	 9.6820	 3.85757	 .009	 .926	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 4	 6.6650	 1.67353	 	 	
	 CG	 22	 10.8714	 6.61335	 .104	 .216	
	 GG	 27	 9.2448	 2.90701	 	 	
rs1042713	 CC	 16	 11.7375	 7.46470	 	 	
	 TC	 22	 9.1668	 3.22202	 2.069	 .137	
	 TT	 14	 8.4421	 2.26784	 	 	
rs1042714	 GG	 28	 8.3968	 2.59463	 	 	
	 CG	 19	 11.5047	 7.11243	 2.565	 .087	
	 CC	 5	 10.7920	 1.39591	 	 	
rs1042717	 CC	 30	 9.3327	 2.67306	 	 	
	 CT	 20	 10.6190	 7.13228	 .695	 .504	
	 TT	 3	 7.6933	 2.49588	 	 	
rs10461985	 GG	 49	 9.8782	 4.98221	 	 	
	 GA	 4	 7.8525	 2.04340	 .643	 .426	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 7	 13.2714	 10.05213	 	 	
	 TC	 31	 9.2758	 3.56286	 2.195	 .122	
	 TT	 14	 9.0864	 3.14151	 	 	
rs10516526	 GG	 44	 9.9750	 5.08903	 	 	
	 GA	 9	 8.5044	 3.34279	 .685	 .412	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 34	 10.0544	 5.47956	 	 	
	 AG	 16	 9.3244	 3.71267	 .207	 .814	
	 GG	 2	 8.3100	 2.74357	 	 	
rs1059823	 TT	 12	 10.5317	 8.20241	 	 	
	 TC	 23	 10.0639	 3.54031	 .574	 .567	
	 CC	 18	 8.7550	 3.21733	 	 	
rs10844154	 TT	 9	 8.2611	 1.97708	 	 	
	 TG	 31	 10.2161	 5.90080	 .568	 .570	
	 GG	 13	 9.5685	 3.11235	 	 	
rs11001819	 GG	 21	 10.0343	 6.94425	 	 	
	 GA	 24	 9.5733	 3.13364	 .073	 .929	
	 AA	 8	 9.3700	 1.90118	 	 	
rs11046966	 AA	 27	 9.5956	 3.28722	 	 	
	 AG	 19	 10.7553	 6.78026	 1.237	 .299	
	 GG	 7	 7.4300	 2.97886	 	 	
rs11172113	 AA	 8	 12.0875	 10.13915	 	 	
	 AG	 20	 9.7065	 2.91673	 1.257	 .293	
	 GG	 25	 8.9844	 3.41291	 	 	
rs1129055	 GG	 32	 9.1131	 3.47332	 	 	
	 GA	 18	 9.4050	 3.12920	 0.087	 .769	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 12	 9.4525	 3.15823	 	 	
	 TC	 32	 10.3281	 5.66517	 .871	 .425	
	 CC	 9	 7.9456	 3.03127	 	 	
rs1131620	 CC	 8	 12.5850	 9.50683	 	 	
	 CT	 31	 9.2758	 3.56286	 1.695	 .194	
	 TT	 14	 9.0864	 3.14151	 	 	
rs1138272	 CC	 46	 9.4924	 4.85884	 	 	
	 CT	 5	 10.5140	 4.22687	 .203	 .654	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 33	 9.3761	 3.62315	 	 	
	 GA	 16	 10.5656	 6.85557	 .338	 .715	
	 AA	 4	 9.2450	 5.09503	 	 	
rs1155563	 CC	 1	 10.6200	 -	 	 	
	 CT	 23	 10.4204	 6.44986	 .392	 .678	
	 TT	 27	 9.1896	 3.28335	 	 	
rs11556218	 TT	 41	 10.0344	 5.18835	 	 	
	 TG	 12	 8.6692	 3.37255	 .734	 .396	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 27	 9.0559	 3.38598	 	 	
	 CT	 21	 10.2362	 6.51100	 .595	 .555	
	 TT	 5	 11.1940	 3.34900	 	 	
rs11677877	 TT	 46	 9.8107	 5.11978	 	 	
	 TG	 6	 9.3950	 2.64021	 .038	 .847	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 43	 10.0170	 5.05816	 	 	
	 GA	 10	 8.4710	 3.72999	 .824	 .368	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 33	 9.4521	 5.87865	 	 	
	 GA	 19	 10.2032	 2.43241	 .140	 .869	
	 AA	 1	 9.6600	 -	 	 	
rs12504628	 TT	 33	 9.4521	 5.87865	 	 	
	 TC	 19	 10.2032	 2.43241	 .140	 .869	
	 CC	 1	 9.6600	 -	 	 	
rs12899618	 .	CC†	 40	 8.8408	 3.26219	 	 	
	 CT	 13	 12.4469	 7.50861	 5.961	 .018	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 49	 9.7582	 5.03594	 	 	
	 GA	 4	 9.3225	 .62222	 .029	 .865	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 26	 9.7423	 6.20869	 	 	
	 TC	 22	 9.9036	 3.29286	 .093	 .911	
	 CC	 5	 8.8520	 2.41140	 	 	
rs1800450	 CC	 41	 9.6856	 4.88364	 	 	
	 CT	 11	 10.1518	 5.03704	 .237	 .790	
	 TT	 -	 -	 -	 	 	
rs5030737	 GG	 48	 9.9735	 5.01492	 	 	
	 GA	 5	 7.3420	 1.20348	 1.346	 .251	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 10.2810	 6.45991	 	 	
	 GT	 25	 9.3008	 3.30185	 .231	 .795	
	 TT	 7	 9.5743	 4.31599	 	 	
	
	
	
	
	
	 	
*Calculated	using	One-way	ANOVA	
†Significant	different	from	CT	
SNP-	Single	Nucleotide	Polymorphism	
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Table	S	22-Associations	between	one	minute	sit-to-stand	test	and	genetic	variants	
SNP	 Genotype	 N	 Median	 IQR	 Chi-Square	 p-value*	
rs10011792	
	
CC	 32	 28.5000	 22	to	32.75	 	 	
CT	 20	 26.0000	 18.50	to	33.75	 0.109	 0.742	
TT	 -	 -	 -	 	 	
rs1042522	 CC	 4	 30.0000	 22	to	34.25	 	 	
	 CG	 22	 24.0000	 16.50	to	31.25	 3.233	 0.199	
	 GG	 27	 29.0000	 22	to	35	 	 	
rs1042713	 CC	 21	 22.0000	 14.25	to	31	 	 	
	 TC	 24	 28.5000	 21.75	to	33	 4.763	 0.092	
	 TT	 14	 30.5000	 24	to	35	 	 	
rs1042714	 GG	 27	 31.0000	 24	to	35	 	 	
	 CG	 20	 24.0000	 17.25	to	31	 6.672	 .038	
	 CC	 5	 23.0000	 15	to	25.50	 	 	
rs1042717	 CC	 30	 26.0000	 21.75	to	33.25	 	 	
	 CT	 21	 26.0000	 16	to	31.50	 2.989	 0.224	
	 TT	 2	 -	 -	 	 	
rs10461985	 GG	 49	 26.0000	 20.50	to	32.50		 	 	
	 GA	 4	 32.5000	 23	to	36.75	 1-057	 .304	
	 AA	 -	 -	 -	 	 	
rs1051303	 CC	 6	 22.5000	 17	to	34.25	 	 	
	 TC	 32	 29.0000	 9.22	to	34.50		 2.558	 .278	
	 TT	 14	 26.5000	 16.75	to	31.75	 	 	
rs10516526	 GG	 43	 26.0000	 20	to	33	 	 	
	 GA	 10	 26.5000	 20.25	to	37	 .081	 .776	
	 AA	 -	 -	 -	 	 	
rs1051740	 AA	 34	 25.5000	 20	to	32.50	 	 	
	 AG	 16	 29.5000	 22	to	34.50	 .854	 .652	
	 GG	 2	 28.5000	 26	to	-	 	 	
rs1059823	 TT	 12	 28.5000	 23.75	to	35	 	 	
	 TC	 23	 21.0000	 16	to	33	 3.329	 .189	
	 CC	 18	 29.0000	 24	to	33.75	 	 	
rs10844154	 TT	 9	 29.0000	 21	to	35	 	 	
	 TG	 31	 28.0000	 21	to	33	 .423	 .809	
	 GG	 13	 25.0000	 18	to	33.50	 	 	
rs11001819	 GG	 21	 29.0000	 22	to	32	 	 	
	 GA	 24	 27.5000	 20.25	to	35.75	 .962	 .618	
	 AA	 8	 23.0000	 20.50	to	30.50	 	 	
rs11046966	 		AA†	 27	 24.0000	 18	to	29	 	 	
	 AG	 20	 30.0000	 24	to	33.75	 8.706	 .013	
	 GG	 6	 35.5000	 29	to	47	 	 	
rs11172113	 AA	 8	 32.5000	 15.75	to	36.75	 	 	
	 AG	 19	 26.0000	 22	to	32	 1.331	 .514	
	 GG	 26	 26.0000	 17.75	to	32.25	 	 	
rs1129055	 GG	 32	 26.0000	 20	to	35.75	 	 	
	 GA	 18	 27.5000	 24	to	31.25	 .003	 .960	
	 AA	 -	 -	 -	 	 	
rs1130866	 TT	 12	 24.5000	 18.50	to	32.75	 	 	
	 TC	 32	 26.0000	 20.25	to	34.75	 .414	 .813	
	 CC	 9	 29.0000	 25.50	to	30	 	 	
rs1131620	 CC	 7	 23.0000	 20	to	24	 	 	
	 CT	 32	 29.0000	 22	to	34.50	 2.920	 .232	
	 TT	 14	 26.5000	 16.75	to	31.75	 	 *	
rs1138272	 		CC#	 46	 29.0000	 22.75	to	34.25	 	 	
	 CT	 5	 20.0000	 14	to	21.50	 5.258	 .012	
	 TT	 -	 -	 -	 	 	
rs1143634	 GG	 32	 29.0000	 21.25	to	33.75	 	 	
	 GA	 17	 26.0000	 18	to	30.50	 1.525	 .467	
	 AA	 4	 32.5000	 15.50	to	37.50	 	 	
rs1155563	 CC	 1	 24.0000	 -	 	 	
	 CT	 22	 26.0000	 19.50	to	32.75	 .587	 .746	
	 TT	 28	 29.5000	 20.50	to	33.75	 	 	
rs11556218	 TT	 41	 26.0000	 20	to	33.50	 	 	
	 TG	 12	 29.0000	 22.75	to	32.75	 .368	 .544	
	 GG	 -	 -	 -	 	 	
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rs11614913	 CC	 28	 29.5000	 23.25	to	35	 	 	
	 CT	 20	 24.5000	 21	to	32	 4.842	 .089	
	 TT	 5	 20.0000	 12.50	to	26	 	 	
rs11677877	 TT	 46	 26.0000	 20.75	to	34.25	 	 	
	 TG	 6	 30.0000	 16.25	to	33	 .080	 .778	
	 GG	 -	 -	 -	 	 	
rs11739136	 GG	 42	 26.0000	 20	to	33.25	 	 	
	 GA	 11	 29.0000	 24	to	33	 .607	 .436	
	 AA	 -	 -	 -	 	 	
rs12477314	 GG	 33	 30.0000	 24	to	35.50	 	 	
	 GA	 19	 23.0000	 20	to	29	 3.911	 .141	
	 AA	 1	 20.0000	 -	 	 	
rs12504628	 TT	 33	 31.0000	 24	to	36	 	 	
	 TC	 19	 23.5000	 17.75	to	29.50	 6.397	 .041	
	 CC	 1	 20.0000	 -	 	 	
rs12899618	 CC	 41	 28.0000	 20.50	to	34.50	 	 	
	 CT	 12	 25.0000	 18	to	30.50	 1.021	 .312	
	 TT	 -	 -	 -	 	 	
rs12922394	 GG	 49	 28.0000	 20.50	to	33.50	 	 	
	 GA	 4	 23.0000	 17.50	to	30.75	 .601	 .438	
	 AA	 -	 -	 -	 	 	
rs1303	 TT	 26	 29.0000	 19.50	to	33.50	 	 	
	 TC	 22	 26.0000	 20.75	to	32.50	 .817	 .665	
	 CC	 5	 32.0000	 22.50	to	38	 	 	
rs1800450	 CC	 40	 27.0000	 22	to	33	 	 	
	 CT	 12	 23.5000	 14.25	to	38.50	 .530	 .466	
	 TT	 -	 -	 .	 	 	
rs5030737	 GG	 48	 26.0000	 20.25	to	33	 	 	
	 GA	 5	 29.0000	 21	to	33	 .006	 .939	
	 AA	 -	 -	 -	 	 	
rs7041	 GG	 21	 29.0000	 20.50	to	34.50	 	 	
	 GT	 25	 26.0000	 20.50	to	32	 1.107	 .575	
	 TT	 7	 24.0000	 17	to	29	 	 	
	
	
	
	
	
	
	
	
*Calculated	using	Kruskal-Wallis	test	
†Significant	different	from	AG	
#Significant	different	from	CT		
SNP-	Single	Nucleotide	Polymorphism	
IQR-	Interquartile	range	
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Folha de informação ao participante 
O Sr./Sra. está a ser convidado/a para participar no estudo de investigação clínica 
intitulado: “GENIAL – Marcadores genéticos e clínicos na trajetória da DPOC”. Mas, antes 
de decidir, é importante que compreenda porque é que a investigação está a ser realizada 
e o que é que a mesma envolve. Por favor, leia a informação com atenção e discuta a sua 
participação com outros, se assim o entender. Se houver algo que não esteja claro para si 
ou necessitar de informação adicional, por favor pergunte aos investigadores (contactos no 
final deste documento). Use o tempo que precisar para decidir se deseja ou não participar.  
Muito obrigado desde já por ler a informação. 
Qual é o propósito do estudo? 
Este estudo visa determinar o papel das mutações genéticas associadas ao 
desenvolvimento e trajetória da Doença Pulmonar Obstrutiva Crónica (DPOC) e identificar 
os marcadores clínicos (e.g., dispneia; número de exacerbações; função pulmonar; 
tolerância ao exercício) capazes de detetar episódios de exacerbações agudas da DPOC 
(episódios de agravamento dos sintomas respiratórios que é acima da sua variação normal 
do dia-a-dia e leva à alteração da medicação). 
A suscetibilidade para desenvolver DPOC varia consideravelmente entre indivíduos, 
sugerindo que outros fatores de risco para além do tabaco (principal fator de risco) podem 
influenciar o desenvolvimento da doença. Estudos recentes demonstraram que a 
suscetibilidade genética pode desempenhar um papel determinante na patogénese da 
DPOC. Contudo, pouco se sabe acerca desta relação entre o desenvolvimento da doença 
e o perfil genético dos pacientes. Da mesma forma, sabe-se que a deterioração clínica dos 
pacientes é altamente dependente da frequência e gravidade das exacerbações agudas, 
e que pacientes com função pulmonar semelhante apresentam níveis diferentes de 
incapacidade/suscetibilidade às exacerbações agudas. Assim, os resultados deste estudo 
irão potencialmente contribuir para melhorar o conhecimento sobre a DPOC e informar 
sobre as estratégias para prevenir, detetar precocemente e gerir as exacerbações agudas. 
Para que seja possível alcançar estes objetivos vimos então solicitar a sua participação 
neste estudo que será realizado na Escola Superior de Saúde da Universidade de 
Aveiro/iBiMED, centros de saúde e centro hospitalar do Baixo Vouga, Centro Hospitalar do 
Médio Ave, Hospital Pedro Hispano e Hospital Distrital da Figueira da Foz. 
Porque é que fui escolhido? 
Foi escolhido/a porque é uma pessoa saudável, com doença pulmonar obstrutiva crónica 
em fase estável ou cuidador/a de uma pessoa com esta doença. Para o estudo, precisamos 
de dados de aproximadamente 400 pessoas, com uma condição clínica semelhante à sua, 
que aceitem participar. 
Tenho de participar? 
A decisão de participar, ou não, é completamente sua. Se decidir participar vai-lhe ser 
pedido que assine um formulário de consentimento informado mas, é totalmente livre de 
desistir a qualquer momento, sem que para tal tenha de dar qualquer justificação. A decisão 
de desistir ou de não participar, não afetará a qualidade dos serviços de saúde ou qualquer 
outro, que lhe são prestados agora ou no futuro. 
O que me acontecerá caso decida participar? 
Se decidir participar, após assinar e entregar aos investigadores o consentimento 
informado, será feita uma avaliação do seu estado de saúde geral. Primeiro, serão 
gravados os sons dos seus pulmões durante aproximadamente 20 segundos (3 
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repetições), com um microfone, como se fosse um estetoscópio, que está ligado a um 
computador portátil. Seguidamente, ser-lhe-á medido o peso e a altura numa balança. 
Depois, ser-lhe-á avaliada a força dos seus músculos da respiração e a capacidade 
respiratória, através de dois testes que consistem em inspirar e soprar para um 
equipamento. A avaliação da força dos seus músculos da coxa e braço realizar-se-ão de 
seguida através de um aparelho que se encosta à região do corpo em teste, é-lhe pedido 
que realize o máximo de força que conseguir e em breves segundos, o aparelho indica a 
força daquele músculo. Veremos também a sua tolerância ao exercício através do teste de 
sentar e levantar de uma cadeira. Ser-lhe-á também pedido para colocar um bocadinho de 
saliva para um copo (semelhante ao que utiliza quando realiza análises clínicas) para 
posterior análise. Mediremos também a quantidade de oxigénio no seu sangue e a sua 
frequência cardíaca através de um oxímetro (aparelho pequeno que se coloca no seu 
indicador e nos dá a informação desses valores em segundos). De seguida avaliaremos a 
sua frequência respiratória observando a sua região abdominal e mediremos a tensão 
arterial com um medidor de tensão arterial digital. Por último, ser-lhe-á pedido que 
responda a um questionário para avaliar o seu nível de atividades física e um outro para 
avaliar o impacto da sua doença no seu dia-a-dia. Se for cuidador de um doente com DPOC 
ou residir com o mesmo, ser-lhe-á também pedido que use um acelerómetro por 1 semana. 
Nenhum dos testes realizados provoca qualquer dor ou desconforto. A duração da 
avaliação será de aproximadamente 45 minutos e poderão ser realizadas em sua casa ou 
possivelmente nas instalações do Lab3R na Universidade de Aveiro, de acordo com a sua 
preferência. 
No caso de ter DPOC terá também a possibilidade, no caso de experienciar uma 
exacerbação do seu estado de saúde, de realizar uma intervenção no sentido de melhorar 
o seu estado de saúde e ter a sua condição monitorizada durante 3 semanas. 
Quais são os efeitos secundários, desvantagens e riscos se eu resolver participar? 
Não existem efeitos secundários, desvantagens ou riscos de participar no estudo. 
Quais são os possíveis benefícios se eu resolver participar? 
Toda a informação clínica recolhida será fornecida aos participantes para que seja do seu 
conhecimento e, no caso de sofrer um agravamento dos sintomas, beneficiará de um 
acompanhamento semanal do seu estado de saúde prestado por um fisioterapeuta 
respiratório qualificado. Para além disso, a informação obtida neste estudo, através da sua 
participação, poderá ajudar a melhorar o conhecimento sobre a patogénese da DPOC e, a 
prevenção, diagnóstico precoce e gestão das exacerbações agudas, uma doença crónica 
que afeta cerca de 800.000 portugueses. 
A minha participação será confidencial?  
Toda a informação recolhida no decurso do estudo será mantida estritamente confidencial 
e mantido o anonimato. Os dados recolhidos serão salvaguardados com um código e 
palavra-passe, para que ninguém o/a possa identificar. Apenas os investigadores do 
projeto terão acesso aos seus dados. 
O que acontecerá aos resultados do estudo? 
Os resultados do estudo serão analisados e incorporados em Dissertações de Mestrado e 
Teses de Doutoramento e alguns serão publicados em Jornais Científicos. No entanto, em 
nenhum momento o Sr./Sra. será identificado/a. Se gostar de obter uma cópia de qualquer 
relatório ou publicação, por favor diga ao investigador com quem contactar. 
Quem é que está a organizar e a financiar o estudo?  
Este estudo foi financiado pelo Programa Operacional Competitividade e 
Internacionalização - COMPETE, através do Fundo Europeu de Desenvolvimento Regional 
- FEDER (POCI-01-0145-FEDER-016701), e pela Fundação para a Ciência e Tecnologia 
(PTDC/DTP-PIC/2284/2014). Este estudo foi também parcialmente apoiado pelo 
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COMPETE através do FEDER e da FCT através do projeto  UID/BIM/04501/2013. O estudo 
decorre na Universidade de Aveiro em colaboração com o ACES e Centro Hospitalar do 
Baixo Vouga, Centro Hospitalar do Médio Ave, Hospital Pedro Hispano e Hospital Distrital 
da Figueira da Foz. 
Contactos para mais informações sobre o estudo 
Alda Marques (Investigadora Responsável) 
Escola Superior de Saúde da Universidade de Aveiro, 
Telefone 234 372 462 
e-mail: amarques@ua.pt 
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Termo de Consentimento Livre e Esclarecido 
Título do Projeto: “GENIAL – Marcadores genéticos e clínicos na trajetória da DPOC”. 
Nome do Investigador Principal: Prof. Doutora Alda Sofia Pires de Dias Marques 
 
Por favor leia e assinale com uma cruz (X) os quadrados seguintes. 
1. Eu confirmo que percebi a informação que me foi dada e tive a oportunidade 
de questionar e de me esclarecer. 
 
2. Eu percebo que a minha participação é voluntária e que sou livre de desistir, 
em qualquer altura, sem dar nenhuma explicação, sem que isso afete qualquer 
serviço de saúde ou qualquer outro que me é prestado.  
3. Eu compreendo que os dados recolhidos durante a investigação são 
confidenciais e que só os investigadores do projeto da Universidade de Aveiro 
têm acesso a eles. Portanto, dou autorização para que os mesmos tenham 
acesso a esses dados.  
4. Eu compreendo que os dados recolhidos durante o estudo podem ser 
utilizados para publicação em Revistas Científicas e usados noutras 
investigações, sem que haja qualquer quebra de confidencialidade. Portanto, 
dou autorização para a utilização dos dados para esses fins.  
5. Eu concordo então em participar no estudo. 
 
 
 
 
 
 
________________________ 
Nome da pessoa 
                     
 
 
 
 
 
 
_________ 
Data 
 
 
 
 
 
___________________________ 
Assinatura 
 
 
________________________ 
Nome do Investigador(a) 
 
 
_________ 
Data 
 
 
___________________________ 
Assinatura 
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Protocolo do Participante 
 
Data___/___/____              Código _____________ 
       Dia   Mês   Ano 
 
A. INFORMAÇÃO SÓCIO-DEMOGRÁFICA 
A1. Género     (1) [    ] feminino         (2) [    ] masculino 
A2. Data de Nascimento ___/___/____ (dia/mês/ano) 
A3. Habilitações literárias:   
(1) Não frequentou o sistema de ensino formal [    ] (2) Até ao 1º ciclo Ensino Básico (4º ano) [    ] 
(3) Até ao 2º ciclo Ensino Básico (6º ano) [    ] (4) Até ao 3º ciclo Ensino Básico (9º ano) [    ] 
(5) Até ao Ensino Secundário (12º ano) [    ] (6) Curso Médio [    ] 
(7) Ensino Superior [    ]   
 
A4. Estado Civil:  
(1) solteiro [    ]  (2) casado [    ] (3) separado [    ] 
(4) divorciado [    ]  (5) viúvo [    ]  (6) união de facto   [    ] 
                   
A5. Ocupação habitual: 
(1) Trabalho remunerado  [   ] (2) Trabalho não remunerado [   ] 
(3) Estudante [   ] (4) Trabalho doméstico [   ] 
(5) Reformado [   ] (6) Desempregado (motivo saúde) [   ] 
(7) Desempregado (outros motivos) [   ] (8) Outro 
     Especifique________________ 
[   ] 
B. INFORMAÇÃO SUCINTA SOBRE SAÚDE 
B1. Composição Corporal:         
Altura: ________m     Peso: _________kg        % Massa Gorda: _________         IMC: _________ 
B2.a Tem hábitos tabágicos? 
(1) NÃO [    ]           (2) SIM          [    ]   
 
Se SIM, 
quantidade diária______________  
desde que ano/idade __________         
 
B2.b Se respondeu NÃO, tem história anterior de hábitos tabágicos? 
(1) NÃO [    ]           (2) SIM          [    ]   
 
quantidade diária______________  
número de anos _________         
B3. Comorbilidades_______________________________________________________________________ 
B4. Medicação (prescrita pelo médico ou adquirida sem receita médica)______________________________ 
B5. Oxigenoterapia de longa duração 
 
(1) NÃO [    ]           (2) SIM          [    ]           se SIM, especificar 
Litros/min______Horas/dia_________Tipo________________ 
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B6. Ventilação não invasiva 
 
(1) NÃO [    ]           (2) SIM          [    ]           se SIM, especificar 
Tipo_______________________Horas/dia________________ 
B7. Internamento hospitalar nos últimos 3 meses? e no último ano? 
(1) NÃO [    ] 
          
(2) SIM          Último ano [    ]  se SIM, especificar o(s) motivo(s) e a duração 
1____________________________________; ________dias 
2____________________________________; ________dias 
3____________________________________; ________dias 
B8. Episódio ida ao serviço de urgência últimos 3 meses? e no último ano? 
(1) NÃO [    ]           (2) SIM          3M [    ]  
Último ano [    ]  
se SIM, especificar o(s) motivo(s)  
1____________________________________;  
2____________________________________;  
3____________________________________;  
B9. No último ano, quantas crises de problemas respiratórios teve? (uma crise implica um agravamento dos 
sintomas respiratórios, para além da variabilidade normal de dia para dia, que implica procurar ajuda médica 
ou alterar a sua medicação) 
Nenhuma 
crise 
[    ]           1 crise 
  
[    ]           2 crises  
 
[    ] 
 
3 crises [    ] Outro____          
 
B10. Dispneia (mMRC) 
Grau 0 [   ] Grau 1 [   ] Grau 2 [   ] Grau 3 [   ] Grau 4 [   ] 
Fonte The Global Initiative for Chronic Obstructive Lung Disease. (2015). Global Strategy for Diagnosis, Management, and Prevention of 
Chronic Obstructive Pulmonary Disease - 2015 Update: The Global Initiative for Chronic Obstructive Lung Disease, Inc. 
 
B11. Atividade física  
a) Quantas vezes por semana, costuma realizar 20 minutos de atividade física intensa que o faz suar ou ficar 
ofegante? (por exemplo, jogging, levantamento de grandes pesos, cavar, aeróbica ou andar de bicicleta a um 
ritmo rápido) 
3 vezes/semana  [     ]             1 a 2 vezes/semana  [     ]                Nenhuma  [     ] 
b) Quantas vezes por semana, costuma realizar 30 minutos de atividade física moderada ou caminhada que 
aumenta a sua frequência cardíaca ou o faz respirar com mais dificuldade que o normal? (por exemplo, cortar 
a relva, transportar cargas leves, andar de bicicleta a um ritmo regular, ou jogar ténis em duplas) 
 > 5 vezes/semana [   ] 3 a 4 vezes/semana [   ] 
1 a 2 vezes/semana [   ] Nenhuma [   ] 
 
 
Sinais Vitais, SpO2 e outros sintomas 
Frequência Respiratória: Tensão Arterial:_______/_______ 
Saturação de Oxigénio (%): Frequência Cardíaca: 
Escala de BORG modificada (Dispneia) Grau: 
Escala de BORG modificada (Fadiga) Grau: 
Fonte: Borg, G., Borg's Perceived Exertion and Pain Scales. Champaign: IL: Human Kinetics1998, United States of America: Human Kinetics. 
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Aquisição dos Sons Respiratórios Computorizados 
Traqueia [   ]      Anterior direito [   ]       Anterior esquerdo [   ]      Lateral direito [   ] 
Lateral esquerdo [   ]      Posterior direito [   ]      Posterior esquerdo [   ]      Todos [   ] 
 
Espontâneo [   ] 
(0.4L/s – 0.7L/s) [   ] 
(1.0L/s – 1.5L/s) [   ] 
Fonte: Rossi M, A.R.A.Sovijärvi, P. Piirilä V, L.,, F.Dalmasso, J.Vanderschoot. Environmental and subject conditions and breathing 
manoeuvres for respiratory sound recordings. European Respiratory Review. 2000;10:77: 611-5 
 
 
Recolha de saliva [    ] 
 
 
Zaragatoa [    ] 
 
 
 
Espirometria [    ] 
Valores Teste 1 Teste 2 Teste 3 Teste 4 Teste 5 
FEV1%      
FVC      
FEV1/FVC      
Fonte: Miller, M. R. (2005). Standardisation of spirometry. European Respiratory Journal, 26(2), 319-338. doi: 
10.1183/09031936.05.00034805 
 
Força Muscular Isométrica (dinamómetro) 
Grupo Muscular  Teste 1 Teste 2 Teste 3 
Extensores do joelho D    
Handgrip D    
D: Dominante 
Fonte: O'Shea, S.D., N.F. Taylor, and J.D. Paratz, Measuring Muscle Strength for People With Chronic Obstructive Pulmonary Disease: Retest 
Reliability of Hand-Held Dynamometry. Archives of Physical Medicine and Rehabilitation, 2007. 88(1): p. 32-36 
 
Avaliação da Força Músculos respiratórios 
 Teste 1 Teste 2 Teste 3 Teste 4 Teste 5 
PIM (cmH2O)      
PEM (cmH2O)      
Fonte: ATS/ERS Statement on respiratory muscle testing. American journal of respiratory and critical care medicine 166: 518-624, 2002. 
 
Teste das 5 repetições sentar-levantar 
 Teste 1 Teste 2 Teste 3 Teste 4 Teste 5 
Tempo (s)      
Fonte: Jones, S. E., Kon, S. S., Canavan, J. L., Patel, M. S., Clark, A. L., Nolan, C. M., . . . Man, W. D. (2013). The five-repetition sit-to-stand 
test as a functional outcome measure in COPD. Thorax, 68(11), 1015-1020. doi: 10.1136/thoraxjnl-2013-203576 
Teste de 1 minuto sentar-levantar 
 Teste 1 Teste 2 Teste 3 Teste 4 Teste 5 
Repetições      
 
Fonte: Ozalevli S, Ozden A, Itil O, Akkoclu A. Comparison of the sit-to-stand test with 6min walk test in patients with chronic obstructive 
pulmonary disease. Respiratory medicine. 2007;101(2):286-93. 
 
Acelerómetro [    ]        Par: _______ 
(apenas DPOC + cuidador) 
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Teste de Avaliação da DPOC – CAT 
Este questionário irá ajudá-lo a si e ao seu profissional de saúde a medir o impacto que a DPOC (Doença 
Pulmonar Obstrutiva Crónica) está a ter no seu bem-estar e no seu quotidiano. As suas respostas e a pontuação 
do teste podem ser utilizadas por si e pelo seu profissional de saúde para ajudar a melhorar a gestão da sua 
DPOC e a obter o máximo benefício do tratamento. Para cada um dos pontos a seguir, assinale com um (X) o 
quadrado que melhor o descreve presentemente. Certifique-se que seleciona apenas uma resposta para cada 
pergunta. 
Por exemplo: Estou muito feliz     0     1     2     3     4    5    Estou muito triste 
Nunca tenho tosse 0 1 2 3 4 5 Estou sempre a tossir 
Não tenho nenhuma 
expetoração (catarro) no 
peito 
0 1 2 3 4 5 
O meu peito está 
cheio de 
expetoração 
(catarro) 
Não sinto nenhum aperto 
no peito 0 1 2 3 4 5 
Sinto um grande 
aperto no peito 
Não sinto falta de ar ao 
subir uma ladeira ou um 
lance de escadas 
0 1 2 3 4 5 
Quando subo 
uma ladeira ou 
um lance de 
escadas sinto 
bastante falta de 
ar 
Não sinto nenhuma 
limitação nas minhas 
atividades em casa 
0 1 2 3 4 5 
Sinto-me muito 
limitado nas 
minhas 
atividades em 
casa 
Sinto-me confiante para 
sair de casa, apesar da 
minha doença pulmonar 
0 1 2 3 4 5 
Não me sinto 
nada confiante 
para sair de 
casa, por causa 
da minha doença 
pulmonar 
Durmo profundamente 0 1 2 3 4 5 
Não durmo 
profundamente 
devido à minha 
doença 
pulmonar 
Tenho muita energia 0 1 2 3 4 5 
Não tenho 
nenhuma 
energia 
Fonte: George, F. H. M. (2013). Diagnóstico e Tratamento da Doença Pulmonar Obstrutiva Crónica.: Direção Geral de Saúde. 
Muito obrigado pela sua colaboração. 
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Escala de Ansiedade e Depressão Hospitalar - HADS 
 
Este questionário foi construído para ajudar a saber como se sente. Pedimos-lhe que leia cada uma das 
perguntas e faça uma cruz (X) no espaço anterior à resposta que melhor descreve a forma como se tem sentido 
na última semana. Não demore muito tempo a pensar nas respostas. A sua reação imediata a cada questão 
será provavelmente mais correta do que uma resposta muito ponderada. Por favor, faça apenas uma cruz em 
cada pergunta. 
(A)1. Sinto-me tenso/a ou nervoso/a: 
      3 □ Quase sempre 
      2 □ Muitas vezes 
      1 □ Por vezes 
      0 □ Nunca 
(D)8. Sinto-me mais lento/a, como se fizesse as 
coisas mais devagar: 
      3 □ Quase sempre 
      2 □ Muitas vezes 
      1 □ Por vezes 
      0 □ Nunca 
(D)2. Ainda sinto prazer nas coisas de que 
costumava gostar: 
      0 □ Tanto como antes 
      1 □ Não tanto agora 
      2 □ Só um pouco 
      3 □ Quase nada 
(A)9. Fico de tal forma apreensivo/a (com 
medo), que até sinto um aperto no estômago: 
      0 □ Nunca 
      1 □ Por vezes 
      2 □ Muitas vezes 
      3 □ Quase sempre 
(A)3. Tenho uma sensação de medo, como se 
algo terrível estivesse para acontecer: 
      3 □ Sim e muito forte 
      2 □ Sim, mas não muito forte 
      1 □ Um pouco, mas não me aflige 
      0 □ De modo algum 
(D)10. Perdi o interesse em cuidar do meu 
aspeto físico: 
      3 □ Completamente 
      2 □ Não dou a atenção que devia 
      1 □ Talvez cuide menos que antes 
      0 □ Tenho o mesmo interesse de sempre 
(D)4. Sou capaz de rir e ver o lado divertido das 
coisas: 
      0 □ Tanto como antes 
      1 □ Não tanto como antes 
      2 □ Muito menos agora 
      3 □ Nunca 
(A)11. Sinto-me de tal forma inquieto/a que não 
consigo estar parado/a: 
      3 □ Muito 
      2 □ Bastante 
      1 □ Não muito 
      0 □ Nada 
(A)5. Tenho a cabeça cheia de preocupações: 
      3 □ A maior parte do tempo 
      2 □ Muitas vezes 
      1 □ Por vezes 
      0 □ Quase nunca 
(D)12. Penso com prazer nas coisas que 
podem acontecer no futuro: 
      0 □ Tanto como antes 
      1 □ Não tanto agora 
      2 □ Bastante menos agora 
      3 □ Quase nunca 
(D)6. Sinto-me animado/a: 
      3 □ Nunca 
      2 □ Poucas vezes 
      1 □ De vez em quando 
      0 □ Quase sempre 
(A)13. De repente, tenho sensações de pânico: 
      3 □ Muitas vezes 
      2 □ Bastantes vezes 
      1 □ Por vezes 
      0 □ Quase nunca 
 
 
(A)7. Sou capaz de estar descontraidamente 
sentado/a e sentir-me relaxado/a: 
      0 □ Quase sempre 
      1 □ Muitas vezes 
      2 □ Por vezes 
      3 □ Nunca 
 
(D)14. Sou capaz de apreciar um bom livro ou 
um programa de rádio ou televisão: 
      0 □ Muitas vezes 
      1 □ De vez em quando 
      2 □ Por vezes 
      3 □ Quase nunca 
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Questionário do Hospital St. George na Doença Respiratória 
Este questionário ajuda-nos a compreender até que ponto a sua dificuldade respiratória o/a perturba e afeta a 
sua vida. Usamo-lo para descobrir quais os aspetos da sua doença que lhe causam mais problemas. Interessa-
nos saber o que sente e não o que os profissionais de saúde acham que serão os seus problemas. 
Leia atentamente as instruções. Esclareça as dúvidas que tiver. Não perca muito tempo nas suas respostas.  
Antes de preencher o questionário, assinale com um “x” a resposta que descreve melhor o seu estado de saúde 
atual: 
Muito bom Bom Moderado Mau Muito mau 
□(1) □(2) □(3) □(4) □(5) 
PARTE 1 
Para cada uma das perguntas seguintes, assinale a resposta que melhor corresponde aos seus problemas 
respiratórios, nos últimos 3 meses. 
Assinale um só quadrado para 
cada pergunta. 
 
Maioria dos dias 
da semana 
Vários dias da 
semana 
Alguns dias 
no mês 
Só com 
infeções 
respiratórias 
Nunca 
1. Durante os últimos 3 meses 
tossi: 
□  □  □  □  □  
2. Durante os últimos 3 meses 
tive expetoração: 
□ □ □ □ □ 
3. Durante os últimos 3 meses 
tive falta de ar: 
□ □ □ □ □ 
4. Durante os últimos 3 meses 
tive crises de pieira (chiadeira 
ou “gatinhos” no peito): 
□ □ □ □ □ 
5. Durante os últimos 3 
meses, quantas crises graves 
de problemas respiratórios 
teve? 
Mais de 3 crises 
 
□ 
3 crises 
 
□ 
2 crises 
  
□  
1 crise 
 
□ 
Nenhuma 
crise 
□ 
6. Quanto tempo durou a pior 
dessas crises? (passe para a 
pergunta 7 se não teve crises 
graves) 
1 semana ou 
mais  
□ 
3 ou mais dias 
 
□ 
1 ou 2 dias  
 
□ 
Menos de 1 
dia 
 
□ 
 
 
7. Durante os últimos 3 
meses, numa semana 
considerada como habitual, 
quantos dias bons (com 
poucos problemas 
respiratórios) teve? 
Nenhum 
 dia  
 
□ 
1 ou 2  
dias  
  
□ 
3 ou 4 dias  
 
 
□  
Quase todos 
os dias  
 
□ 
Todos os dias 
 
□ 
8. Se tem pieira (chiadeira, ou 
gatinhos” no peito), ela é pior 
de manhã? 
Não  
  □ 
       Sim  
□  
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PARTE 2  
Secção 1 
Assinale um só 
quadrado para 
descrever a sua 
doença 
respiratória: 
É o meu maior 
problema 
Causa-me muitos 
problemas 
Causa-me alguns 
problemas 
Não me causa 
nenhum 
problema 
□ □ □ □ 
Se tem ou já teve 
um trabalho pago, 
assinale uma das 
respostas: 
A minha doença 
respiratória 
obrigou-me a parar 
de trabalhar 
A minha doença 
respiratória interfere 
(ou interferiu) com o 
meu trabalho normal 
ou já me obrigou a 
mudar de trabalho 
A minha doença 
respiratória não 
afeta (ou não 
afetou) o meu 
trabalho 
 
□ □ □  
 
Secção 2: Perguntas sobre as atividades que normalmente lhe têm provocado falta de ar nos últimos dias. 
Assinale com “x” a resposta “concordo” ou “não concordo” de acordo com o seu caso: 
 Concordo                        Não concordo 
Quando estou sentado(a) ou deitado(a) □ □ 
A tomar banho ou a vestir-me □ □ 
A caminhar dentro de casa □ □ 
A caminhar em terreno plano □ □ 
A subir um lanço de escadas □ □ 
A subir ladeiras □ □ 
A praticar desportos ou jogos que impliquem esforço 
físico 
□ □ 
 
Secção 3: Mais algumas perguntas sobre a sua tosse e falta de ar nos últimos dias.  
Assinale com “x” a resposta “concordo” ou “não concordo” de acordo com o seu caso: 
 Concordo                        Não concordo 
A minha tosse causa-me dor □ □ 
A minha tosse cansa-me □ □ 
Falta-me o ar quando falo □ □ 
Falta-me o ar quando me inclino para a frente □ □ 
A minha tosse ou a falta de ar perturba o meu sono □ □ 
Fico muito cansado(a) com facilidade □ □ 
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Secção 4: Perguntas sobre outros efeitos causados pela sua doença respiratória nos últimos dias. Assinale 
com “x” a resposta “concordo” ou “não concordo” de acordo com o seu caso: 
 Concordo                        Não concordo 
A minha tosse ou falta de ar envergonham-me em público □ □ 
A minha doença respiratória é um incómodo para a minha família, amigos 
ou vizinhos 
□ □ 
Tenho medo ou receio ou mesmo pânico quando não consigo respirar □ □ 
Sinto que não tenho controlo sobre a minha doença respiratória □ □ 
Não espero melhoras da minha doença respiratória □ □ 
A minha doença tornou-me fisicamente diminuído(a) ou inválido(a) □ □ 
Fazer exercício é arriscado para mim □ □ 
Tudo o que faço parece-me ser um esforço excessivo □ □ 
 
Secção 5: Perguntas sobre a medicação para a sua doença respiratória. Caso não tenha medicação, passe 
para a secção 6. Assinale com “x” a resposta “concordo” ou “não concordo” de acordo com o seu caso: 
 Concordo                        Não concordo 
A minha medicação não me está a ajudar muito □ □ 
Tenho vergonha de tomar os medicamentos em público  □ □ 
A minha medicação provoca-me efeitos secundários desagradáveis □ □ 
A minha medicação interfere muito com o meu dia a dia □ □ 
 
Secção 6: As perguntas seguintes referem-se a atividades que podem ser afetadas pela sua doença 
respiratória. Assinale com “x” a resposta “concordo” se pelo menos uma parte da frase se aplica ao seu caso; 
se não, assinale “não concordo”: 
 Concordo                        Não concordo 
Levo muito tempo a lavar-me ou a vestir-me □ □ 
Demoro muito tempo ou não consigo tomar banho ou um duche □ □ 
Ando mais devagar que as outras pessoas, ou então tenho de parar para 
descansar 
□ □ 
Demoro muito tempo com tarefas como o trabalho de casa, ou então tenho 
de parar para descansar 
□ □ 
Quando subo um lanço de escadas, ou vou muito devagar ou tenho de 
parar para descansar   
□ □ 
Se estou apressado ou se caminho mais depressa, tenho de parar ou 
diminuir o passo 
□ □ 
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 Concordo                        Não concordo 
Por causa da minha doença respiratória, tenho dificuldade em fazer coisas 
como: subir ladeiras, carregar pesos quando subo escadas, tratar do jardim 
ou do quintal, arrancar ervas, dançar, jogar à bola 
□ □ 
Por causa da minha doença respiratória, tenho dificuldade em fazer coisas 
como: carregar grandes pesos, cavar o jardim ou o quintal, caminhar 
depressa (8 quilómetros/hora), jogar ténis ou nadar 
□ □ 
Por causa da minha doença respiratória, tenho dificuldade em fazer coisas 
como: trabalho manual pesado, correr, andar de bicicleta, nadar com 
velocidade, ou praticar desportos muito cansativos 
□ □ 
 
Secção 7:Gostaríamos de saber como é que a sua doença respiratória habitualmente afeta o seu dia a dia. 
Assinale com “x” a resposta “concordo” ou “não concordo”.  
(Não se esqueça que “concordo” só se aplica quando não puder fazer a atividade devido à sua doença 
respiratória). Assinale todas as perguntas que se aplicam a si: 
 Concordo                        Não concordo 
Não sou capaz de praticar desportos ou jogos que impliquem esforço físico □ □ 
Não sou capaz de sair de casa para me divertir □ □ 
Não sou capaz de sair de casa para fazer compras □ □ 
Não sou capaz de fazer o trabalho de casa □ □ 
Não sou capaz de sair da cama ou da cadeira □ □ 
 
 
Assinale com “x” (só um) a resposta que melhor define a forma como é afetado(a) pela sua doença 
respiratória: 
Não me impede de fazer 
nenhuma das coisas que 
eu gostaria de fazer (0)  
Impede-me de fazer uma 
ou duas coisas que eu 
gostaria de fazer (1) 
Impede-me de fazer 
muitas das coisas que 
eu gostaria de fazer (2)    
Impede-me de fazer 
tudo o que eu gostaria 
de fazer (3)  
□ □ □ □ 
 
Muito obrigado pela sua colaboração. 
 
 
	
